Multifunctional Enzymes in the shikimate pathway by Arora, Harshul
Multifunctional Enzymes in the shikimate pathway 
 
 
 
 
 
 
 
 
 
Dissertation 
der Mathematisch-Naturwissenschaftlichen Fakultät 
der Eberhard Karls Universität Tübingen 
zur Erlangung des Grades eines  
Doktors der Naturwissenschaften  
(Dr. rer. nat.) 
 
 
 
 
 
 
vorgelegt von 
Harshul Arora 
aus Neu Delhi, Indien 
 
 
 
Tübingen 
2018 
  
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gedruckt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der 
Eberhard Karls Universität Tübingen. 
 
 
Tag der mündlichen Qualifikation:  06.06.2018 
Dekan: Prof. Dr. Wolfgang Rosenstiel 
1. Berichterstatter: Prof. Dr. Andrei Lupas 
2. Berichterstatter: Prof. Dr. Karl Forchhammer 
 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 To my mother and father………… 
 
 
 
 
 
 
3 
 
Summary 
Multifunctional enzymes are instances of natural fusion proteins, possessing multiple catalytic 
activities. Via the close proximity of their catalytic domains, they take advantage from 
concentration of the reactants and may feature allosteric regulation and substrate channeling 
effects. Substantial progress has been made regarding the kinetic mechanisms of individual 
enzymes, but the knowledge in the areas of multifunctional enzymes and also transient complexes 
is rather limited. The seven step shikimate pathway, which is a metabolic route to aromatic 
compounds, has a number of bifunctional, trifunctional, tetrafunctional and pentafunctional fusion 
proteins in different organisms. Most notable is the pentafunctional AROM complex, which 
comprises the central five steps of the pathway, which has withstood structural characterization 
for decades.  
In this work, we shed light on the pentafunctional AROM complex and the three bifunctional 
enzymes Tm_AroKB, Fp_AroEK and Mb_AroKE of the shikimate pathway by characterizing 
them functionally and structurally and comparing them to their monofunctional homologs. For the 
bifunctional proteins, Tm_AroKB and Fp_AroEK the kinetic analysis revealed that their activity 
is similar to that reported for their monofunctional counterparts. In addition, the kinetic activity of 
the truncated monofunctional Tm_AroKKB was found to be similar to Tm_AroKB. Interestingly, 
no allosteric regulation was observed between the two domains in Tm_AroKB. The kinetic 
analysis of the K domain of Mb_AroKE revealed that it is slower than the other enzymes in this 
study. However, the genome of the respective organism Methanoregula boonei also contains a 
monofunctional Mb_AroK, which might play the major role in the shikimate pathway.  
All crystal structures of the bifunctional enzymes show rigid inter-domain interfaces, with all the 
catalytic sites solvent accessible. Tm_AroKB is a dimer both in solution and in crystalline state. 
Remarkably, it contains an intrinsically bound NAD molecule. In all bifunctional proteins, the 
structure of the individual domains corresponds to that of the monofunctional homologs. However, 
the domain arrangement in the structures of Fp_AroEK and Mb_AroKE are different. Both 
arrangements bring the catalytic sites closer and could be part of potential higher order assemblies. 
Therefore, we hypothesized that the individual enzymes of the pathway form transient complexes 
for efficient substrate funneling and regulation. In silico models of such assemblies were generated 
based on both Fp_AroEK, and Mb_AroKE, via superimposition on the bifunctional proteins 
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Tm_AroKB and At_AroDE. These two models are not identical but they both represent a 
plausible, compact assembly with all active sites solvent accessible.  
Finally, we studied the pentafunctional AROM complex. The catalytic turnover of the AROM 
complex is significantly higher than that of the monofunctional E.coli enzymes. The crystal 
structure of AROM complex, which was found to be different from both in silico models, shows 
that its domains are attached to each other via rigid interfaces and that all the catalytic sites are 
solvent accessible. Using SAXS and XL-MS, we verified that the conformation of the AROM 
complex is very similar in solution and in crystalline state. In a computational approach, we further 
mapped the various conformational states of the individual enzymatic domains from the PDB onto 
the crystal structure, generating a structural ensemble representing the conformational space of the 
AROM complex. This ensemble reveals that the complex is optimized for spatial compatibility of 
the domains, allowing all necessary conformational changes during the catalytic cycle to happen 
without steric clashes between domains. 
Since the shikimate pathway is absent from mammals, it poses a classical drug target. Until now, 
only glyphosate is utilized as a herbicide for targeting the shikimate pathway. The insight obtained 
in this study suggests novel approaches to target the shikimate pathway. Most notable is the 
conformational space of the AROM complex, which is essential in fungi and protists. By targeting 
the conformational flexibility of the complex, catalytically necessary conformational transitions 
could be inhibited, which could result in novel, specific fungicides. 
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Abbreviations 
SKM Shikimic acid 
S3P 3-phosphoshikimic acid lithium salt 
DHQ 3-Dehydroquinic acid potassium salt 
DHS 3-Dehydroshikimic acid 
DAHP 3-Deoxy-D-arabinoheptulosonic Acid 7-Phosphate Disodium Salt 
NAD β-Nicotinamide adenine dinucleotide hydrate 
NADP β-Nicotinamide adenine dinucleotide 2′-phosphate disodium salt 
NADH β-Nicotinamide adenine dinucleotide reduced tetrasodium salt hydrate 
NADPH β-Nicotinamide adenine dinucleotide 2′-phosphate reduced tetrasodium salt 
hydrate 
ATP Adenosine 5′-triphosphate disodium salt hydrate 
ADP Adenosine-5'-diphosphate monosodium salt 
PEP Phospho(enol)pyruvic acid trisodium salt hydrate 
GLP Glyphosate 
PK/LDH Pyruvate Kinase/Lactic Dehydrogenase enzymes from rabbit muscle 
EPSP 5-enolpyruvylshikimate-3-phosphate 
DNA Deoxyribonucleic acid 
SDS Sodium dodecyl sulfate 
LB Lysogeny broth  
IPTG Isopropyl β-D-1-thiogalactopyranoside 
β-ME 2-Mercaptoethanol 
EDTA Ethylenediaminetetraacetic acid 
PNP Purine ribonucleoside phosphorylase 
MESG 2-amino-6-mercapto-7-methylpurine ribonucleoside 
CLANS CLuster ANalysis of Sequences 
Coot Crystallographic Object-Oriented Toolkit 
SSM Secondary-structure-matching 
CD Circular Dichroism 
XDS X-ray Detector Software 
GdnHCl Guanidinium hydrochloride 
SAD Single-wavelength anomalous dispersion 
SAXS Small-angle X-ray scattering 
DSMZ Deutsche Sammlung von Mikroorganismen und Zellkulturen 
TCEP-HCl Tris (2-carboxyethyl)phosphine hydrochloride  
PEG Polyethylene glycol 
EG Ethylene glycol 
OD Optical density 
PAGE Polyacrylamide gel electrophoresis 
IMAC immobilized metal ion affinity chromatography  
DTT Dithiothreitol 
PBS Phosphate buffer saline 
NS-TEM Negative stain Transmission Electron Microscopy  
PETRA Positron-Elektron-Tandem-Ring-Anlage, "positron-electron tandem-ring facility" 
SLS Swiss Light Source 
DLS Diamond Light Source 
PSI Paul Scherrer Institut 
PDB Protein Data Bank 
MST Microscale thermophoresis 
XL-MS Crosslinking and Mass Spectrometry 
SC Screen condition 
EM Electron Microscopy 
PCR Polymerase chain reaction 
PMSF Phenylmethane sulfonyl fluoride 
6 
 
UV Ultraviolet 
EDTA Ethylenediaminetetraacetic acid 
TEV Tobacco Etch Virus 
RMSD Root-mean-square deviation 
CS Conformational space 
LS Light scattering 
EC number Enzyme Commission number 
[S] Substrate concentration 
Vmax Maximal velocity 
KM Michaelis constant  
MM Michaelis-Menten 
kcat Turnover number 
[E] Enzyme concentration 
R2 Coefficient of determination 
S.E. Standard Error 
[Et] Total Enzyme concentration 
PB Protein buffer 
CHM Chorismate 
mdeg millidegrees  
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1. Introduction 
1.1. Enzymes and Metabolic Pathways 
The survival of a living organism depends on a network of synchronous interplay of numerous 
complex chemical reactions. These reactions are needed for all life processes such as energy 
production, movement, communication, reproduction, excretion and so on [1]. The study of these 
reactions forms the basis of biochemistry [2]. Together these reactions constitute the metabolism, 
which comprises the anabolism (synthesis of compounds) and the catabolism (degradation of 
compounds). However, on their own, most of these reactions are too slow to sustain life. To aid 
these reactions, complex molecular machines, called “enzymes” come into play. Enzymes are 
natural catalysts, which greatly accelerate the rates of these chemical reactions with high 
specificity and play a key role in the existence of life [3]. Enzymology is the study of properties 
of enzymes. 
Probably the first clear record of an enzyme-catalyzed reaction was in 1833 when Payen and 
Perosz found an alcohol precipitate of a thermolabile substance, which converted “starch to sugar” 
and named it “diastase” (now called amylase) [4]. In the late 1830s, Louis Pasteur while studying 
the fermentation of sugar to alcohol by yeast, concluded that fermentation was caused by a vital 
force contained within the yeast cells called "ferments", which function only within living 
organisms [5]. In 1878, German physiologist Wilhelm Kühne coined the term enzyme from Greek 
word “ενζυμον”, (in yeast) to emphasize that there is something in yeast, but not the yeast itself 
that catalyzes the fermentation reaction [6]. In 1907, Eduard Buchner could isolate a cell-free 
extract of yeast cells to carry out fermentation. He named this extract, “zymase” and received the 
first Nobel Prize in enzymology [7]. Since this time, many advancements have been made in the 
field of enzymology. 
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Enzymes bind to their substrate molecules with a very high specificity and mediate catalysis to 
release reaction products [8]. Most of these enzymes are proteins; hence, both the substrate 
specificity and the rate acceleration are a result of the precise three-dimensional structure of the 
substrate-binding pockets and the active site [1, 8, 9].  
A metabolic pathway thus, can be defined as a sequence of enzyme-catalyzed reactions, which 
convert one substrate into another [10]. The long list of metabolic pathways includes various 
pathways involved in carbohydrate metabolism, the amino acid metabolism, the lipid metabolism, 
and many more [11]. The reactions of the most fundamental metabolic pathways are usually 
conserved in all organisms, suggesting a common origin and early appearance in the evolution of 
life [8, 12, 13]. 
1.2. Multi-enzyme complexes vs. Multifunctional enzymes 
In metabolic pathways, the individual enzymes usually perform consecutive catalytic steps and the 
product of one enzyme acts as the substrate for the next [14]. In some pathways, multiple enzymes 
form various stable higher order assemblies, to carry out the consecutive steps in a pathway [15]. 
Multienzyme complexes are groups of noncovalently associated enzymes that catalyze two or 
more sequential steps in a metabolic pathway linked by common metabolic intermediates [6, 16]. 
In other words, such multienzyme complexes are massive molecular machines, constituting of 
different enzymes, which transform the substrate multiple times before releasing the final product. 
Even prokaryotic cells, which were once thought of as bags of enzymes with random diffusion and 
no visible compartmentalization, exhibit a high level of coordination of enzymes and are highly 
efficient in controlling the metabolism in the cytoplasm [17]. The three-dimensional organization 
can help concentrate reactants to avoid unfavorable reactions, to remove inhibitory products and 
to channel metabolites from one enzyme to the next [18, 19]. Many instances of multi-enzyme 
complexes are known, two distinguished examples include the pyruvate dehydrogenase complex 
(PDH) and the electron transport chain (ETC). PDH is a large multi-enzyme complex with three 
enzymes and five cofactors, it oxidizes pyruvate to generate acetyl-coA [20, 21]. ETC plays a 
major role in aerobic respiration, it is a multienzyme complex constituting five different enzymes 
[14, 22].  
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On the other hand, multifunctional enzymes are molecules, which contain multiple active sites and 
catalyze more than one enzymatic reaction. The distinction from multienzyme complexes is that 
the subunits are not found as discrete enzymes [23]. Multienzyme complexes are products of more 
than one gene, while a single gene gives rise to a multifunctional enzyme. For example, 
Tryptophan synthase is a dimeric bifunctional enzyme which shows substrate channeling [24]. 
Interestingly, fatty acid synthase exists both as a multienzyme complex and as a multifunctional 
enzyme. The fatty acid synthase (FAS) type 1 in yeast is encoded by two genes, and forms a stable 
α6β6 dodecameric multienzyme complex [25, 26] while mammalian type-1 fatty acid synthase, 
encoded by a single gene, forms an α6 hexamer [26, 27].  
When several enzymes compete for the conversion of the same metabolite, the multifunctional 
enzymes or multienzyme complexes may come to rescue. Some have been shown to transfer the 
substrate directly from one enzyme to another and to regulate the reaction [24]. These 
multifunctional enzymes can thus facilitate efficient substrate channeling and/or the metabolic 
regulation. These enzymes are critical for the communication and cooperation between different 
functions and pathways within a complex cellular system or between cells [28]. Already the 
proximity of catalytic sites can facilitate substrate sequestration, as suggested for folate 
biosynthesis [29, 30]. 
In the field of multifunctional enzymes, knowledge is still rather limited. The recent genome 
sequencing projects have helped in adding new candidates to the repertoire. For example, 23 
bifunctional enzymes have been reported in plants [29]. Now with the improvement in 
crystallographic techniques, SAXS and cryo EM, it is a great time to study the complex 
multifunctional enzymes and multienzyme complexes. 
The shikimate pathway is abundant with various multifunctional enzymes with different domain 
fusions [31-37]. Before discussing the various multifunctional enzymes in the shikimate pathway, 
I will describe shikimate pathway itself. 
1.3. The Shikimate Pathway: Overview 
Aromatic amino acids such as Trp, Tyr and Phe, are essential for protein biosynthesis in all living 
organisms. In addition, derivatives of aromatic compounds such as para-aminobenzoic acid 
(PABA), vitamin K, and ubiquinone are required for the metabolism of all organisms [38]. The 
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seven-step shikimate pathway, shown in Figure 1.1, catalyzes the synthesis of a precursor of 
aromatic compounds in microbes and plants [39, 40]. 
The first compound to be discovered from this pathway was shikimic acid (shikimate, SKM), from 
the plant Illicium religiosum (aniseed) in 1885. The Japanese name of this plant is shikimi-no-ki, 
hence the pathway was named the “shikimate pathway” [41, 42]. As shown in Figure 1.1, the 
precursor of aromatic amino acids, chorismate (CHM) is formed in a seven-step reaction, starting 
from two carbohydrate precursors, D-erythrose-4-phosphate (E4P) and phosphoenolpyruvate 
(PEP). Thereupon, this pathway is a link between the carbohydrate metabolism and the aromatic 
amino acid metabolism [39]. The synthesis of aromatic amino acids branches at CHM, one branch 
leading to Trp through anthranilate, while the other branch leads to Phe and Tyr through prephenate 
(Figure 1.2) [40, 43]. In addition, the aromatic amino acids are precursors of the neurotransmitters 
serotonin, dopamine, epinephrine, and norepinephrine. Industrially, Phe is used for the production 
of the artificial low-calorie sweetener aspartame and SKM serves as the starting material for the 
production of the neuraminidase inhibitor osaltamivir, produced by Roche under commercial name 
Tamiflu ® [44-47]. Some organisms utilize as much as twenty percent of the carbon derived from 
the carbohydrate catabolism in the shikimate pathway [48].  
 
Figure 1.1. The shikimate pathway. The figure shows a schematic representation of seven steps of the 
shikimate pathway enzymes. The enzymes names are abbreviated and the gene names are shown in bold. 
Glyphosate, which inhibits the penultimate step in the pathway, is also shown. 
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The molecular organization and architecture of the shikimate pathway enzymes differs markedly 
between different taxonomic groups [49], with a differential distribution of the shikimate fusion 
genes, both in prokaryotes and eukaryotes [35]. With a few exceptions [34, 50-52], the enzymes 
of the plant shikimate pathway are similar to their prokaryote homologues. Most of the plant 
enzymes function in plastids, and thus usually contain a plastid transit peptide [32, 33, 35, 39, 53-
57].  
Animals lack the shikimate pathway enzymes, and must obtain aromatic compounds through diet 
[38, 39, 43, 58, 59]. Henceforth, the shikimate pathway is a classical drug target [38, 39, 43, 60-
63]. Inactivation of the shikimate pathway genes results in a weakened virulence and a decreased 
survival in a variety of microorganisms [36, 37, 64, 65] including Mycobacterium tuberculosis 
[66] and Salmonella typhimurium [67]. Various drug-screening studies have been carried out on 
M. tuberculosis shikimate pathway enzymes [68-75].  
5-enolpyruvylshikimate-3-phosphate (EPSP) synthase (AroA) of the shikimate pathway is 
inhibited by the broad-spectrum, nonselective herbicide glyphosate (GLP) [N-
(phosphonomethyl)glycine], (Roundup®) [43]. GLP based growth inhibition is a routine test for 
the presence of a shikimate pathway. For example, the presence of the shikimate pathway was 
confirmed in the phylum of Apicomplexa, when treatment with GLP could inhibit the growth of 
Toxoplasma. gondii, Plasmodium falciparum and Cryptosporidium parvum [76]. 
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Figure 1.2 Biosynthesis of aromatic compounds from the shikimate pathway: The figure shows the 
various aromatic compounds that can be synthesized from CHM, which is a product of the shikimate 
pathway. (Adapted from [32, 36]) 
1.4. Examination of seven enzymes of the Shikimate Pathway 
In most prokaryotes, well-characterized monofunctional enzymes carry out all the steps of the 
pathway. However, in eukaryotes, several enzymes of the pathway are fused to form various 
multifunctional assemblies, such as the pentafunctional AROM complex in fungi and 
Apicomplexans (Section 1.5.1.) [77-79], a bifunctional AroDE in plants [33], and a tetrafunctional 
AroN in Acanthamoeba [37]. Only the crystal structure of the five enzymes constituting the 
AROM complex are described here. 
In the following sub-sections all the enzymes are addressed by their gene names and are called 
Aro-, as shown in Figure 1.1, while the AROM complex is called as such. The names of substrates 
are also abbreviated as shown in the Figure 1.1. 
1.4.1. 3-Deoxy-D-arabinoheptulosonate-7-phosphate synthase (DAHPS) 
(EC 2.5.1.2.54) 
3-Deoxy-D-arabino-heptulosonate7-phosphate synthase (DAHPS) catalyzes the first committed 
step of the shikimate pathway, an aldol condensation of phosphoenolpyruvate PEP and E4P to 
produce DAHP (Figure 1.3) [38, 39, 43, 80]. DAHPSs are metalloenzymes, and require divalent 
cations such as Mn2+ or Fe2+ for their activity [43, 81, 82]. The reaction mechanism involves the 
nucleophilic attack of a water molecule on the C2 position of PEP followed by the addition of C3 
of PEP to C1 of arabinose-5-phosphate [38, 83].  
 
Figure 1.3. DAHPS reaction 
DAHPSs can be classified into two unrelated types, type I and type II. The two types share less 
than 10% sequence identity. The overall fold, the residues that interact with PEP and the divalent 
metal ion are completely conserved and are almost identically positioned in the two types [84]. 
17 
 
Type II enzymes were first observed in plants [85], and later in a few microbial species including 
M. tuberculosis and Helicobacter pylori. [84, 86].  
Most of the microorganisms with type I DAHPS have three isozymes, which are classified based 
on their sensitivity to feedback inhibition by one of the three aromatic amino acids. The three 
isoforms are AroF (Tyr-DAHPS), AroG (Phe-DAHPS), and AroH (Trp-DAHPS) [40, 87]. AroG 
is the major isozyme found in microorganisms, and constitutes 80% of the total DAHPS activity, 
while AroF and AroH constitute 20% and 1%, respectively. These enzymes share about 40% of 
sequence identity with each other [38, 88]. 
1.4.2 3-Dehydroquinate synthase (EC 4.2.3.4)  
Dehydroquinate (DHQ) synthase, (AroB) catalyzes the second enzymatic step of the shikimate 
pathway. It converts DAHP to DHQ (Figure 1.4) in five steps. The five steps are alcohol oxidation, 
phosphate elimination, carbonyl reduction, ring opening and intramolecular aldol condensation. 
They are all catalyzed by a single active site. The enzyme requires NAD and a divalent cation such 
as Zn2+ or Co2+ [38, 39, 43, 89, 90] (Figure 1.4). The enzyme avoids undesirable side products by 
providing a potential conformational template in the final steps [39, 57].  
 
Figure 1.4. AroB reaction 
The crystal structure of AroB from Aspergillus nidulans (PDB ID: 1DQS) is demonstrated in 
Figure 1.5. It shows that AroB exists as a functional homodimer containing two AroB subunits. 
Each monomer of AroB can be divided into two subdomains. First, is the N-terminal α/β domain 
consisting of a seven-stranded β-sheet, which constitutes the Rossmann fold and serves as NAD-
binding site. The orientation of NAD is on the opposite side of the sheet to that seen in all other 
known Rossmann type NAD-binding proteins. The C-terminal domain is α-helical and contains 
most of the residues involved in catalysis and in substrate and Zn2+-binding. The mechanism of 
phosphate elimination requires Arg 130 (colored pink sticks, Figure 1.5) from the other monomer 
along with other residues [61]. Bacterial AroB is a monofunctional enzyme. The comparison of 
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crystal structures of bacterial (S. aureus) [91] and fungal AroB show that the overall structure of 
the closed-form is identical in both proteins [92]. 
 
 
Figure 1.5 Cartoon representation of AroB homodimer (from Aspergillus nidulans PDB ID: 1dqs): 
The figure shows the crystal structure of the AroB homodimer in complex with NAD Zn2+ and 
carbaphosphonate. The complete homodimer is shown on the left, and the two identical monomers are 
colored in two different colors, pink and light brown. The N and C termini are marked as N and C. One 
monomer is zoomed on the right and its two constituting domains are highlighted in different colors. The 
orange color shows the N terminal domain containing the Rossmann fold, which comprises β3-β6, and α2-
α5. The Arg 130, which extends contact to the other monomer, is shown as sticks (circled). Zn2+ atoms are 
shown as balls, NAD is shown in black and inhibitor carbaphosphonate is shown in yellow. 
1.4.3 3-Dehydroquinate dehydratase (EC 4.2.1.10) 
Dehydroquinate dehydratase (AroD) catalyzes the third reaction in the shikimate pathway (Figure 
1.6.), which is the dehydration of DHQ to dehydroshikimate (DHS) introducing the first double 
bond in the ring [43]. 
 
Figure 1.6. AroD reaction 
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This reaction is common to both the biosynthetic shikimate pathway and the catabolic quinate 
pathway [40, 93]. AroDs can be divided into two types, AroDI and AroDII [39]. AroDI is primarily 
found in plants, fungi and many bacterial species, including E. coli [94] or S. typhi [95, 96], and is 
exclusively involved in shikimate pathway [94]. In contrast, AroDII can engage in both pathways, 
and is found in the shikimate pathway of M. tuberculosis [96, 97], S. coelicor [98] and H. pylori 
[99]. AroDII participates in the quinate pathway in fungi, which utilize quinate as an energy source 
[60, 100, 101]; it performs a dual function in A. methanolica, which can grow on QUN but not on 
SKM [102]. The two types do not share sequence or structural similarity. AroDI functions as a 
homo-dimer, and catalyzes a syn-elimination of water using a covalent imine intermediate. AroDII 
is active as a homo-dodecamer, and catalyzes an anti-elimination of water, with an enolate 
intermediate. The two enzymes are the result of convergent evolution [103-111]. 
The crystal structure of AroDI from Salmonella enterica is shown in Figure 1.7 (PDB ID: 3M7W) 
[112]. AroDI is a physiological homodimer containing an eight-stranded α/β-barrel forming a TIM 
barrel fold [113]. with an additional “N”-terminal anti-parallel β-sheet region, which restricts the 
substrate entry from one side and finally a flexible lid (LD) that closes on substrate binding [114]. 
 
Figure 1.7. Cartoon representation of AroDI (from Salmonella enterica PDBID: 3M7W): The figure 
shows the crystal structure of the complete homodimer of AroDI, the two identical monomers colored yellow 
and gray. The N and C termini are marked as N and C. One monomer is shown completely in yellow, except 
for the red lid domain (LD). LD, is in closed confirmation as DHQ (pink sticks) is bound. For the second 
monomer, the N terminal antiparallel β- sheets domain (NTD) is shown in yellow, while the TIM barrel is 
shown in gray.  
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1.4.4 Shikimate dehydrogenase (EC 1.1.1.25) 
Shikimate dehydrogenase (AroE) catalyzes the fourth step in the shikimate pathway. It catalyzes 
the reduction of DHS to SKM using NADPH (Figure 1.8). The reaction involves an acid base 
metabolism [38, 115]. AroE activity is reported in four enzyme classes: AroE, ydiB, SDH-like 
(SdhL), and AroE-like1 (ael1) [115]. ydiB is a NAD dependent quinate/shikimate dehydrogenase 
[100, 116]. SdhL from H. influenzae, catalyzes the oxidation of SKM with a much lower turnover 
rate than AroE [117, 118], and ael1 is a recently annotated, functionally distinct SDH subclass that 
binds SKM with high affinity and exhibits measurable activity with quinate [118].  
 
 
Figure 1.8. AroE reaction 
The structure from Helicobacter pylori (PDB ID: 3PHI) is illustrated in Figure 1.9, it possesses 
two structural domains: a catalytic domain and an NADPH binding domain [38]. The domain 
structure is characteristic of NAD(P)H binding domains in dehydrogenases [119, 120]. Various 
AroE sequences also contain two strictly conserved cis-peptide prolines existing in a sharp turn 
linking a β -strand and the following α-helix [119]. 
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Figure 1.9. Cartoon representation of AroE (from Helicobacter pylori PDBID: 3PHI): The figure shows 
the crystal structure of AroE in two colors. The N and C termini are marked. SKM is shown in red as sticks; 
NADPH is shown as orange sticks. The catalytic domain is shown in blue, and NADPH binding domain is 
shown in orange.  
1.4.5 Shikimate kinase (EC 2.7.1.71) 
Shikimate kinase (AroK/SK) catalyzes the fifth enzymatic step, the phosphorylation of the C3-OH 
group of SKM to yield shikimate-3-phosphate (S3P) by utilizing ATP as a co-substrate (Figure 
1.10) [38, 39, 44]. AroK requires a divalent cation such as Mg2+ for its activity [121].  
 
Figure 1.10. AroK reaction 
In E.coli, SK is present in two isoforms, AroL and AroK, both of which are monomers of 19.5 
kDa and contain a type A Walker motif, and share 34% sequence identity [122-125]. Both isoforms 
catalyze the same reaction in vitro but AroL has almost 100 times greater affinity for SKM than 
AroK [125]. Different plant species have a variable number of isoforms, such as three in O. sativa 
(rice), two in A. thaliana and one in tomato [57, 126-128].  
The SK crystal structure from M. tuberculosis (PDBID: 1U8A) is described in Figure 1.11. AroK 
belongs to the Nucleoside Monophosphate (NMP) kinase family and constitutes an α/β/α fold with 
a central five stranded parallel β-sheet flanked by eight α-helices. AroKs are subdivided in three 
domains: Core domain (CD), LID domain (LD) and Nucleotide/SKM binding (SB) domain [129-
134]. The core domain includes the central five stranded parallel β-sheet flanked with helices and 
contains the highly conserved P-loop characteristic of NMP kinase family [135]. The SB domain 
consists of highly conserved residues involved in SKM binding. The structure comprises three 
functional motifs, Walker A-motif (P-loop), Walker B-motif and the Adenine binding motif (A-
loop) [129-134]. 
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Figure 1.11. Cartoon representation of AroK (from M. tuberculosis PDBID: 1U8A): The figure shows 
the crystal structure of AroK with SKM and ATP bound. N and C termini are marked. The LID (LD) (maroon) 
connects α6 and α7; the substrate binding (SB) (green) domain consists of α2, α3 and the N-terminal half 
of α4; and the CORE (gray) constitutes the central five-stranded parallel β-sheet flanked with remaining 
αhelices. SKM is shown as red sticks, while ATP is shown as turquoise sticks. 
1.4.6 5-enolpyruvylshikimate-3-phosphate (EPSP) synthase (EC 2.5.1.19)  
5-enolpyruvylshikimate-3-phosphate (EPSP) synthase AroA catalyzes the sixth and penultimate 
step of the shikimate pathway (Figure 1.12). In a reversible reaction, it transfers the enolpyruvyl 
moiety of PEP to the 5-OH position of S3P, and forms EPSP and inorganic phosphate [38, 43]. In 
the reaction C-O bond cleavage of PEP, exchange of the vinylic protons of PEP occurs [38, 136-
138]. This reaction is one out of only four described reactions that catalyze a C-O bond cleavage 
of PEP instead of a high-energy P-O bond (14.8 kcal/mol). 
  
 
Figure 1.12 AroA reaction 
The other three include the drug target Mur A (UDP-N-acetylglucosamine enolpyruvyl transferase) 
which catalyzes the transfer of 3-OH of PEP to UDP-N-acetylglucosamine (UDP-NAG) [71]; 3-
Deoxy-D-manno-octulosonate 8-phosphate (KDO8PS) [139]; and 3-deoxy-D-arabino-
heptulosonate 7- phosphate (DAHP) synthase (DAHPS) [38]. 
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The nonselective, broad-spectrum herbicide glyphosate [N- phosphonomethyl)glycine,] (Roundup 
® Monsanto) acts as a competitive inhibitor of PEP, competing for the same binding site as of PEP, 
which is very close to S3P [38, 39, 43, 140, 141]. Glyphosate is the only herbicide to target AroA 
[142]. Based on interaction with glyphosate, AroA enzymes are classified into two classes; 
glyphosate-sensitive class I AroA and relatively glyphosate resistant class II AroA. Class I 
includes plants and most bacteria, including E. coli; whereas some bacteria, such as Agrobacterium 
sp. strain CP4 form class II, are naturally glyphosate resistant and therefore used to engineer 
glyphosate resistant crops [43, 141]. Figure 1.12 shows the crystal structure of AroA from Coxiella 
burnetii bound to S3P and Glyphosate (PDB ID: 3SLH) [143].  
 
Figure 1.13. Cartoon representation of AroA (from Coxiella burnetii PDBID: 3SLH): The figure shows 
the crystal structure of AroA with SKM, S3P and Glyphosate bound. N and C termini are marked. One 
domain is shown in gray, while the other one in purple. SKM is shown as red sticks; S3P is shown as brown 
sticks, and GLP is shown as pink sticks.  
The AroA monomer consists of two similar globular domains, an upper and a lower domain, in an 
open or closed conformation depending on the liganded state. Both the N and C termini of the 
protein chain are located in the lower domain. Both the domains are remarkably similar, 
comprising three copies of a βαβαββ-folding unit [144]. The active site lies in the cleft between 
the two domains [38]. Glyphosate binds adjacent to S3P in the PEP-binding site, thereby 
mimicking an intermediate state of the ternary enzyme–substrates complex [140]. 
1.4.7 Chorismate synthase (EC 4.2.3.5)  
Chorismate synthase (AroC) catalyzes the seventh and final step of the shikimate pathway (Figure 
1.14). It catalyzes the trans-1, 4 elimination of phosphate from EPSP (introducing the second 
double bond in the ring) to yield CHM [38, 39, 43]. The reaction requires reduced flavin (FMN) 
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as a cofactor for activity even though the overall reaction is redox neutral as AroB [38, 39, 43, 90, 
145-150]. 
 
Figure 1.14. AroC reaction 
AroCs exist with or without a flavin reductase activity. Monofunctional enzymes, which are 
usually present in bacteria and plants, do not contain a flavin reductase activity and require reduced 
FMN. The bifunctional enzymes carry a flavin reductase activity and, therefore, can reduce FMN 
either using NADPH in fungi or using NADH in M. tuberculosis [39, 43, 151]. Monofunctional 
AroC from E.coli is only active anaerobically while the bifunctional enzymes from N. crassa are 
active aerobically [152, 153]. The AroC from B. subtilis forms a heterotrimeric complex with a 
flavin reductase and AroB and is not active in absence of flavin reductase [153, 154]. 
1.5 Multifunctionality in the shikimate pathway 
Various fusion enzymes are seen in the shikimate pathway (section 1.4) but only the bifunctional 
AroDE found in plants has been characterized structurally and functionally [33]. The crystal 
structure of AroDE and its possible implications are discussed in the first sub-section. Many 
attempts have been made to study the architecture and possible role of the pentafunctional AROM 
complex. Therefore, a short history of the AROM complex is given in the following sub-section. 
This section ends with a comparison between the different types of fusion enzymes found in the 
shikimate pathway. 
1.5.1 Bifunctional dehydroquinate dehydratase-shikimate dehydrogenase 
(AroDE) 
Bifunctional dehydroquinate dehydratase-shikimate dehydrogenase (AroDE) is the bifunctional 
enzyme carrying out the third and fourth enzymatic reactions in the shikimate pathway. The 
reactions include (a) the dehydration of DHQ to DHS to introduce the first double bond in the ring 
and (b) the reversible reduction of DHS into SKM using NADPH [43].  
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The substrate DHQ can also be employed as a substrate for the quinate pathway and hence the 
presence of AroDE can target DHQ to the shikimate pathway [29, 33, 155] [29, 33, 160]. The ratio 
of turnover rates of E:D have been reported to be around 9:1, thus, DHS is not accumulated but 
readily converted to SKM, which increases metabolic flux through the shikimate pathway [87, 
156]. 
Singh et al, [33] reported the crystal structure of AroDE from A. thaliana. (Figure 1.10). The 
structure contains a type I AroD enzyme, with a missing β hairpin, which caps one opening of the 
β barrel. They further proposed that the concave architecture of the enzyme would facilitate the 
transfer of DHS to the E site by increasing the local, effective concentration of DHS at the E site 
[33] (Figure 1.10).  
 
Figure 1.15. Cartoon representation of bifunctional AroDE (PDB ID: 2O7S): The figure shows the 
crystal structure of bifunctional AroDE bound to DHS and NADPH. The N and C termini are marked as N 
and C. D domain is shown in yellow, while E domain is shown in blue, DHS is shown in pink and NADPH 
is shown in orange sticks. Due to the proximity of active sites, this enzyme can facilitate substrate 
channeling.  
1.5.2 History of AROM complex  
In eukaryotes, reactions two to six of the shikimate pathway (conversion of DAHP to EPSP), are 
catalyzed by a single polypeptide called the multifunctional AROM complex [38, 39]. In the 
1960s, an N. crassa auxotrophic mutant strain Y7655a (aromatic-less: arom), was identified. It 
could not grow in the presence of SKM, but required phenylalanine, tryptophan, tyrosine and 
PABA for its growth [157]. In 1967, Giles et al, through complementation analysis, identified that 
this mutant lacks the arom gene cluster. The gene order was BDEKA, and it encoded one protein, 
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catalyzing five different activities, [158]. Phylogenetic studies suggest that the AROM-gene fusion 
was an innovation likely to have been present in the progenitor of modern eukaryotes, retained in 
many lineages, now known to constitute the zygomycete, basidiomycete, and ascomycete fungi, 
apicomplexa, ciliates, and oomycetes [35, 62].  
The early attempts to purify the AROM complex resulted in protein fragments ranging from 165 
kDa to 300 kDa [78, 79, 159-162]. The first nucleotide sequence of arom locus from A. nidulans 
showed a single open reading frame and absence of introns [163].  
Using glyphosate based growth inhibition; the shikimate pathway was shown to be present in the 
phylum of Apicomplexans [76]. Apicomplexa are a phylum of diverse obligate intracellular 
parasites including Plasmodium spp., (malaria), Toxoplasma gondii (toxoplasmosis) and various 
opportunistic pathogens of immunocompromised individuals [164]. Bioinformatic analysis has 
also revealed the presence of the AROM complex in T. gondii [36]. Peek et al, have characterized 
the monofunctional E domain of T. gondii, where it catalyzes the NADP+-dependent oxidation of 
SKM and is sensitive to AroE inhibitors [165]. Recently, a novel arrangement of gene fusions has 
been discovered in A. castellani AroBAKD, (called AroN) with the E domain fused to two other 
genes (Figure 1.16) [37].  
Despite the discovery in 1967, owing to its large size and labile nature, the structural and kinetic 
study of the complete AROM complex has been difficult. The few hypotheses for the existence of 
AROM complex include substrate channeling [164], catalytic facilitation [166], and co-ordinated 
production of all five enzymes [77, 167].  
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Figure 1.16. Various arrangements of steps two to five in shikimate pathway: The figure shows the 
various arrangements possible giving rise to different fusion proteins in shikimate pathway. Each taxonomic 
group is shown with one example organism. The small line before A. thaliana enzymes represents the 
plastid transit signal. IGPS is Indole-3-glycerol-phosphate synthase and PRPI is phosphoribosylanthranilate 
isomerase (Adapted from [37]).  
To summarize the multifunctionality in the shikimate pathway, Figure 1.16 shows the various 
arrangements of the shikimate pathway enzymes. 
1.6. Rosetta stone approach for predicting protein-protein interactions 
1.6.1 The Rosetta stone 
The Rosetta stone aided in the understanding of Egyptian hieroglyphics (Figure 1.17). It is a black 
basalt stone, discovered in 1799, near the town of Rosetta. It was engraved during the Ptolemaic 
Empire at Memphis, Egypt in 196 BC. The carved text contains three different versions of ancient 
writing, by priests honoring the king of Egypt, Ptolemy V. The top and the middle texts are 
in Ancient Egyptian using hieroglyphic script and Demotic script, respectively, while the bottom 
is in Ancient Greek. Remarkably, the Greek passage disclosed that the three scripts had a similar 
meaning [168]. Thus, it solved the riddle of hieroglyphics, a written language that had been “dead” 
for thousands of years. 
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Figure 1.17. The Rosetta stone: The figure shows the Rosetta stone with the same text written on it in 
three different languages. The first two texts are in Egyptian while the third one is in Greek. (Adapted from 
[169]). 
1.6.2 Protein-Protein Interactions 
Marcotte et al, coined the term Rosetta stone method for a computational method, to deduce 
protein-protein interactions from the genomic sequences based on the observation that some pairs 
of interacting proteins have homologs in another organism fused into a single protein chain [170]. 
This method identifies gene-fusion events in complete genomes [171], and predicts functional 
linkage for protein domains that exist both as fusions and as free polypeptides [172]. It helps in 
linking distinct proteins together, and suggests the tendency of functional interactions between the 
linked entities, describing local and global relationships within the proteome [173]. The method is 
illustrated in Figure 1.18. 
  
 
Figure 1.18. The Rosetta stone approach for predicting protein-protein interactions: The top panel 
shows the principle of the Rosetta stone sequence containing the fusion domains, which are homologous 
to two separate sequences in other species. The bottom panel shows the example of the fused sequence 
of TrpC in the E. coli genome, which would inform us that the yeast proteins TrG and TrpF are functionally 
linked, if it was not known that they both catalyze steps in the biosynthesis of tryptophan. (Adapted from 
[179]) 
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1.6.3. Rosetta-stone proteins in the Shikimate Pathway: Objectives of this 
study 
Substantial progress has been made regarding the kinetic mechanisms of individual 
monofunctional enzymes, but our understanding of multifunctional enzymes and interenzyme 
interactions of transient complexes is rather limited. Owing to their short-lived nature, transient 
complexes are hard to grasp for structural and functional characterization. Therefore, we exploit 
“Rosetta-stone” proteins as permanent equivalents of transient complexes. With various 
multifunctional fusion enzymes present, the shikimate pathway serves as an ideal model system to 
decipher the potential transient interactions in different organisms. Most remarkable is the 
pentafunctional AROM complex in fungi, apicomplexans and some protists comprising the central 
five steps of the pathway. In addition, other multifunctional enzymes include various bifunctional, 
trifunctional and tetrafunctional fusion enzymes in many organisms.  
These different fusions give rise to many questions, such as do the individual enzymes of the 
shikimate pathway organize to form higher order assemblies during catalysis? If so, do these 
assemblies vary in different organisms or do they form similar higher order assemblies? To answer 
these questions we hypothesize that the individual enzymes of the pathway form transient 
complexes, resembling the AROM complex, for efficient substrate funneling and regulation, 
during their catalytic cycles. The AROM complex could therefore be the Rosetta-stone of the 
shikimate pathway.  
With this in mind, the following objectives were designed. First, we want to characterize the 
different bifunctional enzymes and the AROM complex functionally, to test for the existence any 
inter-domain allosteric regulation. Second, we want to characterize the bifunctional enzymes and 
the AROM complex structurally, to examine the inter-domain organization. Third, with the 
redundant sets of crystal structures of several natural bifunctional enzymes we want to examine 
the Rosetta stone hypothesis and explore possible higher order assemblies in silico. Finally, we 
want to study the pentafunctional AROM complex and compare the structural and functional 
properties of the AROM complex to the in silico assemblies. The gained knowledge will not only 
help in understanding the shikimate pathway but shall also help to understand how and to which 
extent the individual enzymes of metabolic pathways are generally organized into transient higher 
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order assemblies. Furthermore, it may help in the development of drugs targeting protein 
interactions, and inspire new approaches in metabolic engineering. 
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2. Materials and Methods 
2.1 Materials 
The chemicals for preparing the buffers and for protein purification were from the general stock 
available in the department. The following chemicals were used specifically for this project (Table 
2.1) 
Table 2.1 List of chemicals used in this project 
Name Product name Company & lot no. 
SKM Shikimic acid S5375 Sigma-Aldrich 
S3P 3-phosphoshikimic acid lithium salt 55385 Sigma-Aldrich 
DHQ 3-Dehydroquinic acid potassium salt 96401 Sigma-Aldrich 
DHS 3-Dehydroshikimic acid 05616 Sigma-Aldrich 
DAHP 3-Deoxy-D-arabinoheptulosonic Acid 7-Phosphate 
Disodium Salt 
D232050 Toronto Research 
Chemicals 
NAD β-Nicotinamide adenine dinucleotide hydrate N7004 Sigma-Aldrich 
NADP β-Nicotinamide adenine dinucleotide 2′-phosphate 
disodium salt 
N0505 Sigma-Aldrich 
NADH β-Nicotinamide adenine dinucleotide reduced 
tetrasodium salt hydrate 
N8129 Sigma-Aldrich 
NADPH β-Nicotinamide adenine dinucleotide 2′-phosphate 
reduced tetrasodium salt hydrate 
N201500 Toronto Research 
Chemicals 
ATP Adenosine 5′-triphosphate disodium salt hydrate A26209 Sigma-Aldrich 
ADP Adenosine-5'-diphosphate monosodium salt 02150260 MP Biomedicals 
PEP Phospho(enol)pyruvic acid trisodium salt hydrate P7002 Sigma-Aldrich 
GLP Glyphosate, PESTANAL® 45521 Sigma-Aldrich 
PK/LDH Pyruvate Kinase/Lactic Dehydrogenase enzymes from 
rabbit muscle 
P0294 Sigma-Aldrich 
 
2.2. Bioinformatic Methods  
Pymol was used for visualization and generating pictures [174]. Adobe illustrator was used to 
design the final pictures. 
2.2.1. Cluster map of the shikimate kinase gene fusions 
AroK homologs from archaea, bacteria and eukaryotes, were searched in the non-redundant 
protein sequence database (nr 70), employing two iterations of jackHMMER at default settings 
[175]. E. coli AroK was used as the seed for the first iteration. The resulting sequences were 
clustered in CLANS to generate a two-dimensional map. CLANS (CLuster ANalysis of 
Sequences), is a java based application, which adopts the Fruchterman-Reingold graph layout 
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algorithm to visualize pairwise sequence similarities in either the two-dimensional or the three-
dimensional space [176].  
2.2.2. In silico models 
In silico models based on AroEK and AroKE were built using the secondary-structure matching 
(SSM) algorithm in Coot [177]. 
2.3 Common Biochemical and Biophysical methods 
2.3.1. Cloning, Protein Expression and Purification 
The cloning of each gene is described in later sections. All resulting clones were first analyzed 
with colony PCR, and confirmed by gene sequencing using T7 forward and reverse primers. The 
BigDye ™ Terminator v3.1 Cycle Sequencing Kit was employed for sequencing. Sequencing was 
carried out in house, with the help of an Applied Biosystems 3730XL DNA Analyzer.  
Unless otherwise stated, all the proteins were expressed as C-terminal fusions with a hexa-His tag. 
BL21(DE3) cells and a temperature of 37 ºC were used for protein expression. 5-mL cultures were 
grown for analytical purposes, while 6-liter cultures were grown for preparative purifications. An 
overnight starter culture, from a single colony was grown in the lysogeny broth (LB) medium with 
appropriate antibiotic(s). 
The cultures were grown until an OD600 of 0.6, and were induced with a final concentration of 1 
mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and expressed for four hours. Expression was 
analyzed on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). If needed 
in future, the cell pellet was flash frozen in liquid nitrogen and stored at -80 °C. Protein purification 
was carried out using immobilized metal ion affinity chromatography (IMAC) [185], followed by 
gel filtration chromatography [186]; performed on Aekta protein purification systems (GE 
Healthcare). 
The cell pellet was suspended in 50 mL buffer containing 50 mM Tris-HCl pH 8.0, 300 mM NaCl 
(buffer A), a pinch of lysozyme, a pinch of DNase and a tablet of Roche cOmplete EDTA-free 
Protease Inhibitor Cocktail. The resulting mixture was lysed by sonication at 50 kHz for four 
minutes, 3 times with five-minute intervals followed by ultracentrifugation at 126000 X g rpm for 
50 minutes to remove the cell debris.  
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The supernatant was filtered through Millex filters 0.45 µM followed by 0.22 µM (Millex® 
SLHV033RS and SLGP033RS respectively). The filtrate was applied on 20 mL or 5 mL HisTrap 
HP columns (GE Healthcare).  
After loading, the column was washed thrice, first with buffer A, followed by buffer A 
supplemented with 22.5 mM imidazole and finally with buffer A supplemented with 45 mM 
imidazole respectively. A gradient elution was made with 45-200 mM imidazole over five column 
volumes. The fractions were analyzed by SDS-PAGE, pooled and dialyzed overnight in a buffer 
containing 20 mM Hepes or Tris (pH 8.0), 150 mM NaCl, 2 mM β-mercaptoethanol (β-ME) or 
Tris (2-carboxyethyl)phosphine hydrochloride (TCEP-HCl) (given separately for individual 
proteins). 
The dialyzed samples were concentrated to a final volume less than 5 mL using Merck 10/ 
30/50/100 kDa Amicon Ultra 15 mL centrifugal filters (depending on protein size). The 
concentrated sample was loaded onto a HiLoad Superdex 200 26/60 (S 200, 26/60) or HiLoad 
Superdex 75 26/60 (S 75, 26/60) column (depending on protein size, stated separately for 
individual proteins) (GE Healthcare).  
Gel filtration was performed in the dialysis buffer mentioned above. Fractions containing the 
active protein were pooled, and concentrated to the required concentrations; aliquots were frozen 
in liquid nitrogen and stored at -20 °C until needed. 
2.3.2 Circular Dichroism 
A JASCO J-810 spectropolarimeter was used to measure the CD spectra from 250-200 nm. Protein 
concentration was 0.3-0.5 mg/mL in 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM β-ME. 
Thermal denaturation curves over a temperature range of 20-95 °C with a gradient of 1 ºC/min 
were measured at 220 nm. 
2.3.3 Static Light Scattering 
Static light-scattering experiments were performed with 1 mg/mL protein (100 µL) in the sample 
containing buffer (discussed separately for individual proteins) using a GE Healthcare Superdex 
S75/S200 10/300 GL size-exclusion column connected to a Wyatt MiniDAWN Tristar Laser 
photometer and a JASCO RI-2031 differential refractometer. Wyatt ASTRA V software was used 
for data analysis. 
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2.3.4 Crystallization, crystal freezing, data collection 
The proteins were crystallized in the apo state in combination of various ligands. Initial screening 
was performed in 96-well sitting-drop plates (INTELLI-PLATE® 96 Well, Art Robins 
Instruments) using the various Qiagen crystal screens and the Morpheus screen (Molecular 
dimensions). The crystallization screens were set up using the crystallization robots Honeybee 963 
(Genomic Solutions) and mosquito® crystal (ttp labtech). The plates were stored at 20 ºC and 
imaged periodically for two months with a Rock Imager 182 (Formulatrix). 
The reservoir volume was 50 μl and the drops contained equal volumes of (250 - 550 nl) protein 
and reservoir solution. If optimization of crystallization conditions was needed, the 96-well sitting 
drop grid screens were set up using the dragonfly® screen optimization robot (ttp labtech).  
The crystals were picked up in a small (<1mm) circular loop. The loops were briefly transferred 
into a droplet of reservoir solution, which was supplemented with additional cryo-protectant as 
needed. This loop containing the crystal was flash-cooled and frozen in liquid nitrogen until the 
measurement. Unless otherwise stated, all the data was collected at the beamline X10SA of the 
Swiss Light Source (Villigen, Switzerland), using the PILATUS 6M hybrid pixel detector (Dectris 
Ltd.). The loop containing the crystal was mounted onto the goniometer at the beamline. The data 
was collected at 100 K and a wavelength of 1 Å.  
The detailed crystallization conditions, data collection, and refinement statistics are discussed 
separately for each protein.  
2.3.5 Crystal structure determination 
The diffraction data was analyzed, integrated and scaled employing the XDS program suite [178, 
179]. The structures of AroKB, AroEK and AroKE were solved using the automated molecular 
replacement, with the monofunctional homologs, in the program MOLREP (each case discussed 
individually in later sections) [180]. The structures were refined using Refmac5 [181, 182]. The 
rebuilding was carried out by using the program Coot [183]. The crystal structure solution of the 
AROM complex is discussed in section 2.7.7. 
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2.4 Methods – AroKB 
2.4.1 Cloning, Protein Expression and Purification 
The genes of AroKBs Collimonas fungivorans (Uniprot ID: G0AGG5) (Cf_AroKB), 
Acidiphilium multivorum (Uniprot ID: F0IYK0) (Am_AroKB), Granulibacter bethesdensis 
CGDNIH1 (Uniprot ID: Q0BUI8) (Gb_AroKB), Oxalobacter formigenes (Uniprot ID: C3X6K3) 
(Of_AroKB), were codon optimized for expression in E.coli from Eurofins and cloned into the 
pet22b vector with a C-terminal His tag using NdeI/XhoI restriction sites. Genomic DNA of 
Thermotoga maritima was used as a template to amplify and clone the genes encoding Tm_AroKB 
(Uniprot ID: Q9WYI3) into pet22b vector with a C-terminal His tag using NdeI/XhoI restriction 
sites and Tm_AroKKB in pET His-TEV-Nde-GFP (N-terminal hexa-His tag) using NdeI/BamHI. 
The Tm_AroKB construct was the basis for the construction of the salt bridge mutant, 
Tm_AroKB_SB (R195A, D315A) (C-terminal His tag), which was built using round the horn 
mutagenesis [184] (Appendix A.1.1-A.1.13). In addition, the Tm_AroKB construct was the basis 
for the construction of the FLAG tag containing Tm_AroKB at the N terminal (N-flag-
Tm_AroKB). This construct was also cloned with a C-terminal His tag in pet22b. 
Cf_AroKB, Am_AroKB), Gb_AroKB, Of_AroKB, Tm_AroKB and Tm_AroKB_SB were 
expressed in BL21 (DE3) at 37 °C, while Tm_AroKKB was expressed in BL21 (DE3) at 37 °C and 
BL21 (Gold) at 25 °C. The proteins were dialyzed in the buffer containing 20 mM Tris (pH 8.0), 
150 mM NaCl. S 200, 26/60 was employed for the gel filtration of Tm_AroKB and 
Tm_AroKB_SB; whereas S 75, 26/60 was used for Tm_AroK_KB. 
Due to the restriction sites, the Tm_AroKB and Tm_AroKB_SB contain the additional sequence 
Lys, Leu, Ala, Ala, Ala, Leu and Glu prior to the tag. The N-terminal His tag in the Tm_AroKKB 
was cleaved with TEV protease overnight. Tm_AroKKB and TEV protease were separated with an 
imidazole gradient; (the protein with no tag precedes the His tag bound TEV protease during 
elution). After the His tag cleavage, the Tm_AroKKB retained the additional Gly and His prior the 
first met of the protein sequence. 
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2.4.2. AroKB kinetics 
2.4.2.1 Kinetics for K domain 
K domain kinetics was studied for the Tm_AroKB and Tm_AroKB_SB. K domain was kinetically 
studied by coupling the release of ADP to the pyruvate kinase (PK) (EC 2.7.1.40) and lactate 
dehydrogenase (LDH) (EC 1.1.1.27) reactions. The SKM/ATP dependent oxidation of NADH was 
monitored at 340 nm (Ɛ = 6180 M-1 cm-1) [185]. 
The reaction was monitored in a final volume of 0.1 mL in 96 well-plates (Brand plates® 781662) 
in the Microplate Reader Synergy™ H4 Hybrid or the Synergy™ Mx Monochromator-Based 
Multi-Mode Microplate Readers at 30°C. The range of substrate (SKM/ATP) from 5.2 µM to 300 
µM was analyzed in 11 serially diluted concentrations. The reaction mixture consisted of 50 mM 
HEPES (pH 8.0), 100 mM KCl, 10 mM MgCl2, 0.5 mM ATP, 1.5 mM PEP, 0.3 mM NADH, 9 U 
of LDH, 6 U of PK, Tm_AroKB, and SKM. While quantifying ATP as a substrate, the range of 
ATP was varied in the same way, while SKM was kept at a concentration of 0.5 mM (adapted 
from [186, 187]).  
The serial dilutions of substrates were prepared manually in the reaction buffer, in a ratio of 2:3, 
the highest concentration being 300 µM. Tm_AroKB was added at the end to start the reaction, 
which was monitored at 340 nm for two hours. The experiments also included a no enzyme blank 
for each concentration, and a blank without any substrate.  
The same reaction was repeated in the presence of the substrates for B domain that is 20 µM of 
DAHP and NAD. Data analysis was carried out in Sigma plot, discussed in the results section. 
2.4.2.2 Kinetics for B domain 
B domain kinetics was followed by monitoring the phosphate release employing the, Enzcheck® 
phosphate release kit [188] and measuring the amount of phosphorylated MESG at 360 nm. The 
reaction was carried out at 30 °C. The activity was assayed in a final reaction mixture of 0.1 mL 
in 96-well plates (Brand plates ® 781662). 
For estimating DAHP, the reaction mixture contained 0.3 mM NAD, 0.2 mM Co2+, 0.2 mM 
MESG, 1U of PNPP and 10 nM Tm_AroKB and Tm_AroKB_SB. The range of DAHP from 2 
µM to 150 µM with 11 serially diluted concentrations was analyzed. The serial dilutions were 
prepared manually in the reaction buffer, in a ratio of 2:3, the highest concentration being 150 µM. 
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The reaction was monitored at 30 °C for two hours. While quantifying NAD as a substrate, the 
range of NAD was varied in the same way, while DAHP was kept at a concentration of 0.02 mM 
The same reaction was repeated in the presence of the substrates for K domain that is 20 µM of 
SKM and ATP. 
2.4.2.3 Data analysis 
The Michaelis-Menten model was used for the kinetic analysis. The initial velocity data obtained 
by varying the concentration of substrate [S] is fitted to the Michaelis-Menten (MM) equation (Eq. 
1) to yield maximal velocity values (Vmax) and the Michaelis constant (KM). The final Michaelis-
Menten (MM) curves were generated in SigmaPlot 12.3 (Systat Software, San Jose, CA, SPSS, 
Inc) using nonlinear regression analysis with the enzyme kinetics module of SigmaPlot 12.3. 
𝑣 = (𝑉max∗𝑆)/(𝐾M+𝑆) (1)  
In equation 1, S is the substrate concentration, Vmax is the maximal rate and Km is the substrate 
concentration at which the reaction rate is half its maximal value. Further, the turnover number kcat 
is the number of substrate molecules converted into product by an enzyme site in a unit time kcat/Km 
is the rate constant for the interaction of S and E [189-192]. An error of less than 20% was 
considered for this study. 
2.4.3 Pull down experiments for Tm_AroKB 
Tm_AroKB culture was ordered from DSMZ. The cells were resuspended in lysis buffer (50 mM 
Tris pH 8.0, 150 mM NaCl, 20 mM KCl, 0.5% Nonidet P-40, 5% glycerol, 1 mM PMSF, protease 
inhibitor, DNaseI). Samples were sonicated Sonifier (G. Heinemann), and centrifuged at 48,700 x 
g for 45 minutes at 4 ºC to clear the lysates. The supernatant was collected. Meanwhile, anti-FLAG 
M2 magnetic beads (Sigma) were washed three times with PBS for five minutes. Subsequently N-
flag-Tm_AroKB was coupled to the beads by incubating with the protein for 1hr at RT. Equal 
amounts of cell extract were mixed with coupled beads in binding buffer. 100 µL of the beads 
sample was used for each sample condition. Samples were incubated for four hours at 4 ºC with 
gentle mixing. After incubation, the resin bead was washed 3 times with 1 mL wash buffer (50 
mM Tris pH 8.0, 150 mM NaCl, 20 mM KCl, 0.5% Nonidet P-40) to remove non-specifically 
bound proteins. Target molecules were eluted by incubation of the beads with 200 µL of 0.1 M 
Glycine-HCl, pH 2.0 for 5 minutes with gentle shaking. The resulting sample was neutralized with 
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1 M Tris and loaded on an SDS gel, the mass spectrometric analysis was performed on a Proxeon 
Easy-nLC coupled to an LTQ-Orbitrap XL. The data were processed, using software version 
(1.5.1.0) and had a setting of 1% for the false discovery rate. 
2.4.4 Crystallization and crystal handling 
Crystallization was carried out both for Tm_AroKB and Tm_AroKB_SB. Table 2.2 lists the final 
crystallization conditions. To achieve bigger crystals, hanging drops containing 1.5 μl protein 
solution and 1.5 μl of reservoir solution over a reservoir of 500 μl were set up in EasyXtal plates 
(Qiagen). To study the activity of Tm_AroKB in crystalline state, the crystals were first soaked in 
2.2 M sodium carbonate and later with SKM and ADP for varying time intervals. 
Table 2.2 Crystallization and cryo conditions Tm_AroKB 
Sr.no. Protein name Protein buffer (PB) Conc. 
(mg/ml) 
Screen condition 
(SC) 
Ligands 10 
mM 
Cryo 
1 Tm_AroKB 
(sitting drop) 
20 mM Tris pH 8.0, 150 
mM NaCl 
30 (NH₄)₂SO₄ 
2.2 M 
CH3CO2K 
0.2 M 
SKM SC+30% 
glycerol 
2. Tm_AroKB_SB 
(sitting drop) 
20 mM Tris pH 8.0, 150 
mM NaCl 
30 (NH₄)₂SO₄ 
1.873 M 
CH3CO2K 
0.1 M 
SKM, NAD SC+30% 
glycerol 
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Table 2.3 Data collection and refinement of Tm_AroKB, Tm_AroKB_SB, and Tm_AroKB soaked with 
SKM and ATP 
Data set Tm_AroKB Tm_AroKB_SB Tm_AroKB soaked with SKM 
and ATP 
Wavelength (Å) 1 1 1 
Space group P3121 P3121 P3121 
Unit cell (Å) a = b = 129.53 , c 
= 87.24, α = β = 
90.0 º, ɣ = 120.0 
º 
a = b = 129.41, c 
= 87.25, α = β = 
90.0 º, ɣ = 120.0 
º 
a = b = 130.59, c = 87.83, α = β 
= 90.0 º ɣ =120.0 º 
A. Diffraction statistics 
Resolution 2.90 2.62 2.750 
No. of 
observations 
198638 407829 365220 
Completeness 99.8 (99.2) 99.8 (99.0) 99.9 ( 99.8) 
Redundancy 10.45 17.87 14.167 
I/sigma(I) 15.14 (1.88) 30.69 (8.05) 34.10 (3.24) 
R-meas (%) 11.8 (112.3) 6.1 ( 24.0) 6.7 (95.9) 
CC1/2 99.8 (84.2) 99.9 ( 98.9) 100 (89.0) 
B. Refinement statictics 
Monomers/ASU 1 1 1 
Resolution range 
(Å) 
50 - 2.9 50 - 2.62 50 - 2.75 
No. of unique 
reflections  
18051 24465 21682 
Rcryst (%) 23.87 25.53 24.02 
Rfree (%) 28.82 29.37 27.54 
Rms bond length 
deviation 
0.0057 0.0052 0.0054 
Rms bond angle 
deviation 
1.1810 1.1085 1.1416 
Ramachandran 
statistics (%) 
93.87/4.02/2.11 94.93/3.17/1.90 94.29/3.59/2.11 
 
2.4.5 Denaturation and renaturation 
Tm_AroKB was denatured in the presence of 6 M guanidinium chloride (GdnHCl). The resulting 
solution was loaded onto the 20 mL HisTrap HP column, in buffer A supplemented with 6 M 
GdnHCl. To refold the protein, on column refolding, was attempted using 50 mM Tris-HCl pH 
8.0, 300 mM NaCl, 2 M Arg (buffer B) over 30 column volumes. Further, the column was washed 
with imidazole and Tm_AroKB was purified in the presence of an imidazole gradient (Section 
2.1.2.1). 
The renaturation was also attempted by diluting the denatured Tm_AroKB ten times in the buffer 
containing 50 mM Tris (pH 8.0), 500 mM NaCl, 2 mM DTT at 4 °C (buffer C). 
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2.5 Methods- AroEK 
2.5.1 Cloning, Protein Expression and Purification 
Eubacterium biforme genomic DNA was used as a template to clone the gene encoding (Eb_AroEK) 
(Uniprot ID:B7C8I5) in pET His-TEV-Nco-GFP (N terminal His tag) using the restriction sites NcoI/XhoI. 
The AroEK gene from Faecalibacterium prausnitzii (Fp_AroEK) (Uniprot ID: C7H179) was codon 
optimized for expression in E. coli (Eurofins) and cloned in pet22b (C-terminal His tag) using NdeI/XhoI 
restriction sites (Appendix A.1.4). Owing to the restriction sites, the Fp_AroEK sequence 
contained additional Leu and Glu before the His tag.  
Eb_AroEK was expressed in BL21 (DE3) at 37 °C. Fp_AroEK was expressed in BL21 (DE3) at 
37 °C and in BL21 (pRare) at 25 °C. It was dialyzed in the buffer containing 20 mM Tris (pH 8.0), 
150 mM NaCl, 2 mM β-ME. Gel filtration was carried out using S 75, 26/60. 
2.5.2 AroEK kinetics 
Only the K domain kinetics for ATP was studied for Fp_AroEK in the same way as described for 
Tm_AroKB (section 2.4.2). 
2.5.3 Crystallization and crystal handling 
Crystals for Fp_aroEK of sufficient quality were obtained directly form the initial screen. Table 
2.4 lists the final crystallization conditions for Fp_AroEK. The data collection and refinement 
statistics are discussed in Table 2.6 together with Mb_AroKE. 
Table 2.4 Crystallization conditions of Fp_AroEK 
Protein  Protein buffer Conc. 
(mg/ml) 
Screen condition (SC) Ligands 
10 mM 
Cryo 
Fp_AroEK 
(sitting 
drop) 
20 mM Tris pH 8.0, 
150 mM NaCl, 2 mM 
β-ME 
20 Morpheus D10 
0.12 M Alcohols, 0.1 M Buffer 
3 (pH 8.5) 50% P3 
SKM SC+20% 
PEG 
200 
 
2.6 Methods- AroKE 
2.6.1 Cloning, Protein Expression and Purification 
Methanoplanus petrolearus genomic DNA was used as a template to clone the gene encoding 
Mp_AroKE (Uniprot ID: E1RGC9) in pET His-TEV-Nco-GFP (N terminal His tag) using the 
restriction sites NcoI/XhoI (Appendix 1.7.).  
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The AroKE gene from Methanoregula boonei Mb_AroKE (Uniprot ID: A7I8L9) was codon 
optimized for expression in E. coli (Eurofins) and cloned in pet22b (C-terminal His tag) using 
NdeI/XhoI restriction sites (Appendix 1.8). Owing to the restriction sites, the sequence contained 
the additional Leu and Glu before the His tag. 
The Mp_AroKE gene was expressed in BL21(DE3) cells both at 37 °C and 25 °C. Mb_AroKE 
was expressed in BL21 (DE3) at 37 °C and ArcticExpress cells at 10-12 °C. Mb_AroKE was 
dialyzed in the buffer containing 20 mM Tris (pH 8.0), 150 mM NaCl, 2 β-ME. Gel filtration of 
Mb_AroKE was carried out using S75, 26/60. 
2.6.2 Refolding studies of Mp_AroKE 
Mp_AroKE was exclusively found in the inclusion bodies. To solubilize the inclusion bodies, 
buffer A supplemented with different denaturants such as either 6 M GdnHCl or 8 M urea was 
added to the pellet obtained after the sonication and ultracentrifugation step. After solubilizing and 
ultra-centrifuging, the supernatant was loaded onto the 20 mL HisTrap HP column, and denatured 
Mp_AroKE was eluted with an imidazole gradient, in the presence of denaturants.  
In an attempt to refold, Mp_AroKE was serially dialyzed against the buffer containing 50 mM Tris 
(pH 8.0), 150 mM NaCl, 2 mM DTT, GdnHCl / urea and 2 M Arg at 4 °C, while the concentrations 
of the denaturants and Arg were decreased at each step.  
Another attempt to refold the protein was carried out by diluting the denatured Mp_AroKE ten 
times in buffer C at 4 ºC.  
2.6.3 AroKE Kinetics 
In addition to the substrate range discussed in section 2.4.2, a range of 11 ATP concentrations from 
52 µM and 1.5 mM was also tested. The dilution series were prepared manually with a factor of 
2:3 with 1.5 mM being the highest concentration. 
2.6.4 Mb_AroKE MST experiments 
A serial 1:1 dilution of SKM ranging from 122 nM to 2 mM was prepared and mixed with 1 mM 
Mb_AroKE. MST measurements were performed with a Monolith NT.LabelFree (Nanotemper), 
using various MST power and laser intensity settings to test the general validity of the obtained 
data at a temperature of 25°C, using MST power 20% and laser intensity 20 and 40%. The data 
was analyzed using the NT Analysis 1.5.41 software (Nanotemper). 
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2.6.5 Crystallization and crystal handling 
Initial screens of Mb_AroKE gave sufficient quality crystals in complex with SKM Table 2.4 lists 
the crystallization conditions for Mb_AroKE while Table 2.5 lists the data collection and 
refinement statistics. 
Table 2.5 Crystallization conditions of Mb_AroKE 
Protein Protein buffer Conc. 
(mg/ml) 
Screen condition (SC) Ligands 
10 mM 
Cryo 
Mb_AroKE 
(sitting drop) 
20 mM Tris pH 8.0, 
150 mM NaCl, 2 mM 
β-ME 
41 JCSG 48 
0.04 M K3PO4, 16% PEG 
8000, 20% glycerol 
SKM, 
ADP 
SC+10% 
glycerol 
 
Table 2.6 Data collection and refinement of Fp_AroEK and Mb_AroKE 
Data set Fp_AroEK Mb_AroKE 
Wavelength (Å) 1 1 
Space group P42212 P21 
Unit cell (Å) a = b = 154.5, c = 
56.7, α = β = ɣ = 
90.0 º 
a = 43.72, b = 123.80, 
c = 46.65, α = ɣ = 
90.0 º, β = 97.76 º 
A. Diffraction statistics 
Resolution 2.70 2.15 
No. of 
observations 
510440 181885 
Completeness 99.8(99.3) 98.6 (93.9) 
Redundancy 26.14 3.47 
I/sigma(I) 19.71 (2.66) 9.21(1.87) 
R-meas (%) 14.9 (142.8) 12.5( 75.8) 
CC1/2 99.9 (81.9) 99.4 ( 68.5) 
B. Refinement statistics 
Monomers/ASU 1 1 
Resolution range 
(Å) 
43.94-2.70 35.48 – 1.99 
No. of unique 
reflections  
18513 31476 
Rcryst (%) 23.70 18.0 
Rfree (%) 26.26 22.76 
Rms bond length 
deviation 
0.0043 0.0183 
Rms bond angle 
deviation 
0.8936 1.8902 
Ramachandran 
statistics (%) 
97.53/2.22/0.25 96.85/3.15/0 
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2.7 Methods- AROM complex 
2.7.1 Cloning, Protein Expression and Purification 
The codon optimized AROM genes, (̴ 4.7 kb) from Chaetomium thermophilum (Uniprot ID: 
G0S061) Ct_AROM and Thielavia heterothallica Th_AROM (Uniprot ID: G2QMW9) were 
obtained as two overlapping strings (̴ 2.3 kb each) from Thermofisher scientific. The strings 
overlapped in 27 and 26 base pairs for Ct_AROM and Th_AROM respectively. The two strings 
were combined using the overlapping PCR (Appendix 1.7 and 1.8).  
The resulting full-length genes were cloned in pET 28b using the restriction sites NcoI and XhoI. 
Due to the size of the AROM complex, the sequence was validated by sequencing with various 
primers within the gene. Owing to the vector, the sequence of the AROM complex contains 
additional Leu and Glu prior to the His tag. The AROM complex was dialyzed in the buffer 
containing 20 mM Hepes pH 8.0, 150 mM NaCl, 2 mM TCEP. The AROM complex was 
concentrated using a dialysis bag of 6 kDa MWCO, in the presence of PEG 20000 (no gel filtration 
was carried out).  
For expressing the selenomethionine labeled Ct_AROM complex, the overnight starter culture was 
grown in LB medium. The following day the cultures were centrifuged, and the cells were washed 
twice with phosphate buffered saline (PBS) to remove residual LB. The cells were resuspended in 
minimal media  and divided equally in 6 L of minimal media. The cultures were grown at 30 ºC 
until the OD of 0.6, and induced with 1 mM IPTG. The protein was purified in the same way as 
the native Ct_AROM complex. 
Per liter of M-M contained M95X [193] (200 mL), 1 M MgSO4 (2 mL), 1 M CaCl2 (0.1 ml), 20% 
glucose solution (20 ml), 1% thiamine (0.2 mL), Lys, Thr, Phe, Leu, Ile und Val (ca. 50 – 60 mg 
each) DL-Selenomethionine (ca. 50 – 60 mg).  
2.7.2 Kinetic Analysis of the AROM complex 
2.7.2.1 Assay for BDE domains 
BDE domains were assayed together, measuring the consumption of NADPH at 340 nm (Ɛ = 6180 
M-1 cm-1) [194] (Figure 2.2). The activity was assayed in 384-well plates, (Thermoscientific 
242757); the final volume of the assay mixture was 25 µl. The DAHP range of 0.02 to 0.6 mM 
with 15 serially diluted concentrations was analyzed. The reaction mixture contained 50 mM 
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HEPES (pH 8.0), 100 mM KCl, 10 mM MgCl2, 0.2 mM NAD, 0.2 mM CoCl2, 0.8 mM NADPH, 
0.8 mM ATP, 0.8 mM PEP, 10 nM AROM. The serial dilutions of DAHP in a ratio of 2:3, were 
made in the buffer containing all the cofactors, employing the Piro® pipetting robot, (Dornier 
Labtech systems GmbH). 
The reaction was carried out with a temperature range from 30 to 50 °C. The plate was covered 
with the lid and was incubated at the required temperature for 15 minutes on a heating block. After 
the incubation, the enzyme was added and the reaction was followed for 2 hours at 340 nm. The 
AroBDE reaction was also performed in absence of ATP and PEP. For studying the effect of GLP 
on BDE, the BDE assay was performed in the presence of 0.2 mM GLP. 
2.7.2.2 Assay for KA domains 
In addition, the reactions of KA domains were followed by monitoring the phosphate release 
employing the Enzcheck® phosphate release kit [188] and measuring the amount of 
phosphorylated MESG at 360 nm. The reaction was carried out at 30 °C, as MESG is not 
thermostable. The activity was assayed in a final reaction mixture of 100 µL in 96-well plates 
(Brand plates ® 781662). 
The reaction mixture contained 0.2 mM ATP, 0.2 mM PEP, 0.2 mM MESG, 1U of PNPP and 10 
nM AROM. The range of SKM from 2 µM to 150 µM with 11 serially diluted concentrations was 
analyzed. The serial dilutions were prepared manually in the reaction buffer, in a ratio of 2:3, the 
highest concentration being 150 µM. The reaction was monitored at 30 °C for two hours.  
For measuring the activity of A domain, the phosphate release assay was performed using 150 µM 
S3P, 0.2 mM PEP, 0.2 mM MESG 1U of PNPP and 10 nM AROM. The reaction was studied at 
30 ºC as above. For studying the GLP based inhibition of A domain, AroA assay was performed 
as above in presence of 0.2 mM GLP.  
All the above reactions were monitored in the Microplate Reader Synergy™ H4 Hybrid or the 
Synergy™ Mx Monochromator-Based Multi-Mode Microplate Readers, and were carried out in 
triplicates. Further, the above experiments also included a no enzyme blank for each concentration, 
and a blank without any substrate. 
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2.7.3 Crosslinking Mass spectrometry 
1 mg/ml AROM complex was crosslinked with 1 mM and 250 µM of disuccinimydil suberate. The 
digestion was carried out with endoprotease Lys-C followed by trypsin. The samples were 
measured on an Orbitrap Elite mass spectrometer, and the data was evaluated with the software 
xQuest [199]. 
2.7.4 Small Angle X-Ray Scattering (SAXS) 
SAXS experiments were conducted at the beamline B21, Diamond Light Source (Didcot, UK), 
with X-ray wavelength of 1 Å and a PILATUS 2M detector at a distance of 3.9 m. The samples 
contained 50 μl of either Ct_AROM or Th_AROM at concentrations of 37 mg/mL, 15 mg/mL and 
7mg/mL both as apo proteins and in the presence of various ligands (list of ligands given in Table 
2.7).  
Samples were delivered at 20 °C by an in-line Agilent HPLC with a Shodex Kw-403 column. The 
running buffer consisted of 20 mM HEPES pH 8.0, 150 mM NaCl, 2 mM TCEP and 1% sucrose. 
The continuously eluting samples were exposed for 300 s in 10 s acquisition blocks, and the data 
was pre-processed using in-house software.  
Frames recorded immediately before the elution of the sample were used for the buffer subtraction. 
Buffer subtraction and further analysis were performed with Primus [195] and ScÅtter version 
2.2b [196]. The crystallographic model of Ct_AROM was fit to the resulting SAXS profiles using 
the program FoXS [197].  
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Table 2.7 Ligands employed in the SAXS studies 
Ligands (10 mM) 
SKM 
DHS 
DHQ 
ATP 
NADH 
SKM+ATP 
SKM+NAD 
DHQS+DHS 
SKM+NADH 
DHS+DHQ+SKM 
DHS+NADH+ATP 
SKM+NADATP 
DHS+NADH+ATP 
SKM+ATP+NADH+DHQS 
SKM+ATP+NADH+DHQS+DHS 
 
2.7.5 Negative stain Transmission Electron Microscopy screening 
The Negative stain Transmission Electron Microscopy (NS-TEM) was carried out using glow-
discharged carbon-coated grids. The grids were incubated with 0.1 mg/ml protein solution, stained 
with 1% uranyl acetate and examined with a FEI Tecnai G2 Spirit BioTwin transmission EM at 
120 kV. 
2.7.6 Crystallization and crystal handling 
Various crystallization conditions for both Ct_AROM and Th_AROM were tested. The screen 
condition of Morpheus gave diffracting crystals. The resulting crystals were first optimized in grid 
screens and then in hanging drops. The final optimized conditions, together with the original 
Morpheus condition for Ct_AROM samples are given in Table 2.6. The AROM crystals usually 
grew within two weeks. (Table 2.8)  
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Table 2.8 Crystallization conditions of Ct_AROM 
Sr.no. Protein name Protein Buffer Conc 
mg/ml 
Screen 
condition 
(SC) 
Ligands 
10mM 
Cryo 
1  Ct_AROM (sitting 
drop) 
20 mM Hepes pH 
8.0, 150 mM NaCl, 
2 mM TCEP 
5 Morpheus 
H2 Buffer 1 
pH: 6.5, 0.10 
M aa, 0.03 
mMP2: 60 
%v/v 
SKM, DHQ, 
NADH  
SC 
2.  Ct_AROM 
(hanging drop) 
20 mM Hepes pH 
8.0, 150 mM NaCl, 
2 mM TCEP 
5 Buffer 1 pH: 
6.5, 0.10 M 
aa, 0.03 mM 
P2: 60 %v/v 
SKM, DHQ, 
NADH  
 
SC 
3. Ct_semet_AROM 
(hanging drop) 
20 mM Hepes pH 
8.0, 150 mM NaCl, 
2 mM TCEP 
5 Buffer1 pH: 
6.5, 0.10 M 
aa, 0.03 mM 
P2: 60 %v/v 
SKM, DHQ, 
NADH  
 
SC 
 
2.7.7 Data collection and crystal structure determination AROM complex 
Single wavelength Anomalous dispersion (SAD) data were collected at 100K and a wavelength of 
0.978 Å on Pilatus 6M detector at beamline P14/PETRAII (Hamburg Germany). The data were 
indexed, integrated and scaled to 3.0 Å resolution using XDS. For heavy atom location, we 
employed SHELXD [198].  
Most of the 78 expected heavy atoms corresponding to two chains of AROM in the ASU were 
located, with a prominent drop in peak height after about 75 sites. After phasing, density 
modification and chain tracing with SHELXE, large extents of the AroB and AroA domains and 
several secondary structure elements of the other domains became apparent. The superimposition 
of individual domains from the PDB aided in completing the structure, which was accomplished 
by cyclic chain tracing with Buccaneer [199], manual modeling with Coot [183], and refinement 
with REFMAC5 [182].  
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Table 2.9 Data collection and refinement statistics of Ct_AROM 
Data set Ct_AROM 
Wavelength (Å) 0.978 
Space group P 21 21 2 
Unit cell (Å) a = 153.943, b = 
377.616, c = 
70.882, α = β = ɣ 
= 90.00 º 
A. Diffraction statistics 
Resolution 3.00 
No. of 
observations 
1122232 159766 
Completeness 99.7 (99.3) 
Redundancy 7.04 
I/sigma(I) 13.67 (1.28) 
R-meas (%) 11.2 (144.8) 
CC1/2 99.9 (54.1) 
B. Refinement statistics 
Monomers/ASU 2 
Resolution range 
(Å) 
50 – 3.0 
No. of unique 
reflections  
79855 
Rcryst (%) 21.5 
Rfree (%) 24.0 
Rms bond length 
deviation 
0.02 
Rms bond angle 
deviation 
0.753 
Ramachandran 
statistics (%) 
95.70/3.32/0.98 
 
2.7.8. Conformational space Ct_AROM 
To find structural representatives of the individual domains of AROM, the following five Pfam 
(version 31.0) families were used as starting point: AroB (PF01761), AroA (PF00275), AroK 
(PF01202), AroD (PF01487), and AroE (PF08501). The crystal structures were manually sorted 
based on the resolution and the structure with the highest resolution was picked as the reference 
structure. The reference structures are listed in Table 2.9 
The structures were then clustered based on their differences in the opening angles between the N- 
and C-terminal (Nt and Ct) sub-domains (for AroB, A, K, and E). Further, each pair of structures 
from the same family was superposed first according to the alignment between their Nt sub-
domains and then according to the alignment between their Ct domains. The rotation matrix during 
the 2nd transformation is used to calculate an “open angle difference” between the Nt and Ct sub-
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domains of the two structures. TMalign is used to perform structure alignments. Each pair of 
structures in the same family was compared, and an “open angle difference” matrix was calculated 
accordingly.  
A hierarchical agglomerative clustering with complete linkage was used to cluster the structures 
for each family. A cutoff of 0.15 rad (for AroB, A, and K) or 0.25 rad (for AroE), or 2.0 Å was 
used to acquire the clusters. The structures closest to the cluster centers were chosen as cluster 
representatives (medoids). R was used to perform the clustering. The representative structures for 
each of the four families are listed in the Table 2.10. 
Table 2.9 Reference structures for each of the four flexible domains of AROM: The table shows the 
reference structures selected for each of the four domains based on the best resolution. The structures are 
manually divided into Nt and Ct sub-domains. 
Domain PDB ID Resolution (Å) Chain ID start-end Reference 
AroB 1sg6 1.70 A 4-183, 184-355 [200] 
AroA 3nvs 1.02 A 20-242, 6-19+243-421 [201] 
AroK 2iyv 1.35 A 28-95, 11-27+96-167 [133] 
AroE 3jyo 1.00 A 2-108, 109-283 [202] 
 
Table 2.10. The representative structures for each of the four families.  
AroB (cutoff = 0.15 rad, num = 4) 
1xal_B_1_317.pdb 
1nva_B_1_356.pdb 
5eks_B_1_323.pdb 
3qbd_B_1_320.pdb 
AroA (cutoff = 0.15 rad, num = 7) 
1eps_A_6_420.pdb 
1g6t_A_6_420.pdb 
1rf5_B_4_421.pdb 
2bjb_A_7_419.pdb 
2gg4_A_12_440.pdb 
3roi_A_6_421.pdb 
4gfp_A_6_421.pdb 
AroK (cutoff = 0.15 rad, num = 5) 
3vaa_C_10_172.pdb 
4y0a_A_27_184.pdb 
1zyu_A_11_167.pdb 
2g1j_A_11_167.pdb 
3mrs_A_10_162.pdb 
AroE (cutoff = 0.25, num = 7)  
1vi2_B.pdb 
3toz_H.pdb 
1wxd_B.pdb 
2ev9_A.pdb 
2hk9_C.pdb 
3pwz_A.pdb 
3phi_A.pdb 
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2.8. Methods- other proteins 
2.8.1 Cloning, Protein Expression and Purification 
Genomic DNA of E.coli was used as the template to clone the genes AroB, AroD, AroE, AroL, 
AroK, AroA in pET28b with the restriction sites NcoI and XhoI (C terminal hexa-His tag). E. coli 
enzymes were expressed at 37 ºC. The cells were lysed using French press. The proteins were 
dialyzed in the buffer containing 10/20 mM Tris (pH 8.0), 150 mM NaCl, 2 β-ME. Gel filtration 
was carried out using S 200, 26/60. The E.coli enzymes contained, Leu and Glu prior to the His 
tag. 
2.8.2. Kinetic Analysis of the E. coli enzymes 
In order to make a comparison between the AROM complex and the monofunctional E. coli 
enzymes, the AroBDE kinetics was studied with the AroB, AroD, AroE, AroL, AroA enzymes 
from E. coli. 
The 25 µL reaction mixture contained 50 mM HEPES (pH 8.0), 100 mM KCl, 10 mM MgCl2, 0.2 
mM NAD, 0.2 mM CoCl2, 0.8 mM NADPH, 0.8 mM ATP, 0.8 mM PEP. Each of the E. coli 
enzymes (AroB, AroD, AroE, AroL, AroA) was supplemented at a concentration of 10 nM. The 
DAHP range was the same as in section 2.7.2. The reaction was monitored at 30 ºC in the same 
way as described for the AroBDE kinetics of AROM. (Section 2.6.6). 
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3. Results and Discussion 
3.1 Cluster analysis of the shikimate kinase fusions 
Shikimate pathway enzymes show substantial variance in the molecular and structural organization 
within different taxonomic groups [49]. In most prokaryotes, the seven enzymes are encoded as 
separate well characterized single proteins [39]. Plants encode all monofunctional enzymes except 
one bifunctional fusion protein AroDE [33, 34]. Fungi encode the pentafunctional AROM complex 
(AroBAKDE) [49, 79, 161, 167, 203-207], which was also reported in apicomplexan parasites [36, 
165]. Acanthamoeba, on the other hand, encodes a tetrafunctional AroN lacking the E domain 
(AroBAKD) [37]. There could be many yet unidentified fusion proteins in the pathway. Therefore, 
a detailed study of the evolutionary origins of shikimate pathway is needed. 
Richards et al., performed such a study in 2006. They built phylogenic trees of AroG, AroB, AroE, 
AroK, AroA and AroC [35]. They detected previously unknown AroKB in various classes of both 
gram-positive and gram-negative bacteria. They further identified AroBD from chromalveolates 
and AroDEA from chlamydiae. Although, each of these calculations was based on less than 100 
sequences, the authors already found a variety of previously unreported multifunctional enzymes 
in the shikimate pathway.  
Today, with a vast repertoire of new genomic data available, a new homology search might 
uncover even more yet undiscovered multifunctional enzymes. Therefore, at the beginning of this 
project, a homology search for AroK analogs in the nr-70 database was conducted. Approximately 
5000 sequences were retrieved, 3655 AroKs were manually selected, and were clustered by all-
against-all pairwise similarities as measured by the BLAST p-values to produce a 2-dimensional 
map in CLANS [176] (Figure 3.1).  
Besides the evolutionary relationship of AroKs, this map also shows the different multifunctional 
enzymes, comprising the AroK domain. Various previously unreported multifunctional enzymes 
in the shikimate pathway can be seen in this map. The map shows the extent of the distribution of 
AroKBs (fuchsia stars) among various taxonomic groups. The multiple AroKBs scattered 
throughout the map indicate that AroKB fusion has evolved multiple times. In most of these 
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organisms, AroK and AroB genes are present adjacently in one operon, therefore, only the deletion 
of the stop codon is required for this fusion.  
Interestingly, different fusions between the AroE and AroK domains (blue stars) were detected. 
AroKE fusion occurs in Archaea and AroEK fusion is present in bacteria. The bacterial AroEK 
forms two distant clusters, which suggests that, the AroEK fusion has evolved at least twice. The 
gene arrangement is different in AroEK and AroKE but it is unknown whether there are any 
differences between the domain arrangements of these proteins AroKE and AroEK. Further, a 
novel fusion between AroD and AroK (lemon stars) is also detected in firmicutes.  
The AROM complex (purple stars), other than in fungi, is present in choanoflagellates (single-celled aquatic 
protists), oomycetes (water molds) and chromerida (photosynthetic alveolates, closely related to 
apicomplexan parasites) [208-210]. Further, the tetrafunctional AroN (lavender-blue star) in A. castellanii is 
also visible in the map.  
The other fungal cluster, which does not represent the AROM complex, contains the quinate repressor protein 
(QutR, Uniprot ID: P11637) (bazzar circles). QutR contains homologs to the three C-terminal domains 
(KDE) of the pentafunctional AROM complex and functions as a molecular sensor that detects the 
presence of quinate/shikimate pathway intermediates to control transcription regulation [211, 212].  
With the discoveries in this single AroK-based cluster map, it is apparent that significantly deeper 
and broader evolutionary insights might be obtained in future studies integrating cluster maps of 
the other enzymes of the pathway. 
The presence of these multifunctional enzymes suggests the possibility of existence of a higher 
order assembly. Higher order assemblies are known to concentrate reactants to avoid unfavorable 
reactions, and remove inhibitory products thus channeling metabolites from one enzyme to the 
next [18, 19]. With such prominence of these fusions, it seems likely that the individual enzymes 
of the pathway form transient complexes for efficient substrate funneling and catalysis. It could 
further be that these transient higher order assemblies might resemble the AROM complex.  
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Figure 3.1 Cluster analysis of the shikimate kinase genes: The figure shows the cluster analysis of 
shikimate kinase genes. The sequences are represented by dots and the line coloring reflects BLAST p-
values. The darker a line, the lower the p-value The organisms, which are shown as circles include fungi, 
plants, archaea, terrabacteria, other bacteria and other eukaryotes and are colored with sorrel brown, 
green, red, bazaar, pale blue, and black respectively. The fusions, which are shown as stars include AroKB, 
AroKE, AroEK, AroDK, AROM and AroN are shown as stars and are colored with fuchsia, blue, lemon, 
purple, and lavender-blue respectively. 
 
AroKB, AroKE and AroEK together with AroDE (PDBID: 2O7S) constitute four domains of the 
pentafunctional AROM complex (Figure 3.2). If one could determine the domain arrangements of 
these three bifunctional enzymes, then together with the AroDE, a tetrafunctional hypothetical 
model of the AROM complex can be designed in silico. Further, a kinetic analysis of these 
bifunctional enzymes can also give insights into allosteric regulation between these domains. Not 
only can such a study help us understand the shikimate pathway better, it can also strengthen our 
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knowledge of kinetic mechanisms in vivo. Therefore, a few candidates were selected from AroKB, 
AroKE and AroEK for further studies.  
 
Figure 3.2. Real bifunctional enzymes and hypothetical model of AROM: The figure compares the monofunctional 
enzymes of the pathway with the bifunctional enzymes and shows the hypothetical tetrafunctional hypothetical model. 
A). Five monofunctional enzymes constituting the pentafunctional AROM complex. B). Three bifunctional enzymes 
selected for this study, AroEK, AroKB, and AroKE together with AroDE from literature C). AroKB, 
AroEK/AroKE together with At_AroDE constitute four domains of the pentafunctional AROM complex, with 
only A domain missing, therefore, a hypothetical tetrafunctional model of AROM complex can be designed. 
3.2. AroKB  
The AroKB fusion (Figure 3.3), which involves the second and the fifth enzyme of the pathway, 
occurs very frequently in different taxonomic groups as seen in the CLANS map (Figure 3.1). It 
seems not catalytically efficient if the substrate diffuses out of AroKB for reaction three and four, 
only to catalyze reaction five again by AroKB. Therefore, a channeling effect might not be feasible 
for Tm_AroKB but a regulation between the two domains might regulate the pathway. In addition, 
this fusion could suggest the presence of potential higher order assembly in the cell containing 
AroKB. In this section the purification, biochemical and biophysical properties, kinetic analysis 
and the crystal structural of bifunctional AroKB is discussed. This is further compared to the 
monofunctional Tm_AroKKB and Tm_AroKB_SB. 
 
Figure 3.3 Bifunctional AroKB: The figure shows a hypothetical model of bifunctional AroKB containing 
the fusion of the second and fifth steps of the shikimate pathway.  
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3.2.1 Biochemical and biophysical characterization 
AroKBs from five different organisms were recombinantly expressed in E. coli. AroKB from 
Collimonas fungivorans did not express and AroKBs from Acidiphilium multivorum, 
Granulibacter bethesdensis CGDNIH1, and Oxalobacter formigenes were insoluble. Initial 
optimization did not result in a soluble protein (data not shown). Only the AroKB from 
Thermotoga maritima (Tm_AroKB) yielded soluble protein. T. maritima is a strictly anaerobic, 
rod-shaped, fermentative, and hyperthermophilic [HT] eubacterium. It grows between 55 and 90 
ºC, with an optimum temperature of around 80 ºC [213]. The purified protein is well folded with 
a thermal melting temperature (Tm) of 85 ºC as seen by CD. It migrates as a single species in size 
exclusion chromatography with an average molecular mass of ~116 kDa as determined by static 
light scattering (Figure 3.4). 
A multifunctional enzyme is best studied if a truncated version of the same enzyme is available 
for comparison. Therefore, Tm_AroKKB, which is a 159 amino acid truncated protein containing 
only the monofunctional K domain was also cloned, expressed and purified to study the effect of 
absence of the B domain. The purified protein is a 22 kDa monomer. It is a well-folded protein 
with a thermal melting temperature (Tm) of 70 ºC as seen by CD. (Figure 3.5). It is therefore 
slightly less stable than the bifunctional Tm_AroKB. Therefore, it appears that the presence of the 
second domain has a stabilizing effect on the enzyme. Interestingly, a truncated protein containing 
only the B domain could not be obtained in folded state. 
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Figure 3.4 Biochemical and biophysical properties of Tm_AroKB: A). SDS gel of Tm_AroKB: The gel 
shows the molecular weight of the monomer of the AroKB is 56 kDa. 10 μl of samples were loaded after 
the purification from the Nickel column. The samples were loaded in the buffer containing 50 mM Tris, 300 
mM NaCl and the respective imidazole concentration mentioned in the picture. B). Light scattering of 
Tm_AroKB: 100 μl Tm_AroKB was loaded at a concentration of 1 mg/ml (black profile), onto a S200 size 
exclusion column and the mass of the eluted particles (gray profile) in the peak area was analyzed with 
static light scattering. The horizontal axis of the curve shows volume in mL and the left axis shows the UV 
absorption. The molar mass on the right is shown in the logarithmic scale. C). CD profile of Tm_AroKB: 
400 µL of Tm_AroKB at a concentration of ̴ 0.3 mg/mL was measured in the CD spectrometer. The figure 
shows the far UV CD spectrum, plotted in millidegrees (mdeg) versus wavelength in nanometers (nm) of 
polarized light. D) Thermal stability analysis of Tm_AroKB: 400 µL of Tm_AroKB at a concentration of ̴ 
0.3 mg/mL was measured at a temperature range from 20 ºC to 95 ºC. The temperature is displayed on 
horizontal axis while CD (mdeg) is shown on the vertical axis. The protein is stable up to 85 ºC. 
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Figure 3.4 Biochemical and biophysical properties of Tm_AroKKB A). SDS gel of Tm_AroKKB: The gel 
shows the molecular weight of the monomer of the AroKB is 22 kDa. 10 μl of samples were loaded after 
the purification from the Nickel column. The samples were loaded in the buffer containing 50 mM Tris, 300 
mM NaCl and the respective imidazole concentration mentioned in the picture. B). CD profile of 
Tm_AroKKB: 400 µL of Tm_AroKB at a concentration of ̴ 0.3 mg/mL was measured in the CD spectrometer. 
The figure shows the far UV CD spectrum, plotted in mdeg versus wavelength in nanometers (nm) of 
polarized light. C) Thermal stability analysis of Tm_AroKKB: 400 µL of Tm_AroKB at a concentration of ̴ 
0.3 mg/mL was measured at a temperature range from 20 ºC to 95 ºC. The temperature is displayed on 
horizontal axis while CD (mdeg) is shown on the vertical axis. The protein is stable up to 70 ºC. 
3.2.2 Kinetic analysis of Tm_AroKB 
The activities of both the K and B domains of Tm_AroKB were assayed separately in presence 
and absence of the substrates of the other domain. Due to its thermophilic nature, the true potential 
of the enzyme may possibly only be realized around 80 ºC. However, this temperature cannot be 
employed for the reaction due to the stability of coupling enzymes.  
For the assay of K domain, the release of ADP is coupled to the pyruvate kinase (PK) (EC 2.7.1.40) 
and lactate dehydrogenase (LDH) (EC 1.1.1.27) (PK\LDH) enzymes (Figure 3.6). The SKM/ATP 
dependent oxidation of NADH is in turn monitored at 340 nm (Ɛ = 6180 M-1 cm-1) [185]. The 
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coupling enzyme cocktail of PK/LDH is isolated from rabbit muscle, and therefore denatures 
above 40 ºC (data not shown). K domain kinetics was studied for both substrates SKM and ATP. 
To examine the effect of an increase in temperature, K domain kinetics of Tm_AroKB was 
conducted both at 30 and 40 ºC. The rate of the reaction appears to increase slightly with the 
increase in temperature (data not shown). Therefore, it could be a possibility that the enzyme is 
actually more active than seen here at 30 ºC. 
During the formation of DHQ by the B domain, an inorganic phosphate is released. The AroB 
kinetics was followed by monitoring the continuous phosphate release employing the Enzcheck® 
phosphate release kit [188] and measuring the amount of phosphorylated MESG at 360 nm 
(Figure3.7). The released phosphate is transferred to 2-amino-6-mercapto-7-methylpurine riboside 
(MESG), which is in turn converted to ribose 1-phosphate and 2-amino-6- mercapto-7-
methylpurine by purine nucleoside phosphorylase (PNP). The accompanying change in absorption 
at 360 nm allows quantification of inorganic phosphate (Pi) released in the reaction. To estimate 
the extinction coefficient of phosphate (Ɛ = 14753 M-1 cm-1) a standard curve was prepared; using 
a phosphate concentration range of 4.3 to 150 µM in duplicates (data not shown). MESG is not 
stable beyond room temperature. Therefore, the AroB assay was only carried out at 30 ºC. The 
kinetics for B domain was conducted both for DAHP and NAD. 
 
Figure 3.6 Assay of K domain: The standard method for kinase assay. The method couples the release 
of ADP to PK and LDH and measures the ADP dependent consumption of NADH at 340 nm.  
59 
 
 
Figure 3.7 Assay of B domain: In this method 2-amino-6-mercapto-7-methylpurine riboside (MESG) is 
converted to ribose 1-phosphate and 2-amino-6-mercapto-7-methylpurine by purine nucleoside 
phosphorylase (PNP). The accompanying change in absorption at 360 nm allows quantification of inorganic 
phosphate (Pi) consumed in the reaction.  
Separate experiments were conducted for both the K and B domains of the enzyme in the presence 
of the substrates of the other domain to test for potential allosteric effects; i.e. to measure the effect 
of the presence of the substrates of B domain on K kinetics and vice versa. The experiments for 
both the K and B domains were conducted also for the salt bridge mutant Tm_AroKB_SB, which 
does not contain the bound NAD present in Tm_AroKB (discussed in section 3.2.4). 
Table 3.1 lists the estimated values of the kinetic parameters for each of the different domains of 
Tm_AroKB in comparison to the values reported for monofunctional enzymes in the literature. 
The MM curves for kinetic analysis of the K domain of KB are presented in Figure 3.8. The 
analysis of the K domain of Tm_AroKB was conducted for both substrates, SKM and ATP. The 
kcat/Km falls in the same range, as reported for M. tuberculosis (Table 3.1) [131, 187] which shows 
that at 30ºC, Tm_AroKB is at least as active as enzymes reported in the literature. The analysis of 
Tm_AroKB was also conducted at 40 ºC; it showed a slight increase in the activity (data not 
shown). Therefore, it could be highly likely that the enzyme is much more active than seen in these 
experiments but its true potential cannot be realized at this temperature. 
In comparison, the activity of monofuctional Tm_AroKKB does not change much in the absence 
of the B domain. The kinetic parameters are almost the same as seen for the bifunctional 
Tm_AroKB. Therefore, a difference in activity of the monofunctional enzyme compared to that of 
bifunctional enzyme was not observed. Thus, a regulatory effect of the presence of other domain 
was not visible. 
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Figure 3.8 K domain kinetics of Tm_AroKB: The Figure shows the kinetic analysis of the K domains of 
Tm_AroKB, Tm_AroKB_SB and Tm_AroKKB. The enzyme concentration for Tm_AroKB and 
Tm_AroKB_SB is around 10 nM and for Tm_AroKKB is around 4.5 nM. The enzyme names are indicated in 
the graphs together with their respective curves. A). Tm_AroKB K domain kinetics for SKM: This panel 
compares the SKM kinetics of the K domain between Tm_AroKB and Tm_AroKB_SB in presence and 
absence of substrates of the B domain. B). Tm_AroKKB K domain kinetics for SKM: This panel shows 
the SKM kinetics of Tm_AroK_KB. C). Tm_AroKB K domain kinetics for ATP: This panel compares the 
ATP kinetics of the K domain between Tm_AroKB and Tm_AroKB_SB in presence and absence of 
substrates of the B domain. D). Tm_AroKKB kinetics for ATP: This panel shows the ATP kinetics of 
Tm_AroKKB. Due to differences in protein concentration, the curves for Tm_AroKB and Tm_AroKB_SB are 
not directly comparable. 
The kinetic analysis of the K domain was also carried out in the presence of substrates of the B 
domain to assess the effect of the presence of other substrates. The activity of Tm_AroKB was 
assessed in the presence of 20 µM DAHP and NAD. 
Tm_AroKB contains a bound NAD, which could potentially increase the catalytic turnover of the 
enzyme. To study this effect, a mutant Tm_AroKB_SB, which does not contain this bound NAD 
was designed (section 3.2.4). The kinetic activities for both domains of Tm_AroKB were 
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compared to Tm_AroKB_SB. At first glance, Tm_AroKB_SB seems to be more active than that 
of Tm_AroKB for both substrates SKM and ATP. However, NAD is present in the binding pocket 
of Tm_AroKB, which influences the absorption at 280 nm. Due to this effect, the concentration of 
Tm_AroKB is potentially overestimated in comparison to Tm_AroKB_SB. As the increase in 
activity is not very significant, it can be attributed to this overestimation. 
While the catalytic activity of Tm_AroKB is unaffected in the presence of the substrates of the B 
domain (NAD and DAHP), the activity of Tm_AroKB_SB is decreased. This could be explained 
by a competition between NAD and ATP for the ATP binding site [214]. Therefore, it could be 
that intrinsic binding of NAD in Tm_AroKB is to avoid this competition, rather than to increase 
the catalytic efficiency of the enzyme. The activity of the K domain was determined only in the 
presence of the two substrates of B domain was not carried out separately in this study.  
The MM curves for kinetic analysis of the B domain of Tm_AroKB are presented in Figure 3.9. 
The kinetic analysis of the B domain was conducted for both DAHP and NAD. To our surprise, 
Tm_AroKB, which contains an already bound NAD, showed only negligible activity with NAD 
as a substrate (data not shown). On the other hand, Tm_AroKB_SB, which does not contain bound 
NAD, showed kinetic activity towards NAD. As seen in the Table 3.1, the kinetic parameters fall 
in the range of the kinetic values reported in the literature for A. chinensis and A. nidulans [215, 
216]. 
 
Figure 3.9 B domain kinetics of Tm_AroKB: The figure shows the kinetic analysis of the B domain of 
Tm_AroKB, and Tm_AroKB_SB. The enzyme concentration for Tm_AroKB and Tm_AroKB_SB is around 
10 nM. The enzyme names are indicated in the graphs together with their respective curves. A). B domain 
kinetics of Tm_AroKB for DAHP: This panel compares the DAHP kinetics of the B domain between 
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Tm_AroKB and Tm_AroKB_SB in the presence and absence of substrates of the B domain. B). B domain 
kinetics for NAD: This panel shows the NAD kinetics of the B domain of Tm_AroKB_SB in the presence 
and absence of substrates of the K domain. Due to differences in protein concentration, the curves for 
Tm_AroKB and Tm_AroKB_SB are not directly comparable. 
 
In earlier studies, the kinetic analysis of B domain was coupled to the D assay. This was not done 
here, because the requirement of this study is to analyze the kinetics of the B domain in the 
presence of substrates of the K domain. The reason for not choosing the D coupling is the 
phosphate buffer employed usually for the D kinetics. Phosphate buffer can interact with the ATP 
binding site in K domain because it can bind instead of ATP at the p-loop [133]. Therefore, the 
analysis of the B activity in presence of SKM and ATP cannot be carried out if the assay was 
carried out in phosphate buffer. 
The activity of DAHP was studied for both the B domains of Tm_AroKB and Tm_AroKB_SB. 
The activity of Tm_AroKB_SB was found to be almost 20% higher than that of Tm_AroKB. 
However, as stated previously, the NAD bound to Tm_AroKB contributes to the absorbance of 
Tm_AroKB, leading to an overestimation of the concentration of Tm_AroKB. Therefore, 
conclusions are to be drawn with care. However, the addition of the substrates for the K domain 
clearly reduces the activity for DAHP of the B domain. This could be attributed to the ATP binding 
competing with NAD-binding [214].  
The NAD activity was also tested for both Tm_AroKB and Tm_AroKB_SB. Tm_AroKB did not 
show a significant change with increasing concentration of NAD, this could be attributed to the 
fact it already contains bound NAD and therefore, increasing concentrations of NAD do not make 
any difference (data not shown). 
In the light of these results, a conclusion about the regulatory interactions between the two domains 
cannot be established. 
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Table 3.1 Kinetic parameters of Tm_AroKB: The table shows the kinetic parameters of Tm_AroKB 
obtained in this study and compares them to the values in literature. TS refers to this study. 
 
 
Enzyme Substrate 
(S) 
(µM) 
Substrate 
(other 
domain) 
(20 µM) 
Km ± % 
S.E. 
(µM) 
Et 
(nM) 
kcat ± % 
S.E. 
(s-1) 
kcat/Km 
(s-1 M-1) 
R2 Ref 
Tm_AroKB SKM - 12.85 ± 
10.75% 
10 1.122 ± 
2.6% 
8.73e+4 0.916 TS 
 
DAHP, NAD 14.19 ± 
13.18% 
1.101 ± 
3.2% 
7.76e+4 0.887 
ATP 
 
- 5.98 ± 
15.47% 
0.851 ± 
2.76% 
1.42e+5 0.797 
DAHP, NAD 5.43 ± 
14.88% 
0.866 
±2.65 
1.59e+5 0.777 
DAHP - 6.01 ± 
14.37% 
0.334 ± 
3.4% 
5.56e+4 0.839 
SKM, ADP 5.71 ± 
16.62% 
0.318 ± 
3.79% 
5.57e+4 0.808 
NAD - - - - - 
Tm_AroKB
_SB 
SKM  19.91 ± 
10.9% 
10 1.737 ± 
3.01 % 
8.72e+4 0.933 TS 
NAD 15.65 ± 
12.75% 
2.085 ± 
3.28 % 
1.33e+5 0.904 
ATP  4.46 ± 
16.7% 
3.245 ± 
2.72 % 
7.28e+5 0.72 
DAHP, NAD 5.54 ± 
14.08% 
2.01 ±2.5 
% 
3.63e+5 0.800 
DAHP  6.57 ± 
16.05% 
0.472± 
4.00 % 
7.18e+4 0.845 
SKM, ADP 5.86 ± 
16.62% 
0.404± 
3.92% 
6.89e+4 0.827 
NAD - 2.68 ± 
19.6% 
0.325 ± 
3.62 % 
1.21e+5 0.736 
SKM, ADP 3.99 ± 
19.2% 
0.268 ± 
4.07% 
6.72e+4 0.691 
Tm_AroKKB SKM - 10.67 ± 
18.79%  
4.6 1.595 ± 
4.2% 
1.49e+5 0.777 TS 
ATP - 17.70 ± 
15.83% 
4.6 1.953 ± 
4.3% 
1.10e+5 0.868 
Mtb_AroK SKM - 650 ± 
4.3%, 
410 ± 
4.87% 
- - 9.0e+4, 
1.1e+5 
- [131, 
187] 
ATP - 112 ± 
0.03%, 
83 ± 4.8% 
- - 5.4e+5 
5.3 e+5 
- 
Ac_AroB DAHP - 3.2 ± 
6.5% 
- 0.50 ± 2% 1.56e+5 
 
- [215] 
An_AroB DAHP - 21 ± 9.5% - 6.8 3.24e+5 
 
 [216] 
NAD - 1.9 ± 
5.3% 
 - - 
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3.2.2 Crystal structure of Tm_AroKB in complex with SKM 
Initial crystals of Tm_AroKB were obtained in complex with SKM. Initial crystals diffracted to 
approximately 3 Å resolution. With grid screens, the resolution improved to 2.9 Å. The crystal 
structure of 1DQS was used as the search model for the AroB domain, while 2IYR was used as 
the search model for the AroK domain for molecular replacement. The asymmetric unit contained 
only one Tm_AroKB molecule. The two constitutive domains of the monomer are found to be 
connected via a rigid interface, and the active sites are solvent accessible (Figure 3.10). For the 
catalytic activity, the B domain always exists as a dimer in solution [61, 91, 109, 200, 216-221]. 
In the crystals, this dimer is constructed via crystallographic symmetry (Figure 3.5). The two K 
domains are connected at the outward side of the B domain dimer. Such an arrangement of the 
bifunctional enzyme does not affect the solvent accessibility of the active sites of both K and B 
domain. The protein is bound to the ligands NAD, Zn2+, SKM and SO4
2-. As the protein was co-
crystallized together with SKM, and ammonium sulfate was a component of the crystallization 
buffer, NAD and Zn2+ might have bound to the B domain within the cell. 
The structure of the K domain contains bound SKM and sulfate. SKM binding is similar to 
previously reported structures. The crystallization buffer contained sulfate, which can bind instead 
of phosphate at the p-loop and may occupy a location that is nearly identical with the position of 
the β-phosphates of ATP or ADP relative to the p-loop.  
The architecture of the B domain of Tm_AroKB is closely similar to the B domains from other 
organisms. Each monomer of the B domain is composed of two subdomains, the N-terminal α/β 
domain, containing a Rossmann-fold, and serves as NAD-binding site and the α-helical C-terminal 
domain that contains most of the residues involved in catalysis, including the Zn2+ binding site. 
Formation of each of the two active sites within the dimer requires the interaction of amino acid 
residues from domains N and C of one monomer [61]. Therefore, the side chain of Arg-262 extends 
into the other monomer for catalysis, which is marked in Figure 3.10. 
3.2.3 Tm_AroKB_SB 
No other AroB in the literature contains an intrinsically bound NAD [61, 91, 92, 200, 221]. NADH 
together with Zn2+ or Co2+ is required for catalytic activity of AroB [61, 218]. NADH can be 
regenerated from NAD during the reaction catalyzed by B domain [217]. Therefore, the presence 
of bound NAD/NADH could potentially enhance the catalytic turnover of AroKB. To confirm 
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whether the protein indeed contains bound NAD and not NADH, the absorption spectrum of the 
protein was recorded at 340 nm, but the protein did not show any absorbance at 340 nm (data not 
shown). Further, NAD binding could potentially stabilize the protein and contribute to 
thermostability. Therefore, unfolding and refolding of the protein to release the bound NAD was 
attempted. However, the protein could not be refolded successfully. 
 
Figure 3.10 Crystal structure of Tm_AroKB in complex with SKM and NAD. The figure shows the dimer 
of bifunctional AroKB. The N and C termini are marked. The AroK domain is shown in green and the AroB 
domain is shown in light pink and dirty violet, to highlight the two dimeric domains. The Arg-262, extending 
in the other half of the dimer is shown as pink sticks (circled). SKM is shown as red sticks, while sulfate is 
shown as red and yellow sticks. The AroB domain contains NAD and Zn2+ bound, which are shown in black 
and gray respectively. 
On comparing the crystal structure of Tm_AroKB with the Aspergillus nidulans AroB (An_AroB) 
in complex with Zn2+ and NAD [206], it was observed that the NAD binding pocket of Tm_AroKB 
was less solvent accessible. On a closer look, the NAD-binding pocket in Tm_AroKB was found 
to contain a salt bridge between Arg-195 and Asp-316 (Figure 3.11). Thermophilic proteins are 
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usually reported to have more salt bridges, which can help them achieve higher thermostability 
[222].  
Herein, it was hypothesized that this salt bridge is aiding Tm_AroKB to adapt at higher 
temperatures, while also trapping the NAD the binding pocket, which could potentially stabilize 
the protein and aid catalysis. Thus, a mutant (Tm_AroKB_SB) which contains Ala-195 and Ala-
316 instead of Arg-195 and Asp-316 was designed. If this salt bridge, and thus the less accessible 
binding pocket are contributing to NAD binding, then Tm_AroKB_SB should not contain 
intrinsically bound NAD. The purified protein was well folded, with a thermal melting temperature 
(Tm) of 85 ºC (Figure 3.12). No change in the melting temperature suggests that the salt bridge 
between Arg-195 and Asp-316 does not contribute to the thermostability of this protein. 
Unlike Tm_AroKB, Tm_AroKB_SB did not crystallize in complex with SKM. However, in 
complex with SKM and NADH or SKM, NADH and ADP, crystals were readily obtained under 
the same conditions as for Tm_AroKB. This shows that, NAD is required for the protein 
crystallization but does not affect the thermal stability of this protein. Further, this shows that the 
salt bridge indeed helps the protein in binding NAD tightly intracellularly. 
The Tm_AroKB_SB crystals had the same space group and cell dimensions as the Tm_AroKB 
crystals, so the structure could be solved on the basis of the Tm_AroKB coordinates. Figure 3.13 
shows the crystal structure of Tm_AroKB_SB containing Ala at positions 195 and 316. The more 
solvent accessible NAD-binding pocket can be seen in the crystal structure but NAD is bound at 
the same orientation. Thus, the salt bridge between Arg-195 and Asp-316 is not necessary for 
correct NAD binding, but helps entrapping NAD in the binding site.  
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Figure 3.11 NAD-binding pocket: The Figure compares the NAD-binding pocket of Tm_AroKB with the 
NAD-binding pocket of A. niger AroB. Only one monomer of AroB is shown for both. The figure shows both 
proteins in combination with NAD and Zn2+. The surface is shown in pink color while the cartoon is shown 
in gray color. The salt bridge, which makes the binding pocket less accessible, is shown in yellow. A) 
Transparent surface representation and cartoon representation of Tm_AroKB: The panel shows the 
transparent surface representation of Tm_AroKB on top of its cartoon representation. The salt bridge, which 
makes the NAD-binding pocket less accessible, is visible in the cartoon representation. B) Transparent 
surface representation and cartoon representation of An_AroB: The panel shows the transparent 
surface representation of An_AroB on top of its cartoon representation. The solvent accessible pocket 
present in An_AroB is also seen. C) Zoomed binding pocket surface of Tm_AroKB: This panel shows a 
zoomed surface of NAD-binding pocket. NAD is shown within in the binding pocket as sticks and the part 
of NAD which is not solvent accessible is shown as dashed lines. D) Zoomed binding pocket surface of 
An_AroB: The panel shows the surface representation of NAD-binding pocket zoomed. NAD is shown as 
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sticks and the parts of NAD which are not solvent accessible is shown as lines. The visibility of NAD 
molecule shows that the binding pocket is solvent accessible. E) Cartoon representation of Tm_AroKB 
NAD-binding pocket zoomed: The panel shows the zoomed cartoon representation of Tm_AroKB NAD-
binding pocket. The cartoon representation is shown in gray, while the nitrogen atom of Arg195 and oxygen 
atom of Asp316 forming the salt bridge is shown in blue and red and the salt bridge is shown in yellow. F) 
Cartoon representation of An_AroKB zoomed: The panel shows the zoomed cartoon representation of 
An_AROB NAD binding pocket. An_AroB contains an Asn46 and Pro184 instead of Asp and Arg in 
Tm_AroKB. The nitrogen of Asn is shown in blue while Pro oxygen is shown in red. 
 
 
Figure 3.12 Thermal stability of Tm_AroKB_SB A). CD profile: 400 µL of Tm_AroKB_SB at a 
concentration of ̴ 0.3 mg/mL was measured in the CD spectrometer. The figure shows the far UV CD 
spectrum, plotted in mdeg versus wavelength in nanometers (nm) of polarised light. B) Thermal stability 
analysis: 400 µL of Tm_AroKB_SB at a concentration of ̴ 0.3 mg/mL was measured at a temperature range 
from 20 ºC to 95 ºC. The temperature is displayed on horizontal axis while CD (mdeg) is shown on the 
vertical axis. The protein is stable up to 85 ºC. 
 
 
Figure 3.13 NAD-binding pocket of Tm_AroKB_SB. The figure shows the zoomed cartoon 
representation of one monomer of AroB of Tm_AroKB_SB co-crystallized with SKM and NAD. The cartoon 
is shown in gray color, NAD is shown in black and Zn2+ is shown in gray and is marked. The oxygen of Ala 
is shown in red. NAD is in the same orientation as seen in Tm_AroKB. 
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3.2.4 Crystal structure of the Tm_AroKB in complex with S3P and ADP 
AroK catalyzes the conversion of SKM to S3P with the cofactors ATP and Mg2+ [223]. To follow 
the catalytic turnover in the crystalline state, the crystals of Tm_AroKB were soaked with SKM 
and ATP for time intervals ranging from 30 minutes to 24 hours. The crystals did not degrade 
during the soaking period and diffraction data could be collected at 2.75 Å. However, the 
structures, which were solved using the Tm_AroKB coordinates, always contained only SKM in 
complex with Tm_AroKB. 
We hypothesized that the sulfate present in the ammonium sulfate of the crystallization condition 
can bind instead of phosphate of ATP at the p-loop, [133] and therefore, ATP might not be able to 
bind and catalyze the reaction. Thus, prior to these soaks, the crystals were soaked in 2.2 M sodium 
carbonate for thirty minutes to replace the sulfate present in the condition. Neither the prior soaking 
with sodium carbonate nor the later soaking with SKM and ADP led to crystal degradation, and 
the crystals diffracted to 2.75 Å. The structures were solved using the coordinates of Tm_AroKB 
and now contained both the products S3P and ADP with full occupancy (Figure 3.14). The 
conformation of the K domain is not affected particularly by the binding of either SKM or S3P. 
The binding of ADP shows that the position of the β-phosphates of ADP was nearly identical to 
the location occupied by the sulfate ion [133]. Only two previously reported AroK crystal 
structures (2IYZ, 3MUF) contain both the ligands S3P and ADP [133, 224]. The activity of AroK 
has been assessed in the crystalline state only in 2IYZ, while in 3MUF, the crystals were obtained 
together with S3P and ADP. The K domain from Tm_AroKB is the second crystal structure to 
report the catalytic activity in the crystalline state. 
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Figure 3.14 Tm_AroKB K catalytic activity in crystalline state: The Figure shows the K domain of one 
monomer of AroKB. Both the S3P and ADP are bound in the active site. β-phosphate of ADP is bound 
where a sulfate ion was bound in the previous structure. 
3.3 AroEK 
In this section, the bifunctional fusion protein AroEK, which catalyzes steps four and five of 
shikimate pathway is discussed (Figure 3.15). Unlike AroKB, AroEK catalyzes consecutive steps 
and therefore, this bifunctional enzyme could increase the flux through the shikimate pathway. 
 
Figure 3.15 AroEK: The figure shows the hypothetical model of AroEK, which contains the fusion of the 
fourth and fifth steps of the shikimate pathway. 
3.3.1 Biochemical and biophysical characterization 
For experimental characterization, AroEK proteins from the organisms Eubacterium biforme 
(Eb_AroEK) and Faecalibacterium prausnitzii (Fp_AroEK) were recombinantly expressed in E. 
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coli. AroEK from E. biforme gave an insoluble protein, which could not be solubilized with initial 
optimization (data not shown). Fp_AroEK also formed inclusion bodies when expressed in E. coli 
BL21DE3 at 37 ºC but gave a soluble well-folded protein when expressed in BL21-Gold(DE3) at 
25 ºC. This bifunctional enzyme is annotated only as shikimate kinase in Uniprot. 
F. prausnitzii is a dominant member of human intestinal microbiota therefore optimal growth 
temperature is 37 ºC [225]. The biophysical characterization of Fp_AroEK shows a thermal 
melting temperature (Tm) of ~50 ºC. It migrated as a single species in size exclusion 
chromatography with an average molecular mass of ~50 kDa as determined by static light 
scattering (Figure 3.16).  
 
Figure 3.16 Biochemical and biophysical properties of Fp_AroEK: A) SDS gel of FP_AroEK: The gel 
shows the molecular weight of the monomer of the AroEK is 50 kDa. The gel shows 10 μl of the samples 
loaded after the purification from the Nickel column. The samples were loaded in the buffer containing 50 
mM Tris, 300 mM NaCl and the respective imidazole concentration mentioned in the picture. B) Light 
scattering of FP_AroEK: 100 μl FP_AroEK was loaded at a concentration of 1 mg/ml (black profile), onto 
an S200 size exclusion column and the mass of the eluted particles (gray profile) in the peak area was 
analyzed with static light scattering. The horizontal axis of the curve shows volume in mL and the left axis 
shows the UV absorption. The molar mass on the right is shown in a logarithmic scale. C) CD profile of 
FP_AroEK: 400 µL of FP_AroEK at a concentration of ̴ 0.3 mg/mL was measured in the CD spectrometer. 
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The figure shows the far UV CD spectrum, plotted in mdeg versus wavelength in nanometers (nm) of 
polarized light. D) Thermal stability analysis of FP_AroEK: 400 µL of FP_AroEK at a concentration of ̴ 
0.3 mg/mL was measured at a temperature range from 20 ºC to 95 ºC. The temperature is displayed on 
horizontal axis while CD (mdeg) is shown on the vertical axis. The protein is stable up to 85 ºC. 
3.3.2 Kinetic analysis of Fp_AroEK 
The activity for the substrate ATP for the K domain was analyzed. The kinetic analysis of the K 
domain was conducted in the same way as discussed for Tm_AroKB in section 3.3.2. The kinetic 
analysis shows that Fp_AroEK follows Michaelis-Menten kinetics (Figure 3.16) and the kinetic 
activity falls in the same range as reported for K domains of M. tuberculosis [187] (Table 3.2). A 
detailed kinetic analysis and regulation has yet to be performed. 
 
Figure 3.16 FP_AroEK K kinetics for ATP: The figure shows the kinetic analysis of K domain for ATP for 
Fp_AroEK. The enzyme concentration is around 10 nM.  
Table 3.2 The kinetic parameters of Fp_AroEK 
Enzyme Sub (S) 
(µM) 
Km ± % S.E. 
(µM) 
Et (nM) kcat ± % S.E. 
(s-1) 
kcat/Km (s-
1 M-1) 
R2 Ref 
Fp_AroEK ATP 4.17 ± 19.6 % 14.9 1.73e+0 ± 3.07%
   
4.14e+05 
 
0.649 
 
TS 
 
3.3.3 Crystal structure of Fp_AroEK in complex with SKM 
Initially, Fp_AroEK crystallized in complex with SKM. The crystals diffracted to 2.7 Å. The 
crystal structure of 4YOA was used as the search model for the K domain and the crystal structure 
of 5DZS was used as the search model for the E domain, for molecular replacement. The 
asymmetric unit contained one Fp_AroEK protomer, in which the constitutive domains are 
connected via a rigid interface. Again, the active sites are solvent-accessible (Figure 3.17).  
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SKM is bound to both E and K domains, which were part of the crystallization buffer. SKM can 
bind to both these sites, because it is the substrate for the K domain and the product of the E 
domain. The only difference between DHS (substrate of E domain) and SKM is the presence of 
hydrogen at C-3. Most of the reported AroE crystal structures contain SKM bound to the catalytic 
domain [33, 202, 226-228].  
The domain structure of AroE is essentially identical to the previously reported instances. Some 
AroE contain two conserved cis-peptide prolines existing in a sharp turn linking a β-strand and the 
following α-helix [38, 119, 120]. Only one of such prolines Pro-55 is seen in the E domain of 
AroEK, which is the 2nd proline of the two. The structure of the K domain is similar to the K 
domain of AroKB reported in the previous section. The lid region is disordered in this crystal 
structure and therefore is not present in this structure.  
 
Figure 3.17 Crystal structure of Fp_AroEK in complex with SKM: The figure shows the crystal structure 
of AroEK. The N and C termini are marked. K domain is shown in green and the AroE domain is shown in 
cyan, SKM bound to both E and K domain is shown as red sticks.  
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3.4. Mb_AroKE 
Like AroEK, AroKE also catalyzes steps four and five of shikimate pathway but the gene sequence 
indicates the presence of the K domain before the E domain. The difference between AroEK and 
AroKE is not only the different domain arrangement in the DNA sequence (Figure 3.18), but also 
the presence of a 30-40 aa linker between the two domains. Linkers separate multiple domains in 
a single protein; they are often rigid and function to prohibit unwanted interactions between the 
different domains [229]. To understand the difference between the two proteins, we aimed to 
determine the crystal structures of both proteins. 
 
Figure 3.18 AroKE: The figure shows the hypothetical model of AroKE, which contains the fusion of the 
fourth and fifth steps of the shikimate pathway. 
3.4.1 Biochemical and biophysical characterization 
AroKE proteins were purified from Methanoplanus petrolearus (Mp_AroKE) and Methanoregula 
boonei (Mb_AroKE). Mp_AroKE was insoluble and formed inclusion bodies, which could only 
be purified in denatured state in the presence of either 6 M GnCl or 8 M Urea (Figure 3.19). 
Various attempts to refold the protein, including serial dialysis, on column refolding, and rapid 
dilution, failed. 
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Figure 3.19 Presence of Mp_AroKE in inclusion bodies: A) SDS gel of Mp_AroKE after Nickel column 
in native conditions: The gel shows the complete absence of properly folded Mp_AroKE. The gel shows 
10 μl of the samples loaded after the purification from the Nickel column. The samples were loaded in the 
buffer containing 50 mM Tris, 300 mM NaCl and the respective imidazole concentration mentioned in the 
picture. B) SDS gel of Mp_AroKE after Nickel column in denaturing conditions: The gel shows that 
Mp_AroKE is expressed and can be purified in denaturing conditions. The gel shows 10 μl of the samples 
loaded after the purification from the Nickel column. The samples were loaded in the buffer containing 6 M 
GnCl, 50 mM Tris, 300 mM NaCl and the respective imidazole concentration mentioned in the picture.  
Mb_AroKE also forms inclusion bodies when expressed in E. coli BL21DE3 cells at 37 ºC but it 
is a well-folded protein when expressed in ArcticExpress cells at 10-12 ºC, M. boonei is an 
acidiphilic, hydrogenotrophic methanogen. It was isolated from an acidic (pH 4.0-4.5) and 
ombrotrophic (rain-fed) bog located near Ithaca, NY, USA [230]. The purified protein has a 
thermal melting temperature (Tm) of ~50 ºC as seen by CD. It migrated as a single species in size 
exclusion chromatography with an average molecular mass of ~51 kDa as determined by static 
light scattering (Figure 3.20).  
 
 
Figure 3.20 Biochemical and biophysical properties of Mb_AroKE A) SDS gel of Mb_AroKE: The gel 
shows the molecular weight of the monomer of the Mb_AroKE is 50 kDa. The gel shows 10 μl of the samples 
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loaded after the purification from the Nickel column. The samples were loaded in the buffer containing 50 
mM Tris, 300 mM NaCl and the respective imidazole concentration mentioned in the picture. B). Light 
scattering of Mb_AroKE: 100 μl Mb_AroKE was loaded at a concentration of 1 mg/ml (black profile), onto 
an S200 size exclusion column and the mass of the eluted particles (gray profile) in the peak area was 
analyzed with static light scattering. The horizontal axis of the curve shows volume in mL and the left axis 
shows the UV absorption. The molar mass on the right is shown in the logarithmic scale. C). CD profile of 
Mb_AroKE: 400 µL of Mb_AroKE at a concentration of ̴ 0.3 mg/mL was measured in the. The figure shows 
the far UV CD spectrum, plotted in mdeg versus wavelength in nanometers (nm) of polarized light. D). 
Thermal stability analysis of Mb_AroKE: 400 µL of Mb_AroKE at a concentration of ̴ 0.3 mg/mL was 
measured at a temperature range from 20 ºC to 95 ºC. The temperature is displayed on horizontal axis 
while CD (mdeg) is shown on the vertical axis. The protein is stable up to 85 ºC. 
3.4.2 Kinetic analysis of Mb_AroKE 
 
Figure 3.21 Mb_AroKE K kinetics for ATP: The Figure shows the kinetic analysis of the K domain for 
ATP for Mb_AroKE. The enzyme concentration is around 10 nM.  
Initial kinetic assays showed an unexpected behavior. The kinetic activity for the substrate ATP 
of the K domain was assessed in the same way as for Tm_AroKB and Fp_AroEK in section 3.3.2. 
However, the kinetic analysis did not show a saturation even when an ATP concentration of 1.4 
mM was tested. This behavior is different from what is observed for Tm_AroKB and Fp_AroEK. 
Further, the binding affinity measurements performed with MST failed to show the binding of 
SKM (data not shown). 
A higher concentration to study the saturation has not been yet tested, but the requirement of a 
high amount of substrate is already known for E.coli, which has two shikimate kinases, AroL and 
AroK. Although AroL and AroK have greater than 30% sequence identity, their properties are very 
different. AroL has the KM of 160 µM for SKM and 200 µM for ATP, while AroK has a KM of 20 
mM for SKM [244]. Both the chromosomal location and regulation are distinct for AroK and 
AroL. While AroL plays the dominant role in the shikimate pathway, AroK potentially plays a 
minor role in the pathway and might have other roles [130]. 
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In addition to the bifunctional AroKE, M. boonei also has another monofunctional AroK, which is 
a 166 amino acid protein (Uniprot ID: A7I8L9) [245]. Interestingly, the bifunctional Mb_AroKE 
has only been annotated as AroE. A multiple sequence alignment between the K domains of 
Mb_AroKE, Mb_AroK, Ec_AroL, and Ec_AroK is shown in Figure 3.22. The figure shows that, 
all the conserved sequence elements for AroK are present in all four Mb_AroKE, Mb_AroK, 
Ec_AroL, and Ec_AroK, and they share more than 30% identity, which all functionally relevant 
residues conserved. Therefore, it could be that just like Ec_AroK, the K domain of Mb_AroKE 
plays only a secondary role in the shikimate pathway and has other functions. 
 
Figure 3.22 Sequence alignment of the K domains of Mb_AroKE with Mb_AroK, Ec_AroL and Ec_AroK: The 
figure shows the sequence alignment of the K domains of the two SKs found in M. boonei with the two SKs found in E. 
coli. The Mg2+ coordinating aspartates are highlighted in yellow color, Walker A consensus sequence (Gly–XXXX–Gly–
Lys–Thr/Ser; X is any amino acid) is highlighted in green color, and the Walker B consensus sequence (ZZ–Asp–XX–
Gly; Z is a hydrophobic amino acid) is highlighted in cyan. The figure shows that although Mb_AroKE and Mb_AroK 
share more than 30% identity, they are not identical just like Ec_AroL and Ec_AroK. In addition, the Mb_AroKE is more 
similar to Ec_AroK than to Mb_AroK or Ec_AroL. 
 
3.4.2. Crystal structure of Mb_AroKE in complex with SKM and phosphate 
Initially, Mb_AroKE crystallized in a complex with SKM and phosphate. The crystals diffracted 
to 1.99 Å. The crystal structure of 4YOA was used as the search model for the AroK domain and 
the crystal structure of 2HK9 was used as the search model for the AroE domain, for molecular 
replacement. Again, the crystals contained one Mb_AroKE monomer in the asymmetric unit. 
Again, just like in the Tm_AroKB and Fp_AroKE structures, Mb_AroKE also has a rigid interface 
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connecting the two domains and all the active sites are solvent accessible. The additional linker 
forms an additional helical hairpin which is packed against the E domain. SKM is bound to AroE 
and a phosphate from the crystallization buffer is bound to the AroK domain. The structure of K 
domain is similar to the previously reported and discussed AroKs with the flexible lid disordered. 
Even though SKM was present in the crystallization buffer, it did not bind the K domain of 
Mb_AroKE. This further strengthens the hypothesis that the K domain of Mb_AroKE plays a 
secondary role in the shikimate pathway. 
The structure of the E domain is similar to previously reported AroEs and contains the bound SKM 
in the catalytic domain (Figure 3.23). The two conserved cis-peptide prolines which connect β-
sheet to α-helix are Pro-216 and Pro267. 
 
Figure 3.23 Crystal structure of Mb_AroKE in complex with SKM: The figure shows the crystal structure 
of AroKE. The N and C termini are marked. The AroK domain is shown in green and the E domain is shown 
in cyan. The alpha helical linker between the two domains is shown in gray. SKM bound to AroE is shown 
as red sticks. Phosphate bound to AroK is shown as red and yellow sticks 
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Most interestingly, the observed domain arrangement in Mb_AroKE is entirely different from 
Fp_AroEK  
3.6. In silico models of a hypothetical tetrafunctional AROM complex  
Owing to the large size and low stability, the actual domain architecture of the AROM complex 
has been elusive since its discovery in 1960s. Therefore, using the respective orientations of four 
domains in four bifunctional enzymes as constraints, hypothetical tetrafunctional in silico models 
of the AROM complex were constructed, using the structures of Tm_AroKB, Fp_AroEK and 
Mb_AroKE. These enzymes together with At_AroDE constitute the four domains B, D, E, K of 
the AROM complex (Figure 3.24). To this end, the homologous domains of the bifunctional fusion 
enzymes were superimposed using secondary structure superimposition in COOT [183]. Two 
different models, one based on AroEK and another one based on AroKE were constructed.  
 
 
Figure 3.24. Pentafunctional AROM complex and the crystal structures of four bifunctional enzymes 
for the hypothetical tetrafunctional models: A) the five enzymatic activities of AROM complex, B) crystal 
structure of At_AroDE (PDB ID: 2O7S), C) crystal structure of Tm_AroKB (This study), D) crystal structure 
of bifunctional Fp_AroEK (This study), E) Crystal structure of bifunctional Mb_AroKE (This study) 
 
To build the AroEK based model (Figure 3.25), the E domain of AroEK was superimposed on the 
E domain of AroDE (Figure 3.25.B). The resulting AroDEK showed no steric clashes. Then the K 
domain of AroKB was superimposed on the K domain of AroDEK and the resulting AroBDEK 
(Figure 3.25.C) showed no steric clashes. As AroKB exists as a dimer, the same procedure was 
repeated for the second monomer of AroKB (Figure 3.25.D). The complete model is also shown 
in surface representation in Figure 3.25E.  
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Mb_AroKE and Fp_AroEK have different domain orders; therefore, both plausible hypothetical 
models using both these enzymes were tested. The workflow for both the models was essentially 
the same except for employing Mb_AroKE to construct the AroKE based model. (Figure 3.26). 
For the sake of simplicity, only the surface representation of the AroKE based model is shown. 
Figures 3.25 and 3.26 show that both models exhibit no steric clashes. The substrate path from B 
to D to E to K domains, highlighted in the figures, shows that both models bring the active sites 
closer to each other. This can potentially help in substrate channeling and it can avoid the dilution 
of reactants and facilitate the reactions. In addition, all the catalytic sites are solvent accessible and 
no steric hindrance is observed. Figure 3.27 compares both models and shows that both models 
have different domain arrangements. Thus, both these models could potentially resemble A) 
transient complexes of the individual enzymes of the pathway and B) an incomplete model of the 
AROM complex.  
To test for the existence of such transient assemblies, pull-down experiments using the bifunctional 
proteins could be made. In a preliminary pull-down experiment with the recombinantly expressed 
Tm_AroKB protein (data not shown), no interacting enzymes of shikimate pathway could be 
identified. However, such a study should be repeated in the native environments of these enzymes, 
which was beyond the scope of this study.  
With the two different and both possible hypothetical incomplete models of the AROM complex, 
a study of the AROM complex itself was needed to confirm these models. Therefore, to validate 
these models, studies on the AROM complex were initiated. 
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Figure 3.25. AroEK based hypothetical tetrafunctional model: The figure traces the steps in 
construction of the AroEK based model A). Cartoon representations of the three bifunctional enzymes: 
This panel shows the cartoon representations of At_AroDE, Fp_AroEK and Tm_AroKB. The two monomers 
of the AroB dimer are colored in pink and light brown to highlight the dimeric interface. B). Cartoon 
representation of AroDEK and AroKB: This panel shows the cartoon representation of the result of 
superimposing E domain of Fp_AroEK on the E domain of AroDE. C) Cartoon representation of 
AroBDEK monomer: This panel shows the cartoon representation of superimposition of K domain of 
Tm_AroKB on K on AroDEK. D) Cartoon representation of AroEK based model: The panel shows the 
dimer of AroEk based model. It was constructed by repeating the steps above for the second monomer of 
Tm_AroKB. E). AroEK based model surface representation: The surface representation of AroEK based 
model is shown in this panel. The line of symmetry divides the molecule into two halves; the individual 
domains are marked on one part of the dimer, while the other half traces the possible path that the substrate 
could follow to carry out the reactions.  
 
Figure 3.26 Surface representation of AroKE based model: The figure shows the surface representation 
of KE based model. The line of symmetry divides the molecule into two halves; the two monomers of the 
AroB dimer are colored differently. The individual domains are marked on one part of the dimer, while the 
other half traces the possible path that the substrate could follow to carry out the reactions.  
  
 
Figure 3.27 Comparison of AroEK and AroKE based models: The figure shows the surface 
representations of EK and KE based models. The different domain arrangements are highlighted. 
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3.7. AROM complex 
Owing to its large size and fragile nature, a stable and homogenous AROM complex, which could 
be crystallized, could not be purified earlier [78, 79, 159-162]. Therefore, we searched for a 
thermostable AROM complex. The proteins from C. thermophilum are known to be very robust 
[231] [246]. Thus, the thermophilic fungi Chaetomium thermophilum and Thielavia heterothallica 
were selected for purifying a thermostable AROM complex. C. thermophilum is a thermophilic 
filamentous fungus. It grows on dung or compost with an optimal growth temperature of 50–55 °C 
[232]. T. heterothallica is the teleomorph to Myceliophthora thermophila [233]; it grows 
optimally at 38-45 °C [234].  
3.7.1 Biochemical and biophysical characterization 
The AROM complex was recombinantly purified from C. thermophilum and T. heterothallica. 
Both purified proteins are well-folded with a thermal melting temperature (Tm) of 65 ºC as seen 
in CD. Ct_AROM migrates as a single species in size exclusion chromatography with an average 
molecular mass of ~344 kDa as determined by static light scattering. (Figure 3.28). Ct_AROM 
was visualized on an EM grid using negative staining. Negative stain EM can be used for 
visualizing homogeneity and/or heterogeneity of purified proteins sample [250]. As seen in figure 
(3.29), Ct_AROM shows a homogenous sample with well defined particles and shows no instances 
of aggregation. It is readily visible that Ct_AROM exists as a symmetric dimer and that the sample 
would be well suited for cryoEM.  
84 
 
 
Figure 3.28 Biochemical and biophysical properties of Ct_AROM: A). SDS gel of Ct_AROM: The gel 
shows the molecular weight of the monomer of Ct_AROM is 172 kDa. The gel shows 10 μl of the samples 
loaded after the purification from the Nickel column. The samples were loaded in the buffer containing 50 
mM Tris, 300 mM NaCl and the respective imidazole concentration mentioned in the picture. B). Light 
scattering of Ct_AROM: 100 μl Ct_AROM was loaded at a concentration of 1 mg/ml (black profile), onto 
a S200 size exclusion column and the mass of the eluted particles (gray profile) in the peak area was 
analyzed with static light scattering. The horizontal axis of the curve shows volume in mL and the left axis 
shows the UV absorption. The molar mass on the right is shown in a logarithmic scale. C). CD profile of 
Ct_AROM: 400 µL of Ct_AROM at a concentration of ̴ 0.3 mg/mL was measured. The figure shows the far 
UV CD spectrum, plotted in mdeg versus wavelength in nanometers (nm) of polarized light. D). Thermal 
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stability analysis of Ct_AROM: 400 µL of Ct_AROM at a concentration of ̴ 0.3 mg/mL was measured at 
a temperature range from 20 ºC to 95 ºC. The temperature is displayed on horizontal axis while CD (mdeg) 
is shown on the vertical axis. The protein is stable up to 65 ºC. E). CD profile of Th_AROM 400 µL of 
Th_AROM at a concentration of ̴ 0.3 mg/mL was measured. The figure shows the far UV CD spectrum, 
plotted in mdeg versus wavelength in nanometers (nm) of polarized light. F). Thermal stability analysis 
of Th_AROM: 400 µL of Ct_AROM at a concentration of ̴ 0.3 mg/mL was measured at a temperature range 
from 20 ºC to 95 ºC. The temperature is displayed on horizontal axis while CD (mdeg) is shown on the 
vertical axis. The protein is stable up to 65 ºC.  
 
Figure 3.29 Negative staining of Ct_AROM: The Figure shows, 0.1 mg/ml protein solution, stained with 
1% uranyl acetate and examined with transmission EM. Homogenous, isolated particles are visible in the 
image.  
3.7.2 Kinetic studies of Ct_AROM 
The catalytic activities of individual domains of AROM have been characterized from N. crassa 
and A. niger [77, 204, 216, 235]. Welch et al have also studied the effect of prior incubation of N. 
crassa AROM with DAHP without any other substrates, and they found an increase in the catalytic 
efficiencies of four of the five enzymes [77]. In addition, the catalytic activities of the individual 
domains have been compared from N. crassa and A. nidulans, [204, 216, 235]. The D domain is 
sensitive to presence of certain metal ions. Therefore, the sensitivity of D domain of N. crassa has 
been compared to E. coli [94]. Additionally, B, the N terminal domain of AROM, has been studied 
individually both structurally and kinetically from A. nidulans [61, 91, 216]. Further, the 
bifunctional BA domain from A. nidulans AROM has been expressed in E. coli and could 
complement AroB- and AroA- E.coli strains. However, when the monofunctional A domain is 
purified, it is not active, even when the B domain is present in trans [236].  
As the studies on the individual enzymes have been carried out multiple times earlier, we wanted 
to study the catalytic activity of the whole complex. The AROM complex contains the activities 
of five enzymes (BDEKA) of the shikimate pathway (Figure 3.30). It catalyzes the formation of 
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EPSP from DAHP in the presence of NAD, Co2+/Zn2+, NADPH, ATP and PEP. Formation of 
EPSP cannot be monitored by spectrophotometric or fluorometric assay. The catalytic activity of 
A domain could be measured in four different ways. In the reverse direction, coupling PEP to A.) 
the PK and LDH reactions and monitoring the oxidation at 340 nm as mentioned for the K domain 
kinetics in section 3.2.2. [185, 237] B.) to the PK, HK and G6PDH reactions and monitoring 
NADPH fluorescence at excitation/emission wavelengths of 340/460 nm. In forward direction, C). 
coupling to the CHM (AroC at 275nm) and/or anthranilate synthases, (TrpGD) in a continuous 
fluorimetric assay [238]. D). Measurement of the released phosphate during the activity of A 
domain [237, 239].  
Both methods A) and B) cannot be employed because the AROM complex because of interference 
with the activity of both the K and A domains. Therefore, the reverse activity of A domain cannot 
be studied as K domain releases ADP. Assay of A domain coupled to AroC and TrpGD is still 
being optimized in the laboratory. Additionally, not only A domain releases a phosphate but also 
B domain. Therefore, a phosphate release assay cannot be employed to study the entire AROM 
complex. 
 
Figure 3.30 Kinetic assay of AROM complex: The Figure shows that AROM complex alone catalyzes 
the five activities of shikimate pathway. It is also highlighted that glyphosate inhibits the activity of A domain 
of the AROM complex. 
The assay for the K domain, mentioned in the section 3.2.2 cannot be utilized to study the BDEK 
activities because the NADPH consumption by the AroE activity will compete with the NADPH 
production from the coupled PK/LDH assay. Therefore, the assay of AROM complex was divided 
into two parts. The activities of AroBDE were studied together, and the activities of AroKA were 
studied separately. The data analysis is as explained in section 2.4.2.3 (for Tm_AroKB kinetics). 
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3.7.2.1 Kinetic analysis for BDE domains 
The activities of the three domains B, D and E were measured by studying activity of E domain. 
The activity of E domain can be analyzed by monitoring the formation of NADP+ in reverse 
direction [240] and in forward direction monitoring oxidation of NADPH at 340 nm [194]. Here 
the catalytic activity of E domain was monitored in the forward direction. AroB requires a divalent 
cation such as Co2+ or Zn2+ for its activity. The catalytic activities were compared in the presence 
of both Zn2+ and Co2+. The reaction rate was faster in the presence of Co2+ (data not shown). Table 
3.3 lists all the substrates required for the AROM complex. The substrates until (including) the E 
and substrates until the K domain of the AROM complex are also listed. For initial studies, the 
reaction was carried out in the presence of all the substrates (Figure 3.31A). Ct_AROM is stable 
up to 65 ºC. Therefore, the kinetics for BDE domains was studied at 30 ºC, 40 ºC, 45 ºC and 50 
ºC. The reaction cocktail containing all the components was incubated at the desired temperature 
for 15 minutes before adding the enzyme (10 nM) to start the reaction.  
To test for potential product/substrate inhibition effects, the reaction was also performed with the 
substrates until the E domain and with substrates until the K domain. However, the first results of 
the kinetic analysis of substrates until K were noisy and the data could not be analyzed. This part 
of the study is yet to be repeated. 
Table 3.3 Substrates for AROM complex kinetics 
All substrates Substrates until E domain Substrates until K domain 
DAHP, MgCl2, CoCl2, NAD, 
NADPH, ATP, PEP. 
DAHP, MgCl2, CoCl2, NAD, 
NADPH. 
DAHP, MgCl2, CoCl2, NAD, 
NADPH, ATP. 
 
The activity of AROM complex increases with an increase in temperature until 45 ºC (Figure 
3.31A). In addition, the Ct_AROM complex exhibits product based inhibition. The graph with 
substrates until E shows that the activity decreases substantially, in absence of the complete 
substrate cocktail. The data at 50 ºC was very noisy and could therefore not be analyzed fully. 
However, the maximum velocity at 50 ºC was similar to that at 45 ºC, so the reaction was not 
studied at higher temperatures. 
3.7.2.2 Kinetic analysis of E. coli enzymes 
For a comparison between the monofunctional enzymes in E. coli to the pentafunctional AROM 
complex the activities of E. coli AroB, AroD, AroE, AroL and AroA were measured at AroE as 
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outlined for AROM complex above. The enzyme cocktail contained the five E. coli enzymes at a 
concentration of 30 nM.  
To compare the catalytic activities of the monofunctional E. coli and the pentafunctional AROM 
complex, the assay was carried out in the same way as that of BDE kinetics of Ct_AROM. The 
enzyme concentration employed was three times that of the AROM complex, otherwise the 
reaction could not be measured optimally (Figure 3.31B). As can be seen in Table 3.4, the kcat/KM 
value of E. coli enzymes is three (2.9) times less than that of the AROM complex. Therefore, the 
pentafunctional AROM complex containing five different activities on one chain is almost three 
times faster than a mixture of the monofunctional E. coli enzymes. However, as E. coli and C. 
thermophilum are completely different organisms, further studies are needed to assess the potential 
benefits of the AROM complex as compared to monofunctional enzymes. Studies comparing the 
pentafunctional AROM complex to five AROM mutants, each lacking four activities could 
indicate if and to which extent the presence of all the activities on the same chain aids the catalytic 
activity. 
3.7.2.3 Kinetic analysis of KA domains 
To study the remaining two activities of the AROM complex, the activities of the KA domains 
was studied together. As described in the section 3.7.2 we could only study AroA activity by 
measuring the released phosphate. To measure the released phosphate continuously, the Enzcheck 
phosphate release assay kit [188] was employed. The activity of K and A domains was analyzed 
starting with SKM. The linear region for the Enzcheck phosphate assay extends until 150 µM, 
which was used as the maximum substrate concentration of this assay. Further, MESG is heat 
sensitive, the assay could only be performed at 30 ºC. Figure 3.31 shows the KA kinetics of the 
AROM complex.  
Further, the effect of glyphosate on the AROM complex A was studied. At 150 µM S3P 
concentration, the reaction was carried with 200 µM of PEP, with and without 200 µM of GLP 
(Figure 3.31D). Although, only the velocity at a single substrate concentration of 150 µM was 
determined, the graph clearly shows a reduction of at least 25% in presence of GLP, confirming 
that GLP acts as a competitive inhibitor of the Ct_AROM AroA moiety [140].  
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As seen in the crystal structure of Ct_AROM, (Figure 3.32) the B and A domains are next to each 
other. Therefore, it was hypothesized that this arrangement aids in regulation, i.e., A domain (last 
catalytic subunit) might be regulating B, (first catalytic subunit). Thus, the BDE kinetics were 
repeated in the presence of GLP. However, no influence of GLP on the kinetic behavior was 
observed, so no regulatory effects between the domains could be determined. This suggests that 
the domain arrangement of the AROM complex is optimized to facilitate substrate concentration 
rather than regulation. Further experiments are needed to validate this. Table 3.4 summarizes the 
kinetic analysis of Ct_AROM. 
 
  
Figure 3.31 Ct_AROM kinetics: The figure shows the kinetic analysis of the AROM complex. A). BDE 
kinetics: This panel compares kinetics of BDE domains at different temperatures, and different colors 
represent different experiments. The activity increases with an increase in temperature. The red color 
shows the experiment conducted in the absence of ATP and PEP. The activity when not all the substrates 
are present is significantly decreased B). BDE kinetics with the E. coli enzymes: The experiment shows 
the kinetics carried out by AroB, AroD, AroE, AroL, AroA. The experiment was carried out at an enzymatic 
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concentration of 30 nM. C). KA kinetics: The figure shows Ct_AROM KA kinetics at 30 ºC. D). Ct_AROM 
glyphosate inhibition: The panel shows the absorbance due to phosphate release. 
 
Table 3.4 Catalytic activities of AROM complex 
Activity T 
( ̊C) 
KM ± % S.E. 
(µM) 
Et 
(nM) 
kcat ± % S.E. 
(s-1) 
kcat/KM (s-
1 M-1) 
R2 
BDE for AROM (all sub) 30 28.14 ± 16.5% 10 4.27 ± 4.06% 1.52e+5 0.831 
BDE for AROM (all sub)  40 94.33 ± 34.5% 10 20.49 ± 11.8% 2.17e+5 0.600 
BDE for AROM (sub until E) 40 23.96 ± 33.6% 10 7.88 ± 7.22% 3.29e+5 0.495 
BDE for AROM (all sub) 45 87.90 ± 20.36% 10 24.78 ± 6.5% 2.82e+5 0.825 
BDE E.coli (all sub) 30 101.23± 64.8% 30 9.72 ± 25% 9.60e+4 0.334 
KA AROM (sub from K) 30 11.68 ± 16.69% 10 4.84 ± 4.6% 4.14e+5 0.862 
 
The kinetic study here analyzes the catalytic parameters of various enzymatic activities together, 
therefore the error rates are observed to be higher. Further, the reaction volumes for BDE kinetics 
were 25 µL, such a low volume can also contribute to the error rates. Higher error rates were also 
observed for Tm_AroKB, when the reaction was conducted with 50 µL volumes. 
3.7.3 XL-MS studies Ct_AROM 
In crosslinking mass spectrometry (XL-MS), proteins are chemically crosslinked in their native or 
native-like state and then cleaved to peptides by enzymatic digestion to identify the sequence of 
crosslinked peptides with tandem MS [241]. The DSS crosslinker was employed in the AROM 
crosslinking experiments. DSS is a six-carbon succinimide-type conventional lysine cross-linking 
reagent [242]. DSS, when fully extended, has a 11.4 Å long linker arm, allowing Cα atoms of 
crosslinked lysine residues to be up to ∼24 Å apart. Adding a tolerance of ∼3 Å to both sides, DSS 
can crosslink lysine residues with distances up to 26–30 Å between Cα atoms [243]. Crosslinking 
was carried out at two different concentrations of DSS (250 μM and 1 mM and respectively) to 
confirm no occurrence of aggregation tendencies with stronger cross-linking. The data looks rather 
similar for both cross-linker concentrations. A large number of cross-links are observed, between 
85 and more than 100. The number of false positive crosslinks of the data sets is <5%. The structure 
of the AROM complex could not be predicted from the XL-MS data alone. However, the data 
already suggested that the A domain of the AROM complex was closer to the B domain of the 
AROM complex, rather than the proximity of the K and B domains as predicted by the AroEK and 
AroKE based models. Therefore, it indicated that models do not predict the organization of the 
AROM complex. 
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3.7.4. Crystal structure  
Initially, crystallization trials were set up both for Ct_AROM and Th_AROM both in Apo state 
and in combination with various ligands. While testing different crystallization conditions it was 
observed that both the proteins only crystallized in the presence of a Hepes buffer and TCEP, 
rather than Tris and β-ME. Initial crystals diffracted to 8 Å. As Ct_AROM crystals proved to be 
better reproducible, further crystallization optimization was continued with Ct_AROM.  
Ct_AROM only crystallized in the presence of SKM, DHQ and NAD or alternatively with DHS, 
DHQ and NAD. It was observed that DHS and SKM can be interchangeably used for the 
crystallization condition, but the crystals did not form in the absence of DHQ. The crystals of 
native Ct_AROM diffracted at a resolution of 3.1-3.3 Å. Due to the large size of the protein, the 
crystal structure of the native Ct_AROM could not be solved by molecular replacement. Attempts 
to soak the crystals with platinum, mercury and heavy metal salts for experimental phasing 
deteriorated the data quality. Therefore, crystals were reproduced using Se-met containing 
Ct_AROM, which enabled structure solution via SAD phasing.  
The structure contains two molecules in the asymmetric unit, forming a functional dimer (Figure 
3.32). It is the first reported crystal structure of the AROM complex. The dimerization is mediated 
by the B and D domains. In both monomers, the five constituent domains are connected via rigid 
interfaces and all the active sites are solvent accessible. However, it is visible that two halves of 
the crystal structure are not similar. The two monomers occupy slightly different conformations, 
potentially corresponding to different catalytic states of individual domains. The structure shows 
that the B domain is connected to the A domain rather than the K domain as predicted by the in-
silico models. Therefore, both models based on AroKE and AroEK are not correct in predicting 
the domain arrangement of the AROM complex (Figure 3.33). When the crosslinks obtained 
through XL-MS were mapped on the AROM complex, it was evident that the crosslinks agree 
with the crystal structure to large extents (Figure 3.32 C). 
The structure contains NAD and Zn2+ bound to both B subunits, DHQ or DHS bound to both D 
subunits, SKM bound to both E subunits, both K subunits and one A subunit. The electron density 
at this resolution cannot distinguish well between DHQ and DHS, and therefore it is not clear 
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whether DHS or DHQ is bound to the D domain. However, as the protein was co-crystallized with 
DHQ, it seems the more probable ligand. 
 
Figure 3.32 Crystal structure of Ct_AROM: The figure illustrates the crystal structure of the 
pentafunctional AROM complex. A). Cartoon representation: The structure contains a homodimer. N and 
C termini are shown. SKM is bound to both E, both K and one A domain and is shown in red sticks. NAD 
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bound to B domain is shown in black sticks. DHS, bound to D domain is shown in brown sticks. The line of 
symmetry divides the structure in two monomers. B). Surface representation: The individual domains are 
marked; the B and D domains are colored differently to highlight the dimeric interface. The path, followed 
by the substrates, is traced in the structure. C). XL-MS data mapped on the crystal structure of 
Ct_AROM: The crystal structure is shown in gray with the dimer highlighted in two shades of gray. The 
crosslinks are shown in yellow and the residues connected with the crosslinks are shown in blue and red. 
 
 
Figure 3.33 Hypothetical tetrafunctional AROM models vs crystal structure of AROM complex: The 
Figure shows that arrangement of the AROM complex is different from both predicted models. 
The A domain on the right in Figure 3.32 contained additional electron density in the S3P binding 
site, which was best interpreted with a SKM molecule, while the A domain on the left did not 
contain ligands. Even though SKM is not the usual substrate of AroA, two other crystal structures 
are reported with bound SKM (PDB ID: 2AA9 [244] and 3SLH [143]). SKM can bind to the active 
site in the same orientation as S3P, with the 5-OH pointing towards the PEP-binding site [244].  
3.7.5 Conformational space of Ct_AROM  
The structure shows a compact assembly of the individual domains, in which each domain forms 
an interface to at least one other domain. Ct_AROM has both rigid and flexible parts and four of 
the five domains (B,E,K,A) can exist in different conformations depending on the catalytic state 
[92, 134, 200, 224, 228, 244, 245]. Therefore, the four domains B, A, K, and E, exhibit different 
domain movements based on their catalytic states.  
The crystal structure shows only a static picture of these four domains. Therefore, the 
conformational space of Ct_AROM was explored using representative structures for each of the 
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four domains from the PDB. For the B domain (Figure 3.32, Figure 1.5), the Rossmann-fold is 
rigid at the dimer interface, while the α-helical sub-domain can undergo hinge motions. The 
attachment to α-helical B sub-domain confers additional flexibility to the A domain. Therefore, it 
can adopt various conformations depending on its own catalytic state and depending on the relative 
motion of the B domain. Such a cumulative effect is not found for the K and E domains, which are 
both attached to the rigid D domain, so they can have different conformations depending on only 
their own catalytic states.  
The procedure outlining the mining of the representative structures is described in the section 2.7.8. 
The conformations of the crystal structures of the different monofunctional enzymes from the PDB 
in various catalytic states were mapped onto the Ct_AROM structure and thus, a structural 
ensemble of the accessible conformational states of the AROM complex was generated. Further, 
an analysis of this ensemble indicated that the individual domains can adopt essentially all 
conformations that occur throughout the individual catalytic cycles without steric clashes to other 
domains. To illustrate this conformational space (CS_AROM), a movie of AROM sampling the 
different conformations was generated, highlighting that the structure of the AROM complex is 
optimized for the spatial compatibility of its constitutive domains with respect to their 
conformational changes. The movie is accessible under the following link:  
https://owncloud.tuebingen.mpg.de/index.php/s/SznO2l0DrHoYEmB.  
Further, the XL-MS data was re-evaluated using CS_AROM. To study the distribution of the 
crosslinking restraints predicted by the XL-MS experiment graphically, each of the crosslinks was 
plotted against distance in Å. Similar crosslinks were computed from the different models 
generated in computing CS_AROM. Further, these crosslinks were plotted on the same graph and 
the possible crosslinks within the conformational space were compared to the experimental 
crosslinks (Figure 3.34). As seen in the Figure, most of the residues of Ct_AROM fall in the range 
below 30 Å, which suggests that AROM complex exists mostly in similar conformations in 
solution and in crystalline state. The distribution further indicates that several crosslinks 
correspond to conformations in the conformational space beyond the crystal structure, indicating 
that also other conformations are sampled in solution. 
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Figure 3.34. Graphical distribution of XLMS distance restraints: The figure shows the crosslinks 
between two lysines vs. the distance in Å. The experimental restraints obtained for the AROM complex are 
shown in red and the calculated distances for the models possible in the conformational space are shown 
in gray. Green line shows the distance of 30 Å. The concentration of DSS used for this experiment was 250 
µM. 
3.7.6 SAXS experiments for Ct_AROM 
Small-angle X-ray scattering (SAXS) studies the X-ray scattering of macromolecules in solution 
and predicts the overall shape and structural transitions of biological macromolecules in solution. 
It provides low-resolution information on the shape, conformation and assembly of proteins, and 
various other macromolecular complexes [246]. To understand the possible orientations 
represented by AROM complex, SAXS experiments were conducted both with Apo Ct_AROM 
and Th_AROM and in the presence of various ligands.  
The initial data analysis for Ct_AROM apo protein carried out in Primus [195] is shown in Figure 
3.35. The logarithmic plot of the scattering intensity I vs. q, (Figure 3.35 A.) shows the complete 
range of raw data after buffer subtraction. It does not indicate any aggregations or inter-particle 
interactions. This is further supported by the Guinier plot of log(I(q)) against q2 (Figure 3.35 B.), 
which yields a straight line [247].  
The Kratky plot, I(q)*q2 vs. q (Figure 3.35 C.), exhibits a bell-shaped curve peak at low q and it 
converges to the q axis at high q. This indicates that Ct_AROM is a globular protein without 
pronounced flexibility. The Pair-wise distance distribution function P(r), obtained by indirect 
Fourier transformation of the scattering curve exhibits a single peak and is thus further indicative 
of a globular proteins (Figure 3.35D). It further indicates a maximum length in the particle 
dimension, Dmax, of 165.0 Å, as compared to about 180 Å in the crystal structure. The agreement 
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in the values of Rg and I(0) calculated both from the P(r) function and the Guinier plot indicate a 
good quality of data (Table 3.6).. 
 
  
Figure 3.35 Plots estimating quality analysis of SAXS data A). Logarithmic plot of the scattering 
intensity I (s) (in arbitrary units) vs. s (in Å-1): This plot shows the complete range of the raw data after 
buffer subtraction B) Guinier analysis: The Guinier analysis shows the logarithmic scale of intensity vs s2 
which is a straight line and thus shows no aggregation. C). Kratky plot: The Kratky plot shows that 
Ct_AROM shows a bell shaped curve characteristic of globular proteins. D) Distance distribution function 
plot: The p(r) vs. r (in Å) shows that the maximum dimension of the particle in solution, Dmax. P(r) drops to 
zero on the r axis. 
Table 3.6 Data quality and analysis parameters of Ct_AROM: The table shows the data quality 
analysis of SAXS data, the Rg and I0 estimates  
Total quality estimate 0.75 
Guinier Rg/I0 54.75/0.21 
P(r) Rg/I0 54.74/0.21 
Dmax 165.0 Å 
Porod volume 609000.0 Å3 
Molecular weight (predicted/real/%error) (kDa) 318/344/7.5% 
 
97 
 
In SAXS-based modeling, SAXS profiles are computed for a given atomic structure and are 
compared with the experimental profile [248, 249]. The experimental SAXS curves were fitted to 
the computed SAXS profiles of the crystal structure of Ct_AROM (Figure 3.36). As seen in Figure 
3.36 A, the calculated SAXS profile fits the experimental data very well, with a χ value of 1.92. 
The only region which does not fit the data completely, is the one in the q-range from 0.08 to 0.1 
Å-1. Therefore, it is evident that the Ct_AROM crystal explains the conformation in solution to a 
very good extent.  
To refine the fit, theoretical SAXS profiles were also computed for all constitutive models of the 
CS_AROM ensemble (Section 3.7.5), and compared to the experimental SAXS profile. We thus 
identified AROM conformations that explain the SAXS data better. The best fit was achieved with 
the model 1nva-3roi-4y0a-3fbt-D_with a χ = 1.26. Especially, the fit in the region between 0.08 to 
0.1 Å-1 improved significantly. In the structure of 1nva-3roi-4y0a-3fbt-D_AROM, the AROM 
complex is found in a slightly more relaxed conformation, with the A domains in a more distal 
orientation and a larger cleft between the A and K domains. In contrast, the worst fit was 
achievable with the model B_AROM-1g6t-2iyt-3don-D_AROM (Figure 3.36 C) (χ = 2.12). 
Further, SAXS experiments were performed in presence of various ligands. Figure 3.36 D, E and 
F show the experimental SAXS profile of Ct_AROM in the presence of SKM, ATP, NADH and 
DHQ. This experimental profile was also fitted to computed profile from the crystal structure of 
Ct_AROM (Figure 3.36 D) (χ = 2.69). The fit to the experimental data improved with model 1nva-
A_AROM-3mrs-3don-D_AROM (Figure 3.36 E) (χ = 1.18), which shows the A domain in a more 
extended conformation, while it deteriorated when fitted to the model B_AROM-1g6t-2iyt-3don-
D_AROM (Figure 3.36 F) (χ = 3.14). The crystal structures constituting these models are listed in 
Table 3.7. 
For a surface representation, an outline of the conformational space (CS_AROM) was constructed 
in Pymol. This outline is superimposed with the crystal structure and the model 1nva-2bjb-3mrs-
3fbt-DAROM, which fit the SAXS data best until a cutoff of 0.2 Å-1. (Figure 3.37). The model 
occupies a greater area in the possible space of CS_AROM and it is apparent that it shows the 
AROM complex in a more relaxed conformation than the crystal structure. 
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Figure 3.36 SAXS analysis: The figure shows the experimental SAXS profile (colored) superimposed on 
the computed SAXS profile. The curves are sorted based on the chi values. Red color shows the computed 
SAXS profile based on the crystal structure of Ct_AROM, Green color shows the best fitting computed 
SAXS profile, while yellow color shows the worst fitting computed SAXS profile. A.) SAXS profile of 
Ct_AROM apo and crystal structure of Ct_AROM: The figure compares the experimental SAXS profile 
of Ct_AROM apo to the computed SAXS profile based on crystal structure of Ct_AROM. B.) SAXS profile 
of Ct_AROM apo and model of 1nva-3roi-4y0a-3fbt-D_AROM: The figure compares the experimental 
SAXS profile of Ct_AROM apo, to the computed SAXS profile from the model constituting the crystal 
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structures with PDBIDs: 1nva, 3roi, 4y0a, 3fbt, D_AROM. C.). SAXS profile of Ct_AROM apo and model 
of B_AROM-1g6t-2iyt-3don-D_AROM: The figure compares the experimental SAXS profile of Ct_AROM 
apo, to the computed SAXS profile from the model constituting the crystal structures with PDBIDs: 
B_AROM-1g6t-2iyt-3don-D_AROM. D.) SAXS profile of Ct_AROM +SKM+ATP+NADH+DHQ+DHS and 
crystal structure of Ct_AROM: The figure compares the experimental SAXS profile of 
Ct_AROM+SKM+ATP+NADH+DHQ+DHS to the computed SAXS profile based on the crystal structure of 
Ct_AROM. E.) SAXS profile of Ct_AROM +SKM+ATP+NADH+DHQ+DHS and model of 1nva-
A_AROM-3mrs-3don-D_AROM: The figure compares the experimental SAXS profile of 
Ct_AROM+SKM+ATP+NADH+DHQ+DHS to the computed SAXS profile model constituting the crystal 
structures with PDBIDs:1nva-A_AROM-3mrs-3don-D_AROM. F). SAXS profile of Ct_AROM 
+SKM+ATP+NADH+DHQ+DHS and model of B_AROM-1g6t-2iyt-3don-D_AROM: The Figure 
compares the experimental SAXS profile of Ct_AROM+SKM+ATP+NADH+DHQ+DHS to the computed 
SAXS profile model constituting the crystal structures with PDBIDs: B_AROM-1g6t-2iyt-3don-D_AROM. 
Table 3.7 Crystal structures employed for models 
PDB 
ID 
Domain  Ligands 
bound 
Organism Reference 
1nva AroB Zn2+, ADP Aspergillus niger [91] 
3roi AroA SO42-, Cl- Coxiella burnetii [250] 
3fbt AroME - Clostridium acetobutylicum [251] 
3mrs AroK, R57A - Helicobacter pylori [224] 
1g6t AroA EPSP Escherichia coli [140] 
2iyt AroK Cl- Mycobacterium tuberculosis [133] 
3don AroE Glycerol Staphylococcus epidermidis [226] 
2bjb AroA - Mycobacterium tuberculosis [252] 
4y0a AroK SO42-, SKM Acinetobacter baumannii [134] 
 
 
Figure 3.37. Crystal structure of Ct_AROM and model 1nva-2bjb-3mrs-3fbt-DAROM superimposed 
on the outline of CS_AROM: The figure compares the superimposition of (A.) the crystal structure of 
Ct_AROM (red) (B.) and model 1nva-2bjb-3mrs-3fbt-DAROM (green) in an outline of the surface 
representation of CS_AROM (gray). 
 
These results suggest that Ct_AROM exists in very similar conformations in the crystal structure 
and in solution. While the core, containing the D domain and N-terminal B subdomain, is generally 
rigid the C-terminal B subdomain and the E, K and A domains can sample different conformations 
for different domains depending on the ligand state. This is most evident in the fit of different 
AROM conformations to the SAXS profiles in different ligandation states. 
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3.7.7 Implications of the AROM structure 
The analysis of the conformational space indicated that almost all conformations that occur 
throughout the individual catalytic cycles can be adopted by the individual domains without 
causing steric clashes, and without the need for coordination between the domains. Thus, the 
complex appears to be optimized to concentrate all active sites in the closest possible proximity to 
each other. This is in accordance with the results of the kinetic analysis, which suggested an 
increased catalytic throughput but could not reveal regulatory interactions. This tight spatial 
arrangement could potentially exploited pharmaceutically. The pentafunctional AROM complex 
is present in pathogenic fungi and in various apicomplexan parasites, such as T. gondii, and is 
therefore a relevant drug target [35, 37, 62, 76, 163, 203, 253, 254]. Until now, the only inhibitor 
used as herbicide is glyphosate [142], now, new drugs can be designed by aiming at the flexibility 
between the individual domains, with the aim to restrict the conformational space with an allosteric 
inhibitor. To this end, the defined conformational space of the AROM complex could be targeted 
directly in in silico screening. Further, since Ct_AROM is very robust, it could pose a good model 
system for high throughput screening for AROM inhibitors and fragment based drug discovery. 
Further, based on the crystal structure of the AROM complex, in silico models of related 
multienzymes can be generated. One of them is the tetrafunctional AroN from the pathogen A. 
castalleni (Figure3.38). It is a 130 kDa homolog of the AROM complex that only lacks the C-
terminal E domain [37]. The absence of this domain from AroN is highly remarkable and could 
suggest the formation of higher order assemblies. However, also in absence of this domain, the 
remaining four domains still provides a large conformational space for in silico drug screening.  
The other protein that can be modeled based on the AROM structure to large extents is the QutR 
quinate repressor. It consists of the three C-terminal KDE domains [211] and an N-terminal part 
responsible for the repressor function. Canonically, this N-terminal part interacts with the quinate 
activator, to alter its DNA binding behavior. The QutR protein is of particular interest, as it has in 
intramolecular signaling function. Here, the ligandation state of the KDE domains controls the 
association or dissociation with the quinate activator. It may therefore pose an interesting study 
object to follow allosteric regulatory effects mediated by the KDE domains. 
Lastly, the sophisticated architecture and the apparent functional gain of the AROM complex, 
together with the presence of many other multifunctional enzymes in the shikimate pathway, foster 
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the idea that the monofunctional enzymes of the pathway also form transient complexes. These 
assemblies might resemble the AROM complex or they might resemble part of the models we 
generated. So far, the only reported such assembly is that of AroB from B subtilis, which 
supposedly forms a complex with AroC and NADPH reductase [255]. This in turn fuels the 
hypothesis that also AROM might form complexes with further enzymes, like AroC. 
 
Figure 3.38. In silico models of AroN and QutR: The figure shows the hypothetical models of AroN, 
which lacks the E domain, and QutR, which contains the KDE domains, and connects N-terminally to a 
DNA binding domain.  
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4. Conclusions and Outlook 
The aim of this work was to study multifunctional enzymes of the shikimate pathway, to 
investigate any substrate channeling or reveal regulatory mechanisms, or the formation of higher-
order complexes. Much work has been done on the monofunctional enzymes of the pathway, but 
the knowledge on multifunctional enzymes is scarce. In this study, three bifunctional shikimate 
pathway enzymes (AroKB, AroEK, and AroKE) and the pentafunctional AROM complex were 
selected for functional and structural characterization. 
The AroKB fusion catalyzes the second and fifth step of the pathway, therefore, a channeling effect 
cannot be anticipated, but a regulatory signaling mechanism between the domains seems 
conceivable. The kinetic analysis of Tm_AroKB shows that the kinetics parameters are in a similar 
range as reported for monofunctional bacterial AroKs and AroBs. Interestingly, the kinetic 
parameters of the truncated monofunctional Tm_AroKKB, which is only slightly less thermostable 
than full-length Tm_AroKB, are also in the same range as for the bifunctional full-length protein. 
A significant allosteric regulation between the two enzymatic domains was not detected. 
Consequently, this especially wide-spread fusion of AroK and AroB domains could merely be a 
consequence of their genetic neighborhood within the same operon in many taxonomic groups. 
However, is seems possible that the fusion might be a part of higher order assemblies.  
Both the AroEK and AroKE fusions catalyze subsequent steps of the pathway, therefore, a 
channeling effect is probable. The kinetic analysis of the K domain of Fp_AroEK yielded similar 
parameters as for Tm_AroKB. On the other hand, the K domain of Mb_AroKE was found to be 
considerably slower. Interestingly, Mb also possesses a second, monofunctional AroK. Therefore, 
probably this monofunctional AroK plays a dominant role in shikimate pathway, while the K 
domain of Mb_AroKE might perform other activities. A detailed analysis of potential channeling 
effects is an interesting perspective for future studies. 
The crystal structures of the three bifunctional proteins yielded important and partly unexpected 
insights. In each of the three bifunctional proteins, the two constitutive domains are connected via 
rigid interfaces, such that the active sites are accessible to the solvent.  
The crystal structure of Tm_AroKB is unique because it contains an intrinsically bound NAD and 
Zn2+ in the B domain. This NAD is trapped in its binding pocked by a salt bridge between Arg-
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195 and Asp-316 that is specific to Tm_AroKB. A Tm_AroKB variant without the entrapped NAD 
was successfully designed by mutating these residues to Ala (Tm_AroKB_SB). As NAD is 
recycled in the AroB reaction cycle, the entrapment of this cofactor could potentially serve to 
increase the catalytic efficiency and potentially add to the thermostability of the protein. While the 
latter could be ruled out, a clear trend for the catalytic parameters could not be ascertained.  
In the crystal structures of Fp_AroEK and Mb_AroKE, the individual domains had the architecture 
expected from the monofunctional orthologs. However, the constitutive domains in the two 
structures are arranged differently. Based on the two different arrangements of E and K domains 
found in Fp_AroEK and Mb_AroKE, two different hypothetical in silico models of tetrafunctional 
complexes were constructed by simple superposition to the Tm_AroKB and the previously 
reported At_AroDE structure. While both these models differ in their domain arrangement, both 
are physically plausible as all the catalytic sites are solvent accessible and no steric clashes were 
encountered. These could suggest potential transient higher order complexes that might serve to 
increase the overall performance of the pathway. To test for the existence of such complexes, pull 
down experiments in the native environment of the different proteins are a potential starting point 
for future studies.  
In comparison to the bifunctional proteins, a functional and structural characterization of the 
AROM complex was performed. To circumvent stability issues reported in previous studies, the 
protein was taken from a thermophilic organism.  Ct_AROM is a highly stable and soluble protein. 
In kinetic assays, its catalytic activity increased with temperature. In a simple comparison to a 
mixture of monofunctional enzymes from E coli, Ct_AROM displayed a significantly higher 
turnover rate. This suggests that the architecture of AROM facilitates substrate channeling. 
However, this must be verified by carrying out kinetic studies using a series of functional 
Ct_AROM mutants.  
Finally, the crystal structure of Ct_AROM and its conformational space was solved and analyzed. 
The crystal structure initially revealed the domain arrangement, which is different from both 
tetrafunctional in silico models. All active sites are accessible to the solvent and are arranged for 
short diffusion times between domains responsible for consecutive steps in the pathway. The 
overall conformation of the crystal structure could be confirmed using SAXS and XL-MS data. 
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To understand the dynamics of domain motions during various catalytic states, a structural 
ensemble of the accessible conformational states of the AROM complex was generated by 
mapping the conformations of the crystal structures of the different monofunctional enzymes from 
the PDB in various catalytic states onto the Ct_AROM structure. With this ensemble, the 
conformations that best fit the SAXS data could be identified, which closely resemble the crystal 
structure. Further, this suggested that individual domains could adopt essentially all conformations 
that occur throughout the individual catalytic cycles without steric clashes to other domains, which 
can be demonstrated in a movie of the conformational space. All this structural information can be 
used to infer the structure and conformational space of the tetrafunctional AroN from A. castalleni 
and the QutR repressor. 
As the AROM complex is generally present in pathogenic fungi and apicomplexan parasites, it is 
a highly relevant drug target. Indeed, the catalytic activity of the Ct_AROM complex reduced in 
presence of glyphosate. The robust nature of Ct_AROM could pose a good model system for high 
throughput screening for AROM inhibitors and fragment based drug discovery. It is conceivable 
that novel inhibitors targeting the conformational flexibility needed between the domains can be 
explored.  
Further, it seems possible that in vivo, the AROM complex is associated with even more enzymes 
of the shikimate and also downstream pathways, which are yet to be identified. Consequently, 
future studies should also focus on the identification of potential higher order assemblies in the 
native environment.  
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Zusammenfassung 
Multifunktionale Enzyme sind natürliche Fusionsproteine mit mehreren katalytischen Aktivitäten. 
Durch die räumliche Nähe der katalytischen Domänen profitieren diese Enzyme von der lokalen 
Konzentration der Reaktanten und können zusätzliche Besonderheiten wie allosterische 
Regulation und Substratkanalisierung aufweisen. Während Struktur und Funktion von 
monofunktionalen Enzymen im Allgemeinen sehr gut verstanden sind, sind Studien zu 
multifunktionalen Enzymen und zu Komplexen monofunktionaler Enzyme eher rar. Der 
Shikimatweg, welcher in sieben Schritten zu aromatischen Verbindungen führt, enthält eine Reihe 
bi-, tri-, tetra- und pentafunktionaler Enzyme in unterschiedlichen Organismen. Am 
bemerkenswertesten ist hier der pentafunktionale AROM-Komplex, welcher die zentralen fünf 
Schritte katalysiert, und dessen Struktur über Dekaden hin nicht aufgeklärt werden konnte. 
In dieser Arbeit beleuchten wir diesen AROM-Komplex und die drei bifunktionalen 
Shikimatwegenzyme Tm_AroKB, Fp_AroEK und Mb_AroKE, indem wir sie sowohl funktionell 
als auch strukturell charakterisieren und mit ihren monofunktionalen Gegenstücken vergleichen. 
Für Tm_AroKB and Fp_AroEK erhielten wir katalytische Parameter, die mit denen der bekannten 
monofunktionalen Enzyme vergleichbar sind. Außerdem ist die katalytische Aktivität eines 
verkürzten, monofunktionalen Tm_AroKKB vergleichbar mit der der entsprechenden Domäne des 
bifunktionalen Proteins. Interessanterweise konnten keine allosterischen Effekte zwischen den 
Domänen festgestellt werden. Die Analyse der K-Domäne von Mb_AroKE zeigte eine unerwartet 
niedrige Aktivität, welche deutlich unter der Aktivität der anderen untersuchten Proteine liegt. Das 
Genom des zugehörigen Organismus, Methanoregula boonei, enthält jedoch noch ein weiteres 
monofunktionales AroK-Homolog, welches möglicherweise die Hauptfunktion im Shikimatweg 
übernimmt. 
In den Strukturen der bifunktionalen Proteine sind die einzelnen Domänen rigide miteinander 
verbunden, wobei alle aktiven Zentren zugänglich sind. Tm_AroKB is ein Dimer und enthält 
bemerkenswerterweise ein permanent intrinsisch gebundenes NAD-Molekül. Die Strukturen der 
einzelnen Domänen aller charakterisierten bifunktionalen Proteine entsprechen im Wesentlichen 
denen ihrer monofunktionalen Gegenstücke, jedoch ist die räumliche Domänenanordnung bei 
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Fp_AroEK anders als bei Mb_AroKE. In beiden Anordnungen sind die aktiven Zentren jedoch 
nah beieinander. Es ist somit denkbar, dass diese Proteine Teil eines übergeordneten Komplexes 
sind, welcher den katalytischen Durchsatz des Shikimatwegs steigern könnte. Aus diesem Grund 
wurden im nächsten Schritt in-silico-Modelle solcher Komplexe konstruiert. Diese basieren auf 
der unvoreingenommenen Überlagerung der Strukturen von Fp_AroEK und Mb_AroKE auf die 
von Tm_AroKB und At_AroDE ohne weitere Modifikationen. Beide Modelle stellen trotz ihrer 
Unterschiede plausible, kompakte Komplexe mit zugänglichen aktiven Zentren dar. 
Diese haben wir dann mit dem pentafunktionalen AROM-Komplex verglichen. In kinetischen 
Experimenten zeigte sich ein signifikant höherer Durchsatz als bei monofunktionalen E. coli 
Enzymen. Die Kristallstruktur des AROM-Komplexes zeigt eine sehr kompakte Anordnung von 
rigide miteinander verbundenen Domänen, welche sich jedoch von den in-silico-Modellen 
unterscheidet. Mittels SAXS- und XL-MS-Messungen konnte verifiziert werden, dass die 
Konformation des AROM-Komplexes in Lösung der Konformation im Kristall im Wesentlichen 
sehr ähnlich ist. Um Einblicke in die Konformationsdynamik des AROM-Komplexes zu 
gewinnen, haben wir die unterschiedlichen konformationellen Zustände der einzelnen 
enzymatischen Domänen aus der pdb-Datenbank auf die AROM-Kristallstruktur übertragen und 
somit ein strukturelles Ensemble erstellt, welches den konformationellen Raum des AROM-
Komplexes widerspiegelt. Dieses Ensemble zeigt, dass der AROM-Komplex hinsichtlich der 
räumlichen Kompatibilität seiner Domänen optimiert ist. Ohne jegliche Koordination können die 
einzelnen Domänen ihre katalytisch notwendigen Konformationsänderungen durchlaufen und 
stoßen dabei nicht mit anderen Domänen zusammen.  
Da der Shikimatweg nicht in Säugetieren vorkommt, ist er ein klassisches pharmakologisches 
Angriffsziel. Bis jetzt ist Glyphosat das einzige Herbizid, das im Shikimatweg angreift. Die 
Erkenntnisse dieser Arbeit zeigen neue Angriffspunkte zur Wirkstoffentwicklung auf. Dies betrifft 
insbesondere den AROM-Komplex, welcher essentiell in Pilzen und Protisten ist. Mit dem Ziel, 
katalytisch notwendige Konformationsänderungen zu inhibieren, könnte der konformationelle 
Raum des AROM-Komplexes gezielt angegriffen werden, was zur Entwicklung von neuartigen 
und spezifischen Fungiziden führen könnte.  
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Appendix 
A.1 Sequences 
A.1.1 Thermotoga maritima shikimate kinase and dehydroquinate 
synthase (Tm_AroKB) 
Cloned in pet 22b  
A.1.1.1 Primers  
Forw: GAGAGA CATATG AGAATCTTCCTCGTTGG 
Rev: GAGAGA AAGCTT ATCTACCACCTCCAGAAGC 
A.1.1.2 Restriction sites 
 NdeI/HindIII 
A.1.1.3 DNA sequence 
atg aga atc ttc ctc gtt gga atg atg ggt tct gga aag agc act atc ggt aaa agg att 
tcc gag gtg ctc gac ctt cag ttc ata gat atg gat gaa gag ata gaa aga aga gag gga 
aga agc gtt cga agg att ttc gaa gaa gac ggt gag gag tac ttc cgc ctg aaa gaa aaa 
gaa ctt ctt aaa gaa ctt gtg gaa aga gac aac gtg gtt gtg gca acg ggt gga ggt gtt 
gtg gtc gat cca gag aac aga gag ctt ttg aag aag gaa aag act ctc ttt ctc tac gct 
ccc cct gaa gtg ttg atg gaa aga gta aca aca gag aac aga cct ctt ctg agc gaa gga 
aaa gag aga ata cgg gag atc tgg gaa aag aga aaa cag ttc tac gcg gag ttc aga agg 
atc gac acc tcc agg ttg aac gag tgg gaa aca acc gca ctc gtt gtg ctg gag gct ctg 
gac gag aaa gaa atc tca acg ata gaa aaa cca cac ctg gtg aag atc atc ctc ggt ggc 
ttc aag agg gtg aga aac gaa gag ctg gtt ttc acc acg gag agg gtg gag aag ata tac 
gga agg tac ctc ccg gag aat cgg ctt ctt ttt ccg gat gga gag gaa gtg aag acg ctg 
gag cat gtc tcc aga gcg tac tac gaa ctc atc cga atg gac ttt ccc agg gga aag acc 
ata gcg ggt gtc ggg gga ggt gct ctc acc gac ttc acc ggc ttt gta gcg agc acg ttt 
aaa aga gga gtg gga ctt tct ttc tat cca aca aca ctt ctg gct cag gtg gac gct tcc 
gtt ggt gga aag aat gcc atc gat ttc gct gga gtg aaa aac gtc gtt ggg act ttc aga 
atg cca gac tac gtg atc ata gat ccc acc gtc acg ctt tcc atg gat gag ggc agg ttc 
gaa gag gga gtc gtg gaa gcc ttc aag atg acg att ctt tcg ggt cgc ggg gta gaa ctc 
ttc gat gag ccg gag aag att gag aag aga aat ctc aga gtt ctc agc gag atg gta aaa 
atc tcc gtt gaa gag aaa gcg agg ata gtg atg gaa gat ccc tac gac atg ggt ttg agg 
cac gcc ctg aat ctg gga cac aca ctc ggt cat gtg tac gag atg ctg gaa ggg gta cct 
cac ggt ata gca gta gca tgg ggc atc gaa aaa gag acg atg tac ctg tac aga aaa gga 
ata gtg cct aag gaa acc atg aga tgg atc gta gaa aag gtc aaa cag atc gta cca att 
cct gtt cca tcc gtc gat gtt gag aaa gcc aga aat ctc att ctg aac gac aag aag atc 
ctg aaa ggt tcc aga gtc agg ctt cct tac gtg aaa gaa atc gga aag atc gaa ttc ttg 
gag gtc gat ccg ctc gag ctt ctg gag gtg gta ga 
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A.1.1.4 Amino acid sequence 
MRIFLVGMMG SGKSTIGKRI SEVLDLQFID MDEEIERREG RSVRRIFEED GEEYFRLKEK ELLKELVERD 
NVVVATGGGV VVDPENRELL KKEKTLFLYA PPEVLMERVT TENRPLLSEG KERIREIWEK RKQFYAEFRR 
IDTSRLNEWE TTALVVLEAL DEKEISTIEK PHLVKIILGG FKRVRNEELV FTTERVEKIY GRYLPENRLL 
FPDGEEVKTL EHVSRAYYEL IRMDFPRGKT IAGVGGGALT DFTGFVASTF KRGVGLSFYP TTLLAQVDAS 
VGGKNAIDFA GVKNVVGTFR MPDYVIIDPT VTLSMDEGRF EEGVVEAFKM TILSGRGVEL FDEPEKIEKR 
NLRVLSEMVK ISVEEKARIV MEDPYDMGLR HALNLGHTLG HVYEMLEGVP HGIAVAWGIE KETMYLYRKG 
IVPKETMRWI VEKVKQIVPI PVPSVDVEKA RNLILNDKKI LKGSRVRLPY VKEIGKIEFL EVDPLELLEV 
VLEHHHHHH 
 
Cloned by: Reinhard Albrecht 
A.1.2. Thermotoga maritima shikimate kinase cloned in pET His-TEV-Nde-
GFP (Tm_AroKKB) 
A.1.2.1 Primers  
Forw: GAGAGA CATATG AGAATCTTCCTCGTTGG 
REV: CTCTCT GGATCC TCAAGCCTCCAGCACAACG 
A.1.2.2 Restriction sites 
 NdeI/BamHI 
A.1.2.3 DNA sequence 
atg aga atc ttc ctc gtt gga atg atg ggt tct gga aag agc act atc ggt aaa agg att 
tcc gag gtg ctc gac ctt cag ttc ata gat atg gat gaa gag ata gaa aga aga gag gga 
aga agc gtt cga agg att ttc gaa gaa gac ggt gag gag tac ttc cgc ctg aaa gaa aaa 
gaa ctt ctt aaa gaa ctt gtg gaa aga gac aac gtg gtt gtg gca acg ggt gga ggt gtt 
gtg gtc gat cca gag aac aga gag ctt ttg aag aag gaa aag act ctc ttt ctc tac gct 
ccc cct gaa gtg ttg atg gaa aga gta aca aca gag aac aga cct ctt ctg agc gaa gga 
aaa gag aga ata cgg gag atc tgg gaa aag aga aaa cag ttc tac gcg gag ttc aga agg 
atc gac acc tcc agg ttg aac gag tgg gaa aca acc gca ctc gtt gtg ctg gag gct tga  
A.1.2.4 Amino acid sequence 
MRIFLVGMMG SGKSTIGKRI SEVLDLQFID MDEEIERREG RSVRRIFEED GEEYFRLKEK ELLKELVERD 
NVVVATGGGV VVDPENRELL KKEKTLFLYA PPEVLMERVT TENRPLLSEG KERIREIWEK RKQFYAEFRR 
IDTSRLNEWE TTALVVLEA 
Cloned by: Ulrich Könninger 
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A.1.3 Thermotoga maritima shikimate kinase and dehydroquinate 
synthase salt bridge mutant (Tm_AroKBSB)  
Cloned in pet 22b  
A.1.3.1 Primers 
R 195 to A 
Forw: P-GCG GTGGA GAAGATATACGGAAGG 
Rev: CTCCGTGGTGAAAACCAG 
D315 to A 
Forw: P-CTGA GGGCAGGTTC GAAGAG 
Rev: CCATGGAAAGCGTGACGGTG 
A.1.3.2 Restriction sites 
 NdeI/HindIII 
A.1.3.3 DNA sequence 
atg aga atc ttc ctc gtt gga atg atg ggt tct gga aag agc act atc ggt aaa agg att 
tcc gag gtg ctc gac ctt cag ttc ata gat atg gat gaa gag ata gaa aga aga gag gga 
aga agc gtt cga agg att ttc gaa gaa gac ggt gag gag tac ttc cgc ctg aaa gaa aaa 
gaa ctt ctt aaa gaa ctt gtg gaa aga gac aac gtg gtt gtg gca acg ggt gga ggt gtt 
gtg gtc gat cca gag aac aga gag ctt ttg aag aag gaa aag act ctc ttt ctc tac gct 
ccc cct gaa gtg ttg atg gaa aga gta aca aca gag aac aga cct ctt ctg agc gaa gga 
aaa gag aga ata cgg gag atc tgg gaa aag aga aaa cag ttc tac gcg gag ttc aga agg 
atc gac acc tcc agg ttg aac gag tgg gaa aca acc gca ctc gtt gtg ctg gag gct ctg 
gac gag aaa gaa atc tca acg ata gaa aaa cca cac ctg gtg aag atc atc ctc ggt ggc 
ttc aag agg gtg aga aac gaa gag ctg gtt ttc acc acg gag gcg gtg gag aag ata tac 
gga agg tac ctc ccg gag aat cgg ctt ctt ttt ccg gat gga gag gaa gtg aag acg ctg 
gag cat gtc tcc aga gcg tac tac gaa ctc atc cga atg gac ttt ccc agg gga aag acc 
ata gcg ggt gtc ggg gga ggt gct ctc acc gac ttc acc ggc ttt gta gcg agc acg ttt 
aaa aga gga gtg gga ctt tct ttc tat cca aca aca ctt ctg gct cag gtg gac gct tcc 
gtt ggt gga aag aat gcc atc gat ttc gct gga gtg aaa aac gtc gtt ggg act ttc aga 
atg cca gac tac gtg atc ata gat ccc acc gtc acg ctt tcc atg gct gag ggc agg ttc 
gaa gag gga gtc gtg gaa gcc ttc aag atg acg att ctt tcg ggt cgc ggg gta gaa ctc 
ttc gat gag ccg gag aag att gag aag aga aat ctc aga gtt ctc agc gag atg gta aaa 
atc tcc gtt gaa gag aaa gcg agg ata gtg atg gaa gat ccc tac gac atg ggt ttg agg 
cac gcc ctg aat ctg gga cac aca ctc ggt cat gtg tac gag atg ctg gaa ggg gta cct 
cac ggt ata gca gta gca tgg ggc atc gaa aaa gag acg atg tac ctg tac aga aaa gga 
ata gtg cct aag gaa acc atg aga tgg atc gta gaa aag gtc aaa cag atc gta cca att 
cct gtt cca tcc gtc gat gtt gag aaa gcc aga aat ctc att ctg aac gac aag aag atc 
ctg aaa ggt tcc aga gtc agg ctt cct tac gtg aaa gaa atc gga aag atc gaa ttc ttg 
gag gtc gat ccg ctc gag ctt ctg gag gtg gta gat 
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A.1.3.4 Amino acid sequence 
MRIFLVGMMG SGKSTIGKRI SEVLDLQFID MDEEIERREG RSVRRIFEED GEEYFRLKEK ELLKELVERD 
NVVVATGGGV VVDPENRELL KKEKTLFLYA PPEVLMERVT TENRPLLSEG KERIREIWEK RKQFYAEFRR 
IDTSRLNEWE TTALVVLEAL DEKEISTIEK PHLVKIILGG FKRVRNEELV FTTEAVEKIY GRYLPENRLL 
FPDGEEVKTL EHVSRAYYEL IRMDFPRGKT IAGVGGGALT DFTGFVASTF KRGVGLSFYP TTLLAQVDAS 
VGGKNAIDFA GVKNVVGTFR MPDYVIIDPT VTLSMAEGRF EEGVVEAFKM TILSGRGVEL FDEPEKIEKR 
NLRVLSEMVK ISVEEKARIV MEDPYDMGLR HALNLGHTLG HVYEMLEGVP HGIAVAWGIE KETMYLYRKG 
IVPKETMRWI VEKVKQIVPI PVPSVDVEKA RNLILNDKKI LKGSRVRLPY VKEIGKIEFL EVDPLELLEV 
VDLEHHHHHH 
Cloned by: Harshul Arora 
A.1.4 Feacalibacterium prausnitzii shikimate dehydrogenase and kinase 
(FP_AroEK) 
Codon optimized for expression in E. coli from Eurofins and cloned in pet22b 
A.1.4.1 Primers 
Forw: GAGAGA CATATG GAA TAC GGA CTC ATC GG 
Rev: GAGAGA CTCGAG TTA ATG ACT AAA AAT TTC ATC CAG CG 
A.1.4.2 Restriction sites  
NdeI/XhoI 
A.1.4.3 DNA Sequence 
catatg atg gaa tat ggg ctg att ggt ggc cgg ctg ggt cac tcg tat agc aag gtc att 
cac gag atg ttg tgc ggc tat cgc tat gac ctt tgt ccg ttg ccg acg gaa gag gaa gtc 
cgt gct ttt ctc aca cgt cgc cag ttt cgg gcc atc aac gtg aca att ccc tac aaa ctg 
gtt gtg atg gag tat tgc agc tac atc gat cct cat gcg aaa gcg att aat gcc gtg aac 
acg atc gtg aat cgc aac ggt tta ctg tat ggc tac aat acc gac tat ccg ggt ttc tcc 
tat ctg tgc gat gca cat ggg gtg gag ttc aaa gac cgc acg gta ctg att tta ggg aca 
ggc ggg acc cac aac acc acg tgg gcc gta gcg cat gat cgt ggg gca aag cag att tac 
acc gtt agt cgc cat ccc gat ccg gaa aag ggt gaa tta acc tat gca cag gcc ctg acc 
aca ggt gcg cag att atc atc aat acg act cct gtg ggt atg tac ccg aat gcg gga gta 
tct gcg ttg gat atc acc agc atg ccg ggc ctc gaa gcg gtt att gac gtg att tac aat 
ccg gac aaa acc gaa ctt atc ctg cgt gct gaa gag ctg ggt gtc cca gtt gcc gtg ggt 
ggt ctg gaa atg ctg gta gct caa gcg gtt tat gca gcc gaa ttc ttt ctg gat cgc aaa 
ttc gaa gat gca ggc gcc gaa att gcc cgt gtg acg tcc gag ctg cgc cgt gag cag ttg 
aac att gcg ctg att ggc atg ccg tca tcg ggc aaa agc acc tta ggc cgt gca tta gcc 
gaa cgc tta ggt aaa cgc ttt gta gat ctg gac gag gaa att gtc aag gca gat ggc cgt 
tcg att ccc gac atc ttt gcg gct gaa ggc gaa gca ggc ttc cgc aaa ctg gaa gcc gcg 
caa act gcg cgg ttt gcg cgt gag aat cgc cag gtg att tca tgt gga ggc gga gtt gtg 
aaa gat cca gct aac ctt cgt gcg ctg cat gct aac ggc att gtc ctg ttc atc gat cgt 
ccg ctg gaa gat ctg ctc gtc ggc ggt gga cgc cca ctc agt act tct ccg gaa gcc ctg 
aaa acc atg gaa gcg caa cgc cgc cca ctt tac ctg gct gcc gct gat gca gtt atc ccg 
aac aaa acg acc cct gca gat gcg gtt act gcg gcg atg gaa gcc ttg gac gag atc ttt 
agc cac ctcgag 
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A.1.4.4 Protein Sequence 
MMEYGLIGGR LGHSYSKVIH EMLCGYRYDL CPLPTEEEVR AFLTRRQFRA INVTIPYKLV VMEYCSYIDP 
HAKAINAVNT IVNRNGLLYG YNTDYPGFSY LCDAHGVEFK DRTVLILGTG GTHNTTWAVA HDRGAKQIYT 
VSRHPDPEKG ELTYAQALTT GAQIIINTTP VGMYPNAGVS ALDITSMPGL EAVIDVIYNP DKTELILRAE 
ELGVPVAVGG LEMLVAQAVY AAEFFLDRKF EDAGAEIARV TSELRREQLN IALIGMPSSG KSTLGRALAE 
RLGKRFVDLD EEIVKADGRS IPDIFAAEGE AGFRKLEAAQ TARFARENRQ VISCGGGVVK DPANLRALHA 
NGIVLFIDRP LEDLLVGGGR PLSTSPEALK TMEAQRRPLY LAAADAVIPN KTTPADAVTA AMEALDEIFS 
HLELEHHHHHH 
A.1.5 Methanoregula boonei shikimate dehydrogenase and kinase 
(Mb_AroKE) 
Codon optimized for expression in E. coli from Eurofins and cloned in pet22b 
A.1.5.1 Primers 
Forw: GAGAGACATATGGGCGGCAGCGGCATGAAGGTCGTCCTTACCGC 
Rev: GAGAGAGGATCCTCATGCAAGCATCTCCCG 
A.1.5.2 Restriction sites  
NdeI/XhoI 
A.1.5.3 DNA Sequence 
ggc ggt tct ggt atg aaa cgc att gta ctg ttt ggc tat cgc ggt act ggc aaa act gcg 
atc ggt acc gtt ctg gcg cag aaa ctg ggc gtt ccg ttt ctg gat acg gat gct ctg gtt 
gaa cag caa gct gga cgc acg atc ccg gaa atc ttt cgc gat tcc ggt gaa gcc gga ttt 
cgc gct cgc gaa cgt gaa gcg gtg tct ggt ctg ccg gat cgt gat gcg att atc gcg aca 
ggt ggc ggt gtc gtc atg gac ccg gcg aac atg gaa cat ctg cgg aaa gaa agc gtg tgt 
gtc ctg tta tcg gcg gat ccg aat gtc atc gga cat cgc ctg gcc cat gcc cca cgt ccg 
gct ttg acg agc ctc tca ccc acg gat gag att acg gcg atg ctc aaa cac cgc cgc cct 
gct tac gct gca gcc gca gat ttc tgc att gat aca ggc cgt act acc gcc ggc gaa gcc 
gcc gag aaa atc ctt acg tta ctt ggc gcg ggt agc att ccg gat acc gcc cgt cac acc 
gca gcc cgc tgg ttt gca gca acg cca ctt cct gcg ccg gaa aag gaa gaa ctg gaa cgc 
aaa ttg ctg ggt ccg ggg tat gat ccg cag act cgg ttc ctg ggc gtt gcc ggc tgg ccg 
tgt ggt cat tcg aaa agt cct gtg ctc ttc aac cgt ttg ttt gag cac tac cgc ctc aat 
tgc cac tat acc cgt ttc gaa gcc ccg gaa att ggc cca gtc atg gaa atg gcg cgt ctt 
att tcg gct aaa ggg tta agc gta acc att ccc ttc aaa cag gac gtg atg tcc tac ctg 
gac gag att gat gaa gca gcg cag aaa att ggg gca gta aac acc gtg gtg ttt gcg tgt 
ggc cgt gcg tat ggg tgg aac acc gat tgg atc ggg att cgt aag cct ctg gcc cat ctg 
agt ggc tca cgg gcg gtt ttg ttg ggc gcc ggt ggg gta gct gca gca gcg gcg tat gcg 
ctg cgt gac ctg gat atg gag atc atc atc ctg aat cgc aca ccc gag aag gca cgg gcg 
tta gct gaa cgc aca ggt tgt cgc ttt ggt gcc tgg gac gat ttt gac cgc acg aat ccg 
gat ctg gtt gtt aac gca acc agc att ggc atg caa ccc gat act gga agt ccg tta cgt 
gac gac cag tta aag aaa gag atg acc gtg tgc gac ttg gtg tat act cca ccg gtc acc 
tcc ctg atc gca gcc gcg cgt aaa gcg ggc tgc acc aca att ctg ggc acc gaa acc ttc 
gtg tac caa gca caa gag cag ttt cgc ctg ttc ttc gga att gat gtg cca gac acg acc 
att cgc gaa att ctg gcc 
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A.1.5.4 Protein sequence 
GGSGMKRIVL FGYRGTGKTA IGTVLAQKLG VPFLDTDALV EQQAGRTIPE IFRDSGEAGF RAREREAVSG 
LPDRDAIIAT GGGVVMDPAN MEHLRKESVC VLLSADPNVI GHRLAHAPRP ALTSLSPTDE ITAMLKHRRP 
AYAAAADFCI DTGRTTAGEA AEKILTLLGA GSIPDTARHT AARWFAATPL PAPEKEELER KLLGPGYDPQ 
TRFLGVAGWP CGHSKSPVLF NRLFEHYRLN CHYTRFEAPE IGPVMEMARL ISAKGLSVTI PFKQDVMSYL 
DEIDEAAQKI GAVNTVVFAC GRAYGWNTDW IGIRKPLAHL SGSRAVLLGA GGVAAAAAYA LRDLDMEIII 
LNRTPEKARA LAERTGCRFG AWDDFDRTNP DLVVNATSIG MQPDTGSPLR DDQLKKEMTV CDLVYTPPVT 
SLIAAARKAG CTTILGTETF VYQAQEQFRL FFGIDVPDTT IREILALEHHHHHH 
Cloned by: Harshul Arora 
A.1.6. Chaetomium thermophillum AROM complex  
cloned in pET28b  
A.1.6.1 Primers 
Forw: GAGAGAGAGACCATGGCCACC 
Rev: CACGTTCACGCTCGAGTTCAAC 
A.1.6.2 Restriction sites 
NcoI and XhoI 
A.1.6.3 Gene Sequence 
gag aga gag acc atg gcc acc gca aat gtt gcc ggt gcc ggt ggt agc ggt agc gaa ccg 
acc cgt att gca att ctg ggt aaa gaa gat att atc gtc gat cat ggc atc tgg ctg aat 
ttt gtt gca cat gat ctg ctg caa acc ctg ccg agc agc acc tat gtt ctg att acc gat 
acc aat ctg tat acc acc tat gtg cca ccg ttt cag gca gtt ttt gaa gca gca gca ccg 
cgt gat gtt cgt ctg ctg acc tat gca att ccg cct ggt gaa tat agc aaa agc cgt gaa 
acc aaa gcc gaa att gaa gat tgg atg ctg agc cat gca tgt acc cgt gat acc gtt att 
att gca ctg ggt ggt ggt gtt att ggt gat atg att ggt tat gtt gca gcc acc ttt atg 
cgt ggt gtt cgt ttt gtt cag gtt ccg acc acc ctg ctg gca atg gtt gat agc agc att 
ggt ggt aaa acc gca att gat acc ccg atg ggt aaa aat ctg att ggt gca ttt tgg cag 
cct cgt cgt atc tat att gat ctg gca ttt ctg gaa aca ctg ccg gtt cgt gaa ttt atc 
aat ggt atg gca gaa gtg att aaa acg gca gcc att tgg aat gaa acc gaa ttt acc gca 
ctg gaa gaa aat gca gca gcg att ctg gaa gca gtt cgt agc aaa gca agc agt ccg gca 
gca cgt ctg gca ccg att cgt cat att ctg aaa cgt att gtt ctg ggt agc gca cgt gtt 
aaa gcc gaa gtt gtt agc gca gat gaa cgt gaa ggt ggt ctg cgt aat ctg ctg aac ttt 
ggt cat agc att ggt cat gcc tat gaa gca atc ctg gca ccg cag gtt ctg cat ggt gaa 
tgt gtt gca att ggt atg gtt aaa gaa gca gaa ctg gca cgt tat ctg ggt gtt ctg cgt 
ccg agc gca gtt gca cgt ctg acc aaa ctg att gca agc tat gac ctg ccg acc agc gtt 
cat gat aaa cgc att gca aaa ctg agc gca ggt aaa gaa tgt ccg gtt gat gta ctg ctg 
caa aaa atg gcc gtt gac aaa aaa aac gag ggt cgc aaa aaa aaa att gtt ctg ctg agc 
gca atc ggc aaa acc tat gaa aaa aaa gca acc gtt gtt gat gat cgt gca att cgt ctg 
gtt ctg agc ccg agc gtt cgt gtt aca ccg ggt gtt ccg aaa ggt ctg agc gtt acc gtt 
acc cct ccg ggt agc aaa agt att agc aat cgt gca ctg gtt ctg gca gcc ctg ggt gaa 
ggc acc acc cgt att cat ggc ctg ctg cat agt gat gat gtt cag tat atg ctg gca gca 
att gaa cag ctg cat ggc gca gat ttt tca tgg gaa gat gcc ggt gaa att ctg gtt gtt 
acc ggc aaa ggt ggt aaa ctg caa gca agc aaa gaa ccg ctg tat ctg ggt aat gca ggc 
acc gca agc cgt ttt ctg acc agc gtg gtt gca ctg tgt gca ccg agt gca gtt agc agt 
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acc gtt ctg acc ggc aat gca cgt atg aaa gtt cgt ccg att ggt gcc ctg gtt gat gcc 
ctg cgt gca aat ggt gtt ggt gtt aaa tat ctg gaa aaa gag aaa agc ctg ccg gtt gaa 
gtt gat gca gcc ggt ggt ttt gca ggc ggt gtg att gaa ctg gca gcc acc gtt agc agc 
cag tat gtg agc agc att ctg atg gca gca ccg tat gca cat cag ccg gtt acc ctg cgt 
ctg gtt ggt ggc aaa ccg att agc cag ccg tat att gat atg aca att gca atg atg gcc 
agc ttt ggc att aaa gtt gaa cgt agc gca gaa gat ccg aac acc tat ctg atc ccg aaa 
ggt gtg tat aaa aac cct ccg gaa tat gtg gtt gaa agt gat gca agc agc gca acc tat 
ccg ctg gca gtt gca gca att acc ggc acc acc tgt acc att ccg aat att ggt agc gaa 
agc ctg caa ggt gat gca cgt ttt gca gtt gaa gtg ctg cgt cct atg ggt tgt gcc gtt 
gaa cag acc gca acc agc acc acc gtt aca ggt ccg cct att ggc acc ctg aaa gcc att 
ccg cat gtt gat atg gaa ccg atg acc gat gca ttt ctg acc gca gcc gta ctg gca gca 
gtt gcc gat ggt aca acc cag att aca ggt att gca aat cag cgt gtg aaa gaa tgt aat 
cgt att gca gcc atg aaa gat cag ctg gca aaa ttt ggt gtt cag tgc aat gaa ctg gaa 
gat ggc att gaa gtt att ggt aaa ccg tat caa gaa ctg cgt aat ccg gtt gaa ggt atc 
tat tgc tat gat gat cac cgt gtt gca atg agc cat agc gtt ctg agc acc att agt ccg 
cat ccg gtt ctg att ctg gaa cgt gaa tgt acc gca aaa acc tgg cct ggt tgg tgg gat 
att ctg agc cag ttt ttc aaa gtt cag ctg gat ggt gaa gaa gat ccg acc aaa cgt acc 
acc cag agc acc cag cag gtt cgt aaa ggc acc gat cgt agc att ttt atc gtt ggt atg 
cgt ggt gca ggt aaa agc acc gca ggt cgt tgg atg agc gaa ctg ctg aaa cgt ccg ctg 
gtt gat ctg gat gca gaa ctg gaa cgt cgt gaa ggt atg acc att ccg gaa att att cgt 
ggt gaa cgt ggt tgg gaa ggt ttt cgt cag gca gag ctg gaa ctg ctg caa gat gtt atc 
aaa aat cag agc aaa ggc tac atc ttt agc tgt ggt ggt ggt att gtt gaa acc gaa gca 
gca cgt aaa ctg ctg atc gat tat cat aaa aat ggt ggt ccg gtg ctg ctg gtt cat cgt 
gat acc gat cag gtt gtt gaa tat ctg atg cgt gat aaa acc cgt ccg gca tat agc gaa 
aat att cgc gaa gtt tat gaa cgt cgt aaa ccg tgg ttt tat gaa tgc agc aat ctg caa 
tat cat agt ccg cac gaa gat ggt agc gaa gcc ctg ctg caa cct ccg gca gat ttt gca 
cgt ttt gtt aaa ctg att gca ggt cag agt acc cat ctg gaa gat gtt cgt gca aaa aaa 
cac agc ttt ttt gtt agc ctg acc gtt ccg aat gtt gca gat gca ctg gat att att ccg 
cgt gtt gtt gtt ggt agt gat gca gtt gaa ctg cgt gtt gat ctg ctg gaa agc tat gaa 
ccg gaa ttt gtt gca cgt cag gtt gca ctg ctg cgt gca gca gcc cag gtt ccg att gtt 
tat acc gtt cgt acc cag agc cag ggt ggt aaa ttt cct gat gaa gat tat gat ctg gca 
ctg cgt ctg tat cag aca ggt ctg cgt agc ggt gtg gaa tat ctg gat ctg gaa atg aca 
atg ccg gat cat att ctg caa gca gtt acc gat gca aaa ggt ttt acc agc att att gca 
agc cat cat gat ccg cag tgt aaa ctg agc tgg aaa agc ggt agc tgg att ccg ttt tat 
aac aaa gca ctg caa tat ggc gac gtg att aaa ctg gtg ggt gtt gcc cgt gaa atg gca 
gat aat ttt gca ctg acc aac ttt aaa gcc aaa atg ctg gca gcc cat gat aac aaa ccg 
atg att gcc ctg aat atg ggt aca gcc ggt aaa ctg tca cgt gtt ctg aat ggt ttt ctg 
act ccg gtt agc cat ccg gca ctg ccg agc aaa gcc gca ccg ggt cag ctg agc gca acc 
gaa att cgc cag gca ctg agc ctg att ggt gaa att gaa ccg aaa tcg ttt tac ctg ttt 
ggt aaa ccg att agc gca agc cgt agc cct gca ctg cat aat acc ctg ttt tac aaa acg 
ggt ctg ccg cat cat tat agc cgt ttt gaa acg gat gaa gca agc aaa gcc ctg gaa agc 
ctg att cgt agt ccg gat ttt ggt ggt gcc agc gtt acc att ccg ctg aaa ctg gac att 
atg ccg ctg ctg gat agc gcc acc gat gca gcc cgt acc att ggt gca gtt aat acc att 
att cct cag acc cgt gat ggt agc acc aca acc ctg gtt ggc gat aat acc gat tgg cgt 
ggt atg gtt cat gcg ctg ctg cat agt agc ggt agc ggt tca gtt gtt cag cgt acc gca 
gca ccg cgt ggt gcc gca atg gtt gtg ggt agc ggt ggc acc gca cgt gca gca att tat 
gcc ctg cat gat ctg ggt ttt gca ccg att tgg att gtt gcg cgt agc gaa gaa cgt gtt 
gcc gaa ctg gtt cgt ggt ttt gat ggc tat gat ctg cgt cgt atg acc tct ccg cat cag 
ggt aaa gat aat atg ccg agc gtt gtt att agc aca att ccg gca acc cag ccg att gat 
ccg agc atg cgt gaa gtg att gtt gaa gtt ctg aaa cat ggt cat ccg agc gca gaa ggt 
aaa gta ctg ctg gaa atg gca tat cag cct ccg cgt aca ccg ctg atg acc ctg gca gaa 
gat cag ggt tgg cgt acc gtt ggt ggt ctg gaa gtt ctg gca gca cag ggt tgg tat cag 
ttt caa ctg tgg acc ggc att act ccg ctg tat gaa gaa gca cgc gca gca gtt atg ggt 
gaa gat agc gtt gaa ctc gag cgt gaa cgt g 
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A.1.6.4 Amino acid Sequence 
MATANVAGAG GSGSEPTRIA ILGKEDIIVD HGIWLNFVAH DLLQTLPSST YVLITDTNLY TTYVPPFQAV 
FEAAAPRDVR LLTYAIPPGE YSKSRETKAE IEDWMLSHAC TRDTVIIALG GGVIGDMIGY VAATFMRGVR 
FVQVPTTLLA MVDSSIGGKT AIDTPMGKNL IGAFWQPRRI YIDLAFLETL PVREFINGMA EVIKTAAIWN 
ETEFTALEEN AAAILEAVRS KASSPAARLA PIRHILKRIV LGSARVKAEV VSADEREGGL RNLLNFGHSI 
GHAYEAILAP QVLHGECVAI GMVKEAELAR YLGVLRPSAV ARLTKLIASY DLPTSVHDKR IAKLSAGKEC 
PVDVLLQKMA VDKKNEGRKK KIVLLSAIGK TYEKKATVVD DRAIRLVLSP SVRVTPGVPK GLSVTVTPPG 
SKSISNRALV LAALGEGTTR IHGLLHSDDV QYMLAAIEQL HGADFSWEDA GEILVVTGKG GKLQASKEPL 
YLGNAGTASR FLTSVVALCA PSAVSSTVLT GNARMKVRPI GALVDALRAN GVGVKYLEKE KSLPVEVDAA 
GGFAGGVIEL AATVSSQYVS SILMAAPYAH QPVTLRLVGG KPISQPYIDM TIAMMASFGI KVERSAEDPN 
TYLIPKGVYK NPPEYVVESD ASSATYPLAV AAITGTTCTI PNIGSESLQG DARFAVEVLR PMGCAVEQTA 
TSTTVTGPPI GTLKAIPHVD MEPMTDAFLT AAVLAAVADG TTQITGIANQ RVKECNRIAA MKDQLAKFGV 
QCNELEDGIE VIGKPYQELR NPVEGIYCYD DHRVAMSHSV LSTISPHPVL ILERECTAKT WPGWWDILSQ 
FFKVQLDGEE DPTKRTTQST QQVRKGTDRS IFIVGMRGAG KSTAGRWMSE LLKRPLVDLD AELERREGMT 
IPEIIRGERG WEGFRQAELE LLQDVIKNQS KGYIFSCGGG IVETEAARKL LIDYHKNGGP VLLVHRDTDQ 
VVEYLMRDKT RPAYSENIRE VYERRKPWFY ECSNLQYHSP HEDGSEALLQ PPADFARFVK LIAGQSTHLE 
DVRAKKHSFF VSLTVPNVAD ALDIIPRVVV GSDAVELRVD LLESYEPEFV ARQVALLRAA AQVPIVYTVR 
TQSQGGKFPD EDYDLALRLY QTGLRSGVEY LDLEMTMPDH ILQAVTDAKG FTSIIASHHD PQCKLSWKSG 
SWIPFYNKAL QYGDVIKLVG VAREMADNFA LTNFKAKMLA AHDNKPMIAL NMGTAGKLSR VLNGFLTPVS 
HPALPSKAAP GQLSATEIRQ ALSLIGEIEP KSFYLFGKPI SASRSPALHN TLFYKTGLPH HYSRFETDEA 
SKALESLIRS PDFGGASVTI PLKLDIMPLL DSATDAARTI GAVNTIIPQT RDGSTTTLVG DNTDWRGMVH 
ALLHSSGSGS VVQRTAAPRG AAMVVGSGGT ARAAIYALHD LGFAPIWIVA RSEERVAELV RGFDGYDLRR 
MTSPHQGKDN MPSVVISTIP ATQPIDPSMR EVIVEVLKHG HPSAEGKVLL EMAYQPPRTP LMTLAEDQGW 
RTVGGLEVLA AQGWYQFQLW TGITPLYEEA RAAVMGEDSV ELERERLEHHHHHH 
Cloned by: Reinhard Albrecht 
A.1.7. Thielavia heterothallica AROM complex cloned in pET28b with NcoI 
and XhoI 
A.1.7.1 Primers 
Forw: GAGAGAGAGACCATGGCCG 
Rev: CTCTCTCTCTCTCGAGGCTGC 
A.1.7.2 Restriction sites 
NcoI and XhoI 
A.1.7.3 Gene Sequence 
gag aga gag acc atg gcc ggt aca agc agc agc ggt ccg acc cgt att gca att ctg ggt 
aaa gaa gat att gtt gtc gat cat ggc atc tgg ctg aat ttt gtt acc cat gat ctg ctg 
caa aat ctg ccg agc agc acc tat gtt ctg att acc gat acc aat ctg tat cac acc tat 
gtg cca ccg ttt cag gca gtt ttt gaa gca gcc gca ccg aaa gat gtt cgt ctg ctg acc 
tat gca att ccg cct ggt gaa tat agc aaa ggt cgt gaa acc aaa gcc gaa att gaa gat 
tgg atg ctg agc cat acc tgt acc cgt gat acc gtt att att gca ctg ggt ggt ggt gtt 
att ggt gat atg att ggt tat gtt gca gcc acc ttt atg cgt ggt gtt cgt ttt gtt cag 
gtt ccg acc acc ctg ctg agc atg gtt gat agc agc att ggt ggt aaa acc gca att gat 
gtt ccg atg ggt aaa aat ctg att ggt gca ttt tgg cag ccg aaa cgc att tat atc gat 
ctg gca ttt ctg gaa acc ctg ccg gtt cgt gaa ttt atc aat ggt atg gca gaa gtg att 
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aaa acg gca gcc att tgg aat gaa gca gaa ttt acc gca ctg gaa gaa aac gca ccg gct 
att ctg gaa gca att cgt agt aaa ggt agc agc ccg agc gca cgt ctg gca ccg att cgt 
cat att ctg aaa cgt att gtt ctg ggt agt gcc ggt gtt aaa gca cag gtt gtt agc gca 
gat gaa cgt gaa ggt ggt ctg cgt aat ctg ctg aac ttt ggt cat agc att ggt cat gcc 
tat gaa gca atc ctg gca ccg cag gtt ctg cat ggt gaa tgt gtt gca att ggt atg gtt 
aaa gaa gca gaa ctg gca cgt ttt ctg ggt gtt ctg cgt ccg gat gca gtt gca cgt ctg 
acc aaa tgt att gca agc tat gac ctg ccg acc agc gtt cat gat aaa cgc att gca aaa 
ctg agc gca agc aaa gaa tgt ccg gtt gat gtg ctg ctg caa aaa atg gca gtt gac aaa 
aaa aac gaa ggc agc aaa aaa aaa atc gtt ctg ctg agc gcc att ggc aaa acc tat gaa 
ccg aaa gca acc gtt gtt gat gat cgt gcc att cgt att gtg ctg agc ccg agc att cgt 
gtt aca ccg ggt gtt ccg gaa aat ctg agc gtt agc gtt acc cct ccg ggt agc aaa agc 
att agc aat cgt gca ctg att ctg gca gcc ctg ggt gaa ggc acc acc cgt att cat ggc 
ctg ctg cat agt gat gat acc cag tat atg ctg acc gcg att gca cag ctg gaa ggt gca 
acc tat acc tgg gaa gat gcc ggt gaa gtt ctg gtt gtt aaa ggt aaa ggt ggt aaa ctg 
aaa gca agc gca gaa ccg ctg tat ctg ggt aat gca ggc acc gca agc cgt ttt ctg acc 
agc gtg gtt gca ctg tgt agc ccg acc agt gtt agc agc acc gtt ctg acc ggc aat gca 
cgt atg aaa gtt cgt ccg att ggt ccg ctg gtt gat gca ctg cgt gca aat ggt gtt ggt 
gtt aaa tat ctg gaa aaa gag aaa agc ctg cct gtt cag gtg gat gca aat gca ggt ttt 
gcg ggt ggt ctg att gaa ctg gca gcc acc gtt agc agc cag tat gtg agc agc att ctg 
atg gct gca ccg tat gca cat aaa cct gtt acc ctg cgt ctg gtt ggt ggc aaa ccg att 
agc cag ccg tat att gat atg acc att gcc atg atg gcc agc ttt ggt att aat gtt gaa 
cgt agc agc gaa gat ccg aac acc tat cat att ccg cag ggt gtg tac aaa aat ccg gca 
gat tat gtt gtt gaa agt gat gca agc agc gca acc tat ccg ctg gca gtt gca gca att 
acc ggc acc acc tgt acc att ccg aat att ggt agc gca agc ctg caa ggt gat gca cgt 
ttt gca gtt gaa gtg ctg cgt ccg atg ggc tgt acc gtt gaa cag acc gaa acc agc acc 
acc gtt aca ggt ccg cct att ggc acc ctg aaa gcc att gaa cat gtt gat atg gaa ccg 
atg acc gat gca ttt ctg acc gca agc gtg ctg gca gca gtt gca agc ggt aca acc cgc 
att aca ggt att gca aat cag cgt gtt aaa gag tgt aat cgt att gca gcc atg aaa gat 
cag ctg gca aaa ttt ggt gtg cat tgt aat gaa ctg gaa gat ggt att gaa gtt acc ggc 
aaa ccg tat caa gag ctg caa aac ccg acc gat ggt gtt tat tgt tat gat gat cac cgt 
gtt gcc atg agc ttt agt gtt ctg gca acc gca gca ccg cat cgt gtt ctg atc ctg gaa 
cgt gaa tgt acc gca aaa acc tgg cct gga tgg tgg gat att ctg agc cag gca ttt aaa 
gtt cat ctg gca ggt gaa gaa gat ccg acc aaa aaa cag gtt gtt cag ccg agc ggt agc 
ggc acc gat cgt agc att ttt atc att ggt atg cgt ggt gca ggt aaa agc acc gca ggt 
cgt tgg atg agc gaa att ctg caa cgt ccg ctg gtt gat ctg gat gtt gaa ctg gaa cgt 
cgt gaa ggt atg acc att ccg gaa att att cgt ggt gaa cgt ggt tgg gaa ggt ttt cgt 
aaa gca gag ctg gaa ctg ctg gaa gat gtt atc aaa aat cag agc aaa ggc tac atc ttt 
agc tgt ggt ggt ggt att gtt gaa acc gaa gaa gca cgt aaa ctg ctg att agc tat cat 
aaa agc ggt ggt tgt gtt ctg atg gtt cat cgt gat acc gat cag gtt gtt gaa tat ctg 
atg cgt gat aaa acc cgt ccg gca tat agc gaa aat att cgc gaa gtt tat tat cgt cgc 
aaa ccg tgg ttt gaa gaa tgc agc aat ttt cag tat cat agt ccg cat ctg gat ggt agc 
gaa gca ctg cgt ggt ccg cct gtt gat ttt tca cgt ttt ctg agc gtt att tgt ggt cgt 
agc cgt cat ctg gaa gaa gtg cgt aaa aaa aaa cac agc ttt ttt gtt agc ctg acc gtg 
ccg aat att agc acc gca ctg gat att att ccg ggt gca gtt gtt ggt agt gat gca gtt 
gaa ctg cgt gtt gat ctg ctg gaa agc tat gat ccg gaa ttt gtt gca cat cag gtt gca 
ctg ctg cgt agc gtt gcc aaa att ccg att gtt tat acc gtt cgt acc gtt agc cag ggt 
ggt cgt ttt ccg gat gat gat tat gaa ctg gca cgc cgt ctg tat cag att ggt ctg cgt 
aca ggt gtg gaa ttt ctg gat ctg gaa gtt acc atg cct gcc gat att ctg gaa gca gtt 
acc gtg agc aaa ggt ttt acc cgt att att gca agc cat cat gat ccg cag agc aaa ctg 
agc tgg cgt aat ggt agc tgg att ccg ttt tat aac aaa gcc ctg caa tat ggc gac gtg 
att aaa ctg gtt ggt atg gca ggc gaa att agc gat aat ttt gca ctg acc agc ttt aaa 
acc aaa atg ctg gca gca cat gat acc ccg att att gcg ctg aat atg ggt ccg gca ggt 
aaa ctg agc cgt gtg ctg aat ggt ttt atg act ccg gtt agc cat ccg gat ctg cct gca 
aaa gca gca ccg ggt cag ctg agc gca acc gaa att cgt cag gca ctg gca ctg att ggc 
gaa ctg gaa ccg aaa agt ttt tac ctg ttt ggt aaa ccg att agc agc agc cgt agt ccg 
gca ctg cat aat acc ctg ttt ggc gca aca ggt ctg ccg cat cat tat agc ctg ttt gaa 
acg gat aaa gcc agt gat gtt cag gat ctg att cgt gca ccg cat ttt ggc ggt gca agc 
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gtt acc att ccg ctg aaa ctg gac att gtt ccg ctg ctg gat gat att agc gaa gcc gca 
cgt gca att ggt gca gtt aat acc att att ccg att ccg agc gca gca aaa ggt gat aac 
aaa acc acc ctg ctg ggt gat aat acc gat tgg cgt ggt atg gtt ttt gcc ctg cgt agt 
gcc ggt gtt gca agc cct ccg ggt gcc ggt atg gtt gtg ggt agc ggt ggc acc acc cgt 
gca gcc att tat gcc ctg cat agc ctg ggt tat gca ccg att tat gtt gtt gca cgt aca 
ccg gaa cgt gtt aaa gaa ctg gca ggc ggt ttt ccg gca gat tat cgt att cag cat ctg 
gca acc cgt gaa gaa gca gtt gcg gtt gca gtt gca gca cgt cat gaa ctg ccg acc gtt 
gtg att agc acc att cct gcg gat aaa ccg atc gat agc ggt atg cgc gaa gtt ctg gtt 
acc gca ctg caa ggt ggt ggt gca gca ggt aaa gaa aaa ggt gaa ccg cgt gtg ctg ctg 
gaa atg gca tat aca ccg cgt cat aca ccg ctg atg cag ctg gca gaa gat gca ggt tgg 
gtt aca att ccg ggt ctg gaa gta ctg gca gcc cag ggt tgg tat cag ttt caa ctg tgg 
acc ggc att act ccg ctg tat gca gat gca cgt gcc gca gtt atg ggt aat gaa agc agc 
ctc gag aga gag aga g 
A.1.7.4 Amino acid Sequence 
MAGTSSSGPT RIAILGKEDI VVDHGIWLNF VTHDLLQNLP SSTYVLITDT NLYHTYVPPF QAVFEAAAPK 
DVRLLTYAIP PGEYSKGRET KAEIEDWMLS HTCTRDTVII ALGGGVIGDM IGYVAATFMR GVRFVQVPTT 
LLSMVDSSIG GKTAIDVPMG KNLIGAFWQP KRIYIDLAFL ETLPVREFIN GMAEVIKTAA IWNEAEFTAL 
EENAPAILEA IRSKGSSPSA RLAPIRHILK RIVLGSAGVK AQVVSADERE GGLRNLLNFG HSIGHAYEAI 
LAPQVLHGEC VAIGMVKEAE LARFLGVLRP DAVARLTKCI ASYDLPTSVH DKRIAKLSAS KECPVDVLLQ 
KMAVDKKNEG SKKKIVLLSA IGKTYEPKAT VVDDRAIRIV LSPSIRVTPG VPENLSVSVT PPGSKSISNR 
ALILAALGEG TTRIHGLLHS DDTQYMLTAI AQLEGATYTW EDAGEVLVVK GKGGKLKASA EPLYLGNAGT 
ASRFLTSVVA LCSPTSVSST VLTGNARMKV RPIGPLVDAL RANGVGVKYL EKEKSLPVQV DANAGFAGGL 
IELAATVSSQ YVSSILMAAP YAHKPVTLRL VGGKPISQPY IDMTIAMMAS FGINVERSSE DPNTYHIPQG 
VYKNPADYVV ESDASSATYP LAVAAITGTT CTIPNIGSAS LQGDARFAVE VLRPMGCTVE QTETSTTVTG 
PPIGTLKAIE HVDMEPMTDA FLTASVLAAV ASGTTRITGI ANQRVKECNR IAAMKDQLAK FGVHCNELED 
GIEVTGKPYQ ELQNPTDGVY CYDDHRVAMS FSVLATAAPH RVLILERECT AKTWPGWWDI LSQAFKVHLA 
GEEDPTKKQV VQPSGSGTDR SIFIIGMRGA GKSTAGRWMS EILQRPLVDL DVELERREGM TIPEIIRGER 
GWEGFRKAEL ELLEDVIKNQ SKGYIFSCGG GIVETEEARK LLISYHKSGG CVLMVHRDTD QVVEYLMRDK 
TRPAYSENIR EVYYRRKPWF EECSNFQYHS PHLDGSEALR GPPVDFSRFL SVICGRSRHL EEVRKKKHSF 
FVSLTVPNIS TALDIIPGAV VGSDAVELRV DLLESYDPEF VAHQVALLRS VAKIPIVYTV RTVSQGGRFP 
DDDYELARRL YQIGLRTGVE FLDLEVTMPA DILEAVTVSK GFTRIIASHH DPQSKLSWRN GSWIPFYNKA 
LQYGDVIKLV GMAGEISDNF ALTSFKTKML AAHDTPIIAL NMGPAGKLSR VLNGFMTPVS HPDLPAKAAP 
GQLSATEIRQ ALALIGELEP KSFYLFGKPI SSSRSPALHN TLFGATGLPH HYSLFETDKA SDVQDLIRAP 
HFGGASVTIP LKLDIVPLLD DISEAARAIG AVNTIIPIPS AAKGDNKTTL LGDNTDWRGM VFALRSAGVA 
SPPGAGMVVG SGGTTRAAIY ALHSLGYAPI YVVARTPERV KELAGGFPAD YRIQHLATRE EAVAVAVAAR 
HELPTVVIST IPADKPIDSG MREVLVTALQ GGGAAGKEKG EPRVLLEMAY TPRHTPLMQL AEDAGWVTIP 
GLEVLAAQGW YQFQLWTGIT PLYADARAAV MGNESSLERE RLEHHHHHH 
 
Cloned by: Reinhard Albrecht 
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